<SEC-DOCUMENT>0001144204-18-053648.txt : 20181012
<SEC-HEADER>0001144204-18-053648.hdr.sgml : 20181012
<ACCEPTANCE-DATETIME>20181012160148
ACCESSION NUMBER:		0001144204-18-053648
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20181012
DATE AS OF CHANGE:		20181012

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-227400
		FILM NUMBER:		181120252

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>tv504501_424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Filed pursuant
to Rule <FONT STYLE="text-transform: uppercase">424(</FONT>b<FONT STYLE="text-transform: uppercase">)(4)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="text-transform: uppercase"><B>R</B></FONT><B>egistration
No. 333-227400</B></P>




<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><B>PROSPECTUS</B></TD>
    <TD STYLE="width: 34%; text-align: center"></TD>
    <TD STYLE="width: 33%; text-align: right"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2,520,000 Class A Units Consisting of
Shares of Common Stock and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>15,723 Class B Units
Consisting of Series B Convertible Preferred Stock and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>13,672,173 Shares of Common Stock Underlying
the Series B Convertible Preferred Stock and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>13,672,173 Shares of Common Stock Underlying
the Warrants</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering 2,520,000 Class A Units,
each Class A Unit consisting of one share of our common stock and one warrant to purchase one share of our common stock at a price
of 120% of the public offering price of the Class A Units. Each warrant will be exercisable upon issuance and will expire five
years from date of issuance. The shares of common stock and warrants that are part of a Class A Unit are immediately separable
and will be issued separately in this offering. We are also offering the shares of common stock issuable upon exercise of warrants
sold in Class A Units.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also offering to each purchaser
whose purchase of Class A Units in this offering would otherwise result in the purchaser, together with its affiliates and certain
related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock
immediately following the consummation of this offering, the opportunity in lieu of purchasing Class A Units, to purchase Class
B Units. Each Class B Unit will consist of one share of Series B Convertible Preferred Stock, or the Series B Preferred, with
a stated value of $1,000 and convertible into shares of our common stock at the public offering price of the Class A Units, together
with the equivalent number of warrants as would have been issued to such purchaser of Class B Units if they had purchased Class
A Units based on the public offering price. The Series B Preferred do not generally have any voting rights unless and until converted
into shares of common stock. The shares of Series B Preferred and warrants that are part of a Class B Unit are immediately separable
and will be issued separately in this offering<FONT STYLE="font-size: 10pt">.</FONT> The number of shares of our common stock
outstanding after this offering will fluctuate depending on how many Class B Units are sold in this offering and whether and to
what extent holders of Series B Preferred shares convert their shares to common stock. We are also offering the shares of common
stock issuable upon exercise of warrants sold in Class B Units and upon conversion of the Series B Preferred. For each Class B
Unit we sell, the number of Class A Units we are offering will be decreased on a dollar-for-dollar basis. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we will issue a common stock purchase warrant as part of the Class A Unit or Class B unit, the number of warrants sold in this
offering will not change as a result of the change in the mix of Class A Units and Class B Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the NYSE
American under the symbol &ldquo;SYN&rdquo;. On October 10, 2018, the last reported sale price of our common stock on the NYSE
American was $1.46 per share. The public offering price of the Class A Units was determined between us, the underwriters and
investors based on market conditions at the time of pricing, and was at a discount to the market price of our common
stock.  The
public offering price of the Class B Units will be $1,000 per unit. There is no established trading market for the warrants or
the Series B Preferred and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the
warrants or the Series B Preferred on any national securities exchange or other trading market. Without an active trading market,
the liquidity of the warrants and the Series B Preferred will be limited.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves
risk. See &ldquo;Risk Factors&rdquo; beginning on page 15 of this prospectus for a discussion of information that should be considered
in connection with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Class A Unit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Class B Unit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 52%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">1.15&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">1,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">18,621,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.0805&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,303,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.0695&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">930&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,318, 000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-size: 10pt">We have also agreed to reimburse the underwriters
    for certain expenses incurred in connection with this offering.&nbsp;&nbsp;See &ldquo;Underwriting&rdquo; beginning on page
    47 of this prospectus for a description of the compensation payable to the underwriters.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted a 45-day option to the
representative of the underwriters to purchase up to 2,428,825 additional shares of common stock and/or additional warrants to
purchase up to 2,428,825 additional shares of common stock, approximately 15% of the common stock, warrants and/or common stock
issuable upon conversion of the Series B Preferred included in the Class B Units sold in the offering, solely to cover over-allotments,
if any.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that delivery of the securities
offered hereby against payment will be made on or about&nbsp; October 15, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="text-transform: uppercase"><B>A.G.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is&nbsp;October
10, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_001">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_001">3</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_002">THE OFFERING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_002">12</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003">RISK FACTORS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_003">15</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_004">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_004">35</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005">USE OF PROCEEDS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_005">36</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_006">CAPITALIZATION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_006">37</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007">DILUTION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_007">38</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_008">MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_008">39</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009">DIVIDEND POLICY</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_009">40</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_010">DESCRIPTION OF OUR SECURITIES</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_010">41</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_011">45</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_012">UNDERWRITING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_012">47</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_013">NOTICE TO INVESTORS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_013">49</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_014">LEGAL MATTERS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_014">50</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_015">EXPERTS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_015">50</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_016">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_016">50</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_017">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_017">50</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in this prospectus and any free writing prospectus that we have authorized for use in connection with this offering.
Neither we nor the underwriters have authorized anyone to provide you with information that is different. We are offering to sell,
and seeking offers to buy, the securities covered hereby only in jurisdictions where offers and sales are permitted. The information
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or
any sale of the securities covered hereby. Our business, financial condition, results of operations and prospects may have changed
since that date. We are not, and the underwriters are not, making an offer of these securities in any jurisdiction where the offer
is not permitted. You should also read and consider the information in the documents to which we have referred you under the caption
 &ldquo;Where You Can Find Additional Information&rdquo; in the prospectus. In addition, this prospectus contains summaries of
certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which
this prospectus is a part, and you may obtain copies of those documents as described below under the heading &ldquo;Where You
Can Find Additional Information.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For investors outside the United States:
Neither we nor any of the underwriters have taken any action that would permit this offering or possession or distribution of
this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating
to, the offering of the securities covered hereby and the distribution of this prospectus outside of the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This prospectus includes statistical
and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by
third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has
been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
We believe that the data obtained from these industry publications and third-party research, surveys and studies are reliable.
We are ultimately responsible for all disclosure included in this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Except where the context requires otherwise,
in this prospectus the &ldquo;Company,&rdquo; &ldquo;Synthetic Biologics,&rdquo; &ldquo;Synthetic,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo;
and &ldquo;our&rdquo; refer to Synthetic Biologics, Inc., a Nevada corporation, and, where appropriate, its wholly owned subsidiaries.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; text-align: justify"><I>This summary highlights
information contained in other parts of this prospectus or incorporated by reference into this prospectus from our filings with
the Securities and Exchange Commission, or SEC, listed in the section of the prospectus entitled &ldquo;Incorporation of Certain
Documents by Reference.&rdquo; Because it is only a summary, it does not contain all of the information that you should consider
before purchasing our securities in this offering and it is qualified in its entirety by, and should be read in conjunction with,
the more detailed information appearing elsewhere or incorporated by reference into this prospectus. You should read the entire
prospectus, the registration statement of which this prospectus is a part, and the information incorporated by reference herein
in their entirety, including the &ldquo;Risk Factors&rdquo; and our financial statements and the related notes incorporated by
reference into this prospectus, before purchasing our securities in this offering. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a late-stage clinical company focused
on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. Our lead candidates
poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects
of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of <I>C. difficile</I> infection (CDI), overgrowth
of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact
of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation
(IBS-C). Our preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both
local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis, and novel
discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="img03.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&sup1;Designed to degrade excess antibiotic excreted into the
GI tract before the antibiotic reaches the colon and causes dysbiosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&sup2;For use in patients who can&rsquo;t swallow the capsule
or its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&sup3;Designed to degrade non-absorbed
antibiotic remaining in the GI tract before the antibiotic reaches the colon and causes dysbiosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">C - License and collaboration with Cedars-Sinai Medical Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M - Scientific collaboration with Massachusetts General Hospital&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Development of nasogastric tube (NG) dosing is based on guidance
and recommendations by physicians, surgeons, KOLs, our expert steering committee and the U.S. Food and Drug Administration (FDA).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary of Clinical and Preclinical Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 22%; border-bottom: black 1pt solid; text-align: center"><B>Therapeutic Area</B></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 16%; border-bottom: black 1pt solid; text-align: center"><B>Product</B><BR>
    <B>Candidate</B></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 60%; border-bottom: black 1pt solid; text-align: center"><B>Status</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade
    IV beta-lactam antibiotics)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">SYN-004 (ribaxamase)<BR>
    (oral enzyme)</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive Phase 1a/1b data (1Q 2015)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Reported supportive topline data from two Phase 2a clinical trials (4Q 2015 &amp; 2Q 2016)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Initiated Phase 2b proof-of-concept clinical trial (3Q 2015)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Received
        USAN approval of the generic name &ldquo;ribaxamase&rdquo; for SYN-004 (July 2016)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;Completed Enrollment of Phase 2b proof-of-concept clinical trial (3Q 2016)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Awarded contract by the CDC (4Q 2016)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announced
        positive topline data from Phase 2b proof-of-concept clinical trial, including achievement of primary endpoint of significantly
        reducing CDI (1Q 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announced
        additional results from Phase 2b proof-of-concept clinical trial demonstrating SYN-004 (ribaxamase) protected and maintained
        the naturally occurring composition of gut microbes from antibiotic-mediated dysbiosis in treated patients (2Q 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announced
        additional results from Phase 2b proof-of-concept clinical trial funded by a contract awarded by the CDC, demonstrating
        that SYN-004 (ribaxamase) prevented significant change to the presence of certain AMR genes in the gut resistome of patients
        receiving SYN-004 compared to placebo (3Q 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Presented
        additional supportive results regarding several exploratory endpoints from Phase 2b proof-of-concept clinical trial designed
        to evaluate SYN-004&rsquo;s (ribaxamase) ability to protect the gut microbiome from opportunistic bacterial infections
        and prevent the emergence of antimicrobial resistance (AMR) in the gut microbiome (4Q 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;Reached preliminary agreement with the FDA on key elements of a proposed Phase 3 clinical trial program,
        including de-coupled co-primary endpoints designed to evaluate efficacy separate from safety in a patient population being
        treated with a representative selection of IV-beta-lactam antibiotics (1H 2018)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End
        of Phase 2 meeting with FDA held to solidify remaining elements of planned Phase 3 clinical trial (3Q 2018)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expect
        results from End of Phase 2 meeting with FDA (4Q 2018)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clarified
        market/partner needs and identified potential additional indications for SYN-004 in specialty patient populations such
        as allogenic hematopoietic cell transplant recipients</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Plan to initiate clinical trial(s) (2H 2019) which may include a broad Phase 3 clinical trial
        and/or Phase 1/2 clinical trial(s) in a specialty population leading to a subsequent Phase 3 clinical trial</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: center">Treatment of IBS-C</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center">SYN-010<BR>
    (oral modified-release<BR>
    lovastatin lactone)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
                           &nbsp;&nbsp;&nbsp;&nbsp;Collaboration with Cedars-Sinai Medical Center (&ldquo;CSMC&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Reported supportive topline data from two Phase 2 clinical trials (4Q 2015 &amp; 1Q 2016)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Received
        Type C meeting responses from FDA regarding late-stage aspects of clinical pathway (2Q 2016)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Presented
        detailed data supporting previously reported positive topline data from two Phase 2 clinical trials at DDW (May 2016)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held
                           End of Phase 2 meeting with FDA (July 2016)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confirmed
        key elements of Pivotal Phase 2b/3 clinical trial design pursuant to consultations with FDA (1Q 2017)&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Announced
        issuance of key U.S. composition of matter patent providing important intellectual property protection in the U.S until
        at least 2035 (Q2 2018)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.7pt; text-align: justify; text-indent: -20.7pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entered
        into agreement with CSMC for an investigator-sponsored Phase 2 clinical study of SYN-010 to evaluate SYN-010 dose response
        and inform Phase 3 clinical development (Q3 2018)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anticipate
        dosing first patient in the Phase 2b investigator sponsored clinical study during Q4 2018</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anticipate
        data readout from the Phase 2b investigator sponsored clinical study during 2H 2019</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade
    IV carbapenem antibiotics)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SYN-006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(oral enzyme)</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Identified P2A as a potent carbapenemase that is stable in the GI tract</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Manufactured and formulated research lot for oral delivery (2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;
        &nbsp;&nbsp;&nbsp;Demonstrated microbiome protection in a pig model of ertapenem administration (Q1 2018)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade
    oral beta-lactam antibiotics)&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">SYN-007<BR>
    (oral enzyme)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical
        work ongoing to expand the utility of SYN-004 (ribaxamase) for use with oral beta-lactam antibiotics</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Presented
        supportive data from canine animal model at the Microbiome World Congress, America (Q4 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive data from a second canine animal model demonstrating that when co-administered with oral amoxicillin and oral
        Augmentin, oral SYN-007 did not interfere with systemic absorption of antibiotics but did diminish microbiome damage associated
        with these antibiotics (2Q 2018)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">Preserve gut barrier, treat local GI inflammation, restore gut microbiome</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">SYN-020<BR>
    (oral IAP enzyme)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generated
        high expressing manufacturing cell lines for intestinal alkaline phosphatase (IAP) (1H 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Identified downstream process and tablet formulations (2H 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identified
        three potential clinical indications in areas of unmet medical need including, enterocolitis associated with radiation
        therapy, enterocolitis associated with checkpoint inhibitor therapy for cancer, and microscopic colitis (2H 2018)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Ongoing preclinical efficacy studies</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Anticipated IND filing (Q4 2019)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679; &nbsp;&nbsp;&nbsp;&nbsp;Plan
        to initiate Phase 1 clinical trial (Q1 2020)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">Prevention and treatment of pertussis</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">SYN-005<BR>
    (monoclonal antibody<BR>
    therapies)</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;
        &nbsp;&nbsp;&nbsp;&nbsp;Reported supportive preclinical research findings (2014)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
        University of Texas at Austin (&ldquo;UT Austin&rdquo;) received a grant from the Bill and Melinda Gates Foundation to
        support a preclinical study to evaluate the prophylactic capability of SYN-005 (4Q 2015)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive preclinical data demonstrating hu1B7, a component of SYN-005, provided protection from pertussis for five weeks
        in neonatal non-human primate study (Q2 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported
        supportive preclinical data demonstrating that an extended half-life version of hu1B7, a component of SYN-005, provided
        protection from pertussis for five weeks in a non-human neonatal primate study (Q4 2017)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679; &nbsp;&nbsp;&nbsp;&nbsp;Collaborations
        with Intrexon and UT Austin</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Microbiome-Focused Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our SYN-004 (ribaxamase) and SYN-010 programs
are focused on protecting the healthy function of the gut microbiome, or gut flora, which is composed of billions of microbial
organisms including a natural balance of both &ldquo;good&rdquo; beneficial species and potentially &ldquo;bad&rdquo; pathogenic
species. When the natural balance or normal function of these microbial species is disrupted, a person&rsquo;s health can be compromised.
All of our programs are supported by our growing intellectual property portfolio. We are maintaining and building our patent portfolio
through: filing new patent applications; prosecuting existing applications; and licensing and acquiring new patents and patent
applications. Our plan remains focused on the advancement of our two late-stage clinical programs. We continue to actively manage
resources in preparation for the advancement of our two late-stage microbiome-focused clinical programs, including our pursuit
of opportunities that will allow us to establish the clinical infrastructure and financial resources necessary to successfully
initiate and complete this plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>SYN-004 (ribaxamase)&nbsp;&mdash;&nbsp;Prevention of
C. difficile infections (CDI), overgrowth by pathogenic organisms, and the emergence of antimicrobial resistance (AMR)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-004 (ribaxamase) is a proprietary
oral 75 mg capsule prophylactic therapy designed to degrade certain IV beta-lactam antibiotics excreted into the GI tract and
maintain the natural balance of the gut microbiome to prevent CDI, reduce overgrowth of pathogenic organisms, and suppress the
emergence of antimicrobial-resistant organisms. Published clinical literature has also suggested that preventing microbiome damage
caused by IV beta-lactam antibiotics excreted into the GI tract may have potential therapeutic benefit as a means of preventing
acute graft-vs-host disease in hematopoietic cell transplant patients. SYN-004 (ribaxamase) is a beta-lactamase enzyme intended
to be administered as two-75 mg capsules which, when released in the proximal small intestine, can degrade beta-lactam antibiotics
in the GI tract without altering systemic antibiotic levels. Beta-lactam antibiotics are a mainstay in hospital infection management
and include the commonly used penicillin and cephalosporin classes of antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2012, we acquired a series
of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention of CDI, the leading healthcare-associated
infection that generally occurs secondary to treatment with IV antibiotics from Prev ABR LLC. The acquired assets include a pre-Investigational
New Drug (IND) package for P3A, Phase 1 and Phase 2 clinical data for P1A, manufacturing processes and data, and a portfolio of
issued and pending U.S. and foreign patents intended to support an IND and Biologics License Application (BLA) with the FDA. Utilizing
this portfolio of assets, we developed a proprietary, second generation oral beta-lactamase enzyme product candidate that we now
refer to as SYN-004 or by its generic name &ldquo;ribaxamase&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compared to the first generation oral
enzyme candidate of P1A, we believe that the second generation candidate, SYN-004 (ribaxamase), will have activity against a broader
spectrum of beta-lactam antibiotics, including both penicillins and certain cephalosporins. Due to the structural similarities
between P1A and SYN-004 (ribaxamase), and based on previous discussions with the FDA, certain preclinical data collected on P1A
was used in support of an IND application for SYN-004 (ribaxamase).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, P1A had been evaluated in
four Phase 1 and one Phase 2 clinical trials conducted in Europe. In total, 112 patients and 143 healthy volunteers participated
in these studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>C. difficile</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. <I>difficile</I> is the leading type
of hospital acquired infection and is frequently associated with IV beta-lactam antibiotic treatment. According to a paper published
in BMC Infectious Diseases (Desai K et al. BMC Infect Dis. 2016; 16: 303) the economic cost of CDI was approximately $5.4 billion
in 2016 ($4.7 billion in healthcare settings; $725 million in the community) in the U.S., mostly due to hospitalizations. CDI
is a rising global hospital acquired infection (HAI) problem in which the toxins produced by <I>C. difficile</I> bacteria result
in <I>C. difficile</I> associated diarrhea (CDAD), and in the most serious cases, pseudomembranous colitis (severe inflammation
of the lower GI tract) that can lead to death. The CDC identified <I>C. difficile</I> as an &ldquo;urgent public health threat,&rdquo;
particularly given its resistance to many drugs used to treat other infections. CDI is a major unintended risk associated with
the prophylactic or therapeutic use of IV antibiotics, which may alter the natural balance of microflora that normally protect
the GI tract, leading to <I>C. difficile</I> overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged
length of stay (estimated at 7 days), underlying illness, and immune-compromising conditions including the administration of chemotherapy
and advanced age. In addition, approximately 20% of patients who have been diagnosed with CDI experience a recurrence of CDI within
one to three months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Limitations of Current Treatments and
Market Opportunity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CDI is a widespread and often drug resistant
infectious disease. According to an article published in the New England Journal of Medicine (Leffler DA et al. N Engl J Med 2015;
372:1539-1548), it is estimated that 453,000 patients are infected with <I>C. difficile</I> annually in the U.S., and it has been
reported that approximately 29,000 patients die due to CDI-associated complications each year. Controlling the spread of CDI has
proven challenging, as the <I>C. difficile</I> spores are easily transferred to patients via normal contact with healthcare personnel
and with inanimate objects. There is currently no vaccine or approved product for the prevention of primary (incident) CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to IMS Health Incorporated,*
in 2016, 227 million doses of SYN-004 (ribaxamase)-addressable intravenous Penicillin and Cephalosporin antibiotics were administered
in the United States which may contribute to the onset of CDI. Additional data derived from IMS Health Incorporated states that
in 2016, the worldwide market for SYN-004 (ribaxamase)-addressable intravenous beta-lactam antibiotics was approximately 7.5 billion
doses, which may represent a multi-billion dollar opportunity for us.&nbsp;According to the CDC report <I>Antibiotic Resistance
Threats in the United States, 2013</I>, at least 2 million people in the U.S. each year acquire serious infections with bacteria
that are resistant to one or more of the antibiotics designed to treat those infections, which results in an estimated $20 billion
in excess direct healthcare costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This information is an estimate derived from the use of information
    under license from the following IMS Health Incorporated information service: IMS Health Analytics for the full year 2016.
    IMS expressly reserves all rights, including rights of copying, distribution, and republication.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Update</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 23, 2018, we announced that we
had reached preliminary agreement with the FDA on key elements of a proposed clinical trial program for our planned Phase 3 clinical
trial for ribaxamase. In accordance with recommendations and guidance received from the FDA, we expect the Phase 3 trial to evaluate
the efficacy and safety of ribaxamase as separate, co-primary endpoints in a patient population being treated with a representative
selection of intravenous (IV) beta-lactam antibiotics, which will include ceftriaxone and piperacillin/tazobactam. The inclusion
of more than one beta-lactam antibiotic in this trial is intended to evaluate the potential utility of ribaxamase for co-administration
with a greater number of cephalosporin and penicillin beta-lactam antibiotics. The proposed Phase 3 clinical trial discussed with
the FDA will comprise a global, event-driven clinical trial with a fixed maximum number of patients and will seek to evaluate
the efficacy and safety of ribaxamase in a broader patient population by enrolling patients with a variety of underlying infections.
We expect the primary efficacy endpoint of the proposed Phase 3 trial will be the reduction in the incidence of CDI in the ribaxamase
treatment group compared to placebo. We have also reached preliminary agreement with the FDA to evaluate mortality risk as the
primary safety endpoint for this trial, which will be separate from the primary efficacy endpoint of reduction of the incidence
of CDI. The designation of efficacy and safety as separate and decoupled endpoints is critical for clinical studies of this nature,
where the underlying population is projected to have a comparatively high incidence of safety events that may significantly dilute
the smaller number of CDI events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to continue collaborative discussions
with the FDA to solidify the remaining details of the proposed Phase 3 clinical trial program during an anticipated End of Phase
2 meeting with the FDA in the third quarter of 2018. In parallel with clinical and regulatory efforts, we have recently completed
a Health Economics Outcomes Research study, which was conducted to generate key insights on how we can expect Health Care Practitioners,
or HCPs, to evaluate patient access for ribaxamase while also providing a framework for potential reimbursement strategies. After
evaluating findings from the study, and after extensive discussions with pharmaceutical companies, physicians, research institutions
and clinical development groups worldwide, we believe that there is significant potential value in exploring the development of
SYN-004 (ribaxamase) in a more narrow patient population where the incidence of the disease endpoint is high and the clinical
development may be less costly. One potential narrow patient population for SYN-004 could be allogenic hematopoietic cell transplant
(HCT) recipients, who have a very high risk of CDI, VRE colonization and potentially fatal bacteremia, and acute-graft-vs-host
disease. Published literature has demonstrated a strong association between these adverse outcomes and microbiome damage caused
by IV beta-lactam antibiotics in these patients. Further examination and discussions with key opinion leaders (KOLs) who are experts
in allogenic HCT are ongoing to evaluate a potential clinical development pathway forward for SYN-004 in such a narrow, specialty
patient population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contingent on potential interest from
prospective partners and/or appropriate funding, we anticipate initiating the Phase 3 clinical trial currently under discussion
with the FDA in 2H 2019 which will evaluate SYN-004 (ribaxamase) effects on CDI in a broad and diverse patient population. In
parallel, discussions with KOLs are ongoing to determine if further investigation in the form of a potential Phase 1 and/or Phase
2 clinical trial(s) evaluating SYN-004 (ribaxamase) in a specialized patient population such as allogenic HCT patients may also
and/or alternatively be pursued in 2H 2019. If it is determined that the clinical advancement of SYN-004 is more favorable and
significantly less costly in a specialized patient population, we may elect to prioritize and pursue this strategy in advance
of pursuing the broader, Phase 3 clinical program currently under discussion with the FDA. If approved by the FDA, SYN-004 (ribaxamase)
would be the first available drug designed to prevent primary Clostridium difficile infection by protecting the gut microbiome
from antibiotic-mediated dysbiosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>SYN-010&nbsp;&mdash;&nbsp;Treatment of Irritable Bowel
Syndrome with Constipation (IBS-C)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-010 is our proprietary, modified-release
formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (<I>M. smithii</I>)
in the gut while minimizing disruption to the microbiome. Methane produced by <I>M. smithii</I> is an underlying cause of pain,
bloating and constipation associated with IBS-C, and published reports have associated higher intestinal methane production with
increased constipation severity in IBS-C patients. SYN-010 is intended to act primarily in the intestinal lumen while avoiding
systemic absorption, thereby targeting the major cause of IBS-C, not just the patient&rsquo;s symptoms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2013, through our subsidiary
Synthetic Biomics, Inc. (SYN Biomics), we entered into a worldwide exclusive license agreement with Cedars-Sinai Medical Center
(CSMC) and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases,
including the development of SYN-010 to target IBS-C. We licensed from CSMC a portfolio of intellectual property comprised of
several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes.
An investigational team, led by Mark Pimentel, M.D. at CSMC, discovered that these products may reduce the production of methane
gas by certain GI microorganisms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe SYN-010 may reduce the impact
of methane producing organisms on IBS-C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Irritable Bowel Syndrome</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IBS is a functional GI disorder characterized
by gas, abdominal pain, bloating and diarrhea or constipation, or alternating episodes of both. The illness affects both men and
women; however, two-thirds of diagnosed sufferers are women. The onset of IBS can begin anytime from adolescence to adulthood.
Four bowel patterns may be seen with IBS including: IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (mixed
diarrhea and constipation) and IBS-U (unsubtyped). According to GlobalData&rsquo;s IBS &mdash;&nbsp;Global Drug Forecast and Market
Analysis to 2023 (December 2014&nbsp;), the prevalence of IBS in adults in the United States, Europe and Japan was expected to
be 41.1 million in 2016, and it has been reported that up to 20 percent of all IBS patients have IBS-C. Extensive studies conducted
by Dr. Pimentel and collaborators have shown that overproduction of methane gas is directly associated with bloating, pain and
constipation in IBS-C patients. Investigators at CSMC have discovered that inhibiting intestinal methane production may reverse
constipation associated with IBS-C, and may be beneficial in treating other major diseases such as obesity, insulin resistance
and type 2 diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Limitations of Current Treatments and
Market Opportunity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, the FDA approved therapies
for the treatment of IBS-C include prescription and over-the-counter laxatives, which provide patients with temporary symptomatic
relief and often cause diarrhea, but are not designed to and do not treat the underlying cause of pain, bloating and constipation
associated with IBS-C. Additionally, these same therapies may come with undesirable safety side-effect profiles, the most common
of which is diarrhea. As a result, these therapies have struggled to find adoption in several key markets, including Europe. We
believe this presents an important opportunity for SYN-010. Towards the end of 2017, we engaged outside consultants to evaluate
the potential regulatory pathway towards EMA marketing approval. According to IMS Health Analytics, U.S. sales in 2016 for IBS-C
and Chronic Idiopathic Constipation (CIC) therapeutics as well as OTC laxatives/products were approximately $2.5 billion, representing
a constant annual growth rate (CAGR) of 19% from 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Update </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 5, 2018, we entered into
an agreement with CSMC for an investigator-sponsored Phase 2 clinical study of SYN-010 to be co-funded by us and CSMC (the &ldquo;Study&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Study will provide further evaluation
of the efficacy and safety of SYN-010, our modified-release reformulation of lovastatin lactone, which is exclusively licensed
to us by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<I>M. smithii) </I>in the gut to treat
an underlying cause of irritable bowel syndrome with constipation (IBS-C). The data from this study will provide additional insights
into potential SYN-010 clinical efficacy, including dose response and microbiome effects, ideally solidifying existing clinical
outcomes data, and potentially simplifying Phase 3 clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Study will be conducted out of the
Pimentel Laboratory at CSMC and is expected to be a 12-week, placebo-controlled, double-blind, randomized clinical trial to evaluate
two dose strengths of oral SYN-010 (21 mg and 42 mg) in approximately 150 patients diagnosed with IBS-C. The investigator-sponsored
Study will be led by the gastrointestinal microbiota researcher Ruchi Mathur, M.D., director of Metabolism, Clinical Research
and Administrative Operations at the Medically Associated Science and Technology (MAST) Program at CSMC. The Study is expected
to begin enrollment during the fourth quarter of 2018, contingent upon approval of the clinical study protocol by the CSMC Institutional
Review Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary objective for the Study will
be to determine the efficacy of SYN-010, measured as an improvement from baseline in the weekly average number of complete spontaneous
bowel movements (CSBMs) during the 12-week treatment period for SYN-010 21 mg and 42 mg daily doses relative to placebo. Secondary
efficacy endpoints for both dose strengths of SYN-010 are expected to measure changes from baseline in abdominal pain, bloating,
stool frequency as well as the use of rescue medication relative to placebo. Exploratory outcomes include Adequate Relief and
quality of life measures using the well-validated EQ-5D-5L and PAC-SYM patient questionnaires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that CSMC will dose the first
patient in the investigator-sponsored Phase 2b clinical study in Q4 2018. A data readout from this clinical trial study is anticipated
in 2H 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Allowance of Key U.S. Patent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2018, the United States Patent
and Trademark Office (USPTO) issued U.S. Patent No. 9,956,292 which includes claims related to composition of matter for the use
of anti-methanogenic compositions to treat IBS-C. The patent will provide key intellectual property protection in the U.S. for
SYN-010 and will expire no later than 2035.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Infectious disease outbreaks are increasing
while intervention options are declining due to widespread multidrug-resistant bacteria, increasing numbers of immuno-compromised
patients (e.g., the elderly and cancer patients) and the isolation of new pathogens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>SYN-007&nbsp;&mdash;&nbsp;Prevention
of CDI, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-007 is a specially formulated version
of SYN-004 (ribaxamase) designed to degrade orally administered beta-lactam antibiotics to protect the gut microbiome from antibiotic-mediated
dysbiosis. SYN-007 is formulated for release in the distal small intestine to allow systemic absorption of the oral antibiotic
while still providing protection upstream of the colon and to the gut microbiome. SYN-007 is designed for patients who have been
administered SYN-004 (ribaxamase) in combination with intravenous beta-lactam antibiotics and who are then transferred to an oral
beta-lactam antibiotic, thereby extending gut microbiome protection from antibiotic-mediated dysbiosis. Data from a recent canine
study completed during the second half of 2017 demonstrated that, when co-administered with oral amoxicillin, oral SYN-007 did
not interfere with amoxicillin absorption and did demonstrate protection of the gut microbiome. The data from this canine study
were presented during recent microbiome conferences in Q4 2017 and Q1 2018. A second canine study was completed during Q2 2018
in which oral SYN-007 was co-administered with oral amoxicillin and oral Augmentin. Again, SYN-007 did not interfere with systemic
absorption of the antibiotics but did diminish the microbiome damage associated with these antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>SYN-006&nbsp;&mdash;&nbsp;Prevention
of CDI, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second pipeline product, termed SYN-006,
has the potential to further expand the utility of our SYN-004 (ribaxamase) program to a broader spectrum of IV beta-lactam antibiotics
in the GI tract to include carbapenem antibiotics. Carbapenems are broad-spectrum beta-lactam antibiotics that have been shown
to significantly damage the gut microbiome, incur a high risk for <I>C. difficile</I> infection, and enable GI overgrowth with
multidrug resistant organisms. Carbapenems are frequently a last line of defense antibiotic, therefore the emergence and spread
of carbapenem resistance presents an urgent threat. SYN-006 is a carbapenemase designed to degrade intravenous (IV) carbapenem
antibiotics within the GI tract to maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of
pathogenic organisms and the emergence of antimicrobial resistance (AMR). It is anticipated that, by protecting the gut microbiome
from exposure to carbapenem antibiotics, SYN-006 may potentially diminish the spread of such resistance. At the ID Week 2017 conference,
we presented a poster demonstrating SYN-006&rsquo;s broad activity against four carbapenem antibiotics as well as efficacy in
a canine model. The poster also showed data from a porcine model indicating that the carbapenem, ertapenem, potently damaged gut
microbiomes and mediated expansion of antibiotic resistance genes in the GI tract. More recently, we successfully formulated SYN-006
for oral delivery and evaluated it in a porcine efficacy model in conjunction with IV ertapenem. The data, presented at a clinical
conference during the first quarter of 2018, demonstrated that SYN-006 did not interfere with serum levels of ertapenem and did
diminish antibiotic-mediated dysbiosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>SYN-005&nbsp;&mdash;&nbsp;Pertussis
(Whooping Cough)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SYN-005 program is developing monoclonal
antibodies both as a prophylaxis and a treatment for pertussis. <I>Bordetella pertussis (B. pertussis)</I> is a gram-negative
bacterium that infects the upper respiratory tract, causing uncontrollable and violent coughing. Antibiotic treatment does not
have a major effect on the course of pertussis. While such treatment can eliminate the <I>B. pertussis</I> bacteria from the respiratory
tract, it does not neutralize the pertussis toxin. Infants with pertussis often require hospitalization in pediatric intensive
care units, frequently requiring mechanical ventilation. The incidence of pertussis is increasing due to the declining effectiveness
of the acellular vaccine introduced in the 1990s, exposure of unvaccinated and under-vaccinated individuals including infants
who are not yet fully vaccinated and exposure of individuals whose immunity has diminished over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">According to the Centers
for Disease Control and Prevention (CDC) , there were 24.1 million cases of whooping cough worldwide in 2014, and it is estimated
that <I>B. pertussis </I>infection caused up to 167,700 deaths in children younger than 5 years in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Intrexon Collaboration and The University
of Texas at Austin Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2012, we entered into a worldwide
exclusive channel collaboration with Intrexon develop monoclonal antibody (mAb) therapies for the treatment of certain infectious
diseases not adequately addressed by existing therapies. In December 2012, we initiated mAb development for the prevention and
treatment of pertussis focusing on toxin neutralization. Unlike antibiotics, we are developing a mAb therapy to target and neutralize
the pertussis toxin as a prophylaxis for high-risk newborns and in order to shorten the course, diminish the long-term complications,
and reduce the mortality rate in infected infants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To further the development of this potential
therapy for pertussis, we entered into an agreement with UT Austin to license the rights to certain research and pending patents
related to pertussis antibodies. These research efforts are being conducted at the Cockrell School of Engineering in the laboratory
of Associate Professor, Jennifer A. Maynard, Ph.D., the Laurence E. McMakin, Jr. Centennial Faculty Fellow in the McKetta Department
of Chemical Engineering. Dr. Maynard brings to the project her expertise in defining the key neutralizing epitopes of pertussis
toxin to optimize the potential efficacy of antibody therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Preclinical Development</I> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Working with our collaborator, Intrexon,
and our academic collaborator, UT Austin, we have established a humanized mAb product candidate, SYN-005, designed to neutralize
pertussis toxin, a major cause of pertussis-mediated infant morbidity and mortality. The two humanized mAbs, hu1B7 and hu11E6,
bound tightly to the toxin and potently neutralized the toxin. In addition, the antibodies, individually or in combination, were
highly efficacious in a murine model of pertussis in which they completely mitigated elevations of the white blood cell count
that is characteristic of the illness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2014, and again in September
2014, we received positive preclinical research findings of SYN-005 for the treatment of pertussis in three non-human primate
studies (n = 19). In the latter two pertussis studies in particular, SYN-005 rapidly stopped the rise in white blood cell count
that is characteristic of the disease and accelerated its return to baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2014, we received U.S. Orphan
Drug Designation from the FDA for SYN-005 for the treatment of pertussis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2015, the Bill &amp; Melinda
Gates Foundation awarded a grant to UT Austin to generate preclinical proof-of-concept data in the neonatal non-human primate
model to test the hypothesis that antibody administration at birth may have a role in the prevention of pertussis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In&nbsp;December 2015, the non-human primate
prophylaxis study was initiated by UT Austin to determine if administration of hu1B7, one component of SYN-005, at two days of
age could protect animals from a subsequent pertussis infection. On April 19, 2017, we announced supportive preclinical data demonstrating
hu1B7 provided five weeks of protection from pertussis in neonatal non-human primates. Control animals (n=6), infected with <I>Bordetella
pertussis (B. pertussis)</I> at five weeks of age, demonstrated marked elevations in white blood cell counts and most exhibited
behavioral signs of pertussis, including coughing and diminished activity. In contrast, the experimental animals (n=7), who were
treated with hu1B7 at two days of age and then infected five weeks later, had significantly lower peak white blood cell counts
(p=0.004) that remained within the normal range or were only slightly elevated. Importantly, all seven of the animals that received
prophylactic hu1B7 appeared healthy and none exhibited any behavioral signs of pertussis. Building on this early success, we performed
preclinical testing of a modified version of hu1B7 that has the potential to extend the plasma half-life. The modified hu1B7 achieved
higher plasma levels at five weeks than the parental hu1B7 antibody and was efficacious in preventing clinical pertussis. The
extended half-life antibody has the potential to substantially reduce the required dose and cost for prophylaxis for application
in the Developing World. This current study expands the potential clinical utility beyond treatment to also include prophylaxis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>SYN-020&nbsp;&mdash;&nbsp;Oral Intestinal Alkaline Phosphatase</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-020 is in the preclinical development
stage. SYN-020 is being developed as a modified-release oral dosage form of intestinal alkaline phosphatase (IAP). IAP is an endogenous
enzyme expressed in the upper GI tract that functions as a broadly acting phosphatase that generally serves to maintain GI homeostasis
and promote commensal microbiota. In animal models, IAP is anti-inflammatory, tightens the gut barrier to diminish &ldquo;leaky
gut,&rdquo; and accelerates gut microbiome recovery from antibiotic-mediated dysbiosis. Published reports have demonstrated efficacy
for several indications with oral IAP in many animal models including colitis, antibiotic-mediated dysbiosis, and metabolic syndrome
as well as in a pilot human clinical trial with ulcerative colitis patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Limitations of Current Treatments and
Clinical Update</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite its therapeutic potential, clinical
application of an oral IAP product has been hindered by inefficient manufacturing with a high cost of goods. We have established
manufacturing processes with the potential to yield product with a cost of goods which we believe to be suitable for commercialization.
Recent advances include cell lines that express up to 3 grams/L along with a chromatographic downstream process and potential
tablet formulations. We are currently optimizing these technologies and pursuing animal efficacy studies. During Q2 2018, we completed
several preclinical animal studies that support the clinical utility of SYN-020 for multiple gastrointestinal disorders. We are
currently evaluating and establishing strategies to advance IAP to and through clinical trials for several novel indications,
including enterocolitis associated with radiation therapy for cancer and checkpoint inhibitor therapy for cancer and microscopic
colitis, all of which have unmet medical needs and span a range of market sizes. Importantly, we believe that with a small capital
commitment, we can begin moving SYN-020 towards an IND. We are targeting filing an IND during Q4 2019 and commencing a Phase 1
clinical trial during Q1 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>SYN-200&nbsp;&mdash;&nbsp;Treatment
of Phenylketonuria (PKU)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PKU is a genetic disease that begins at
birth characterized by a deficiency in the liver enzyme that breaks down the essential amino acid phenylalanine (Phe), a building
block of proteins normally obtained through the foods we eat. As a result, Phe accumulates in the body, becoming toxic and leading
to serious health consequences, including profound mental retardation, brain damage, mental illness, behavioral problems, seizures,
tremors, limited cognitive ability and hyperactivity. If left untreated, the most severe form of PKU leads to permanent cognitive
damage. PKU affects more than 14,000 people in the U.S. and 50,000 people in developed nations globally. There is no existing
cure for PKU, requiring patients to maintain a life-long treatment program and a carefully controlled diet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Intrexon Collaboration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2015, we initiated the SYN-200
discovery program for development and commercialization of novel biotherapeutics for the treatment of patients with PKU pursuant
to an exclusive channel collaboration with Intrexon. We intend to utilize Intrexon&rsquo;s&nbsp;ActoBiotics platform to provide
a proprietary method of delivering therapeutic protein to the GI tract through food-grade microbes. This program is in the discovery
stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our predecessor, Sheffield Pharmaceuticals,
Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware corporation
formed in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed our name
to Adeona Pharmaceuticals, Inc. On October 15, 2009, we engaged in a merger with a wholly owned subsidiary for the purpose of
reincorporating in the State of Nevada. After reprioritizing our focus on the emerging area of synthetic biologics and entering
into our first collaboration with Intrexon, we amended our Articles of Incorporation to change our name to Synthetic Biologics,
Inc. on February 15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive offices are located at 9605
Medical Center Drive, Suite 270, Rockville, Maryland 20850. Our telephone number is (301) 417-4364, and our website address is
<I>www.syntheticbiologics.com</I>. The information contained on our website is not part of, and should not be construed as being
incorporated by reference into this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_002"></A><B>The
Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify"><B>Class A Units offered by us</B></TD>
    <TD STYLE="width: 70%; text-align: justify"><P STYLE="margin: 0pt 0">2,520,000 Class A Units. Each Class A Unit will consist of one share of our common stock and a warrant
to purchase one share of our common stock at an exercise price equal to 120% of the public offering price of the Class A Unit,
or $1.38 per share. The Class A Units will not be certificated and the shares of common stock and warrant that are part of such
unit will be immediately separable and will be issued separately in this offering. Assuming no exercise of the over-allotment option
and we sell 2,520,000 Class A Units (and 15,723 Class B Units)  at the public offering price of $1.15
per Class A Unit and $1,000 per Class B Unit, we would issue in this offering an aggregate of 2,520,000 shares of our common stock
and warrants to purchase 16,192,173 shares of our common stock. The actual offering price per each Class A Unit was negotiated
between us and the underwriters based on the trading of our common stock prior to the offering, among other things, and was
at a discount to the market price. We are also offering the shares of common stock issuable upon exercise of warrants sold
in Class A Units.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0"><B> Public Offering Price</B><BR>
                                    <B>Per Class A Unit</B></P>


</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">$1.15 per Class A Unit.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>Class B Units offered by us </B></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">15,723 Class B Units. We are also offering to each purchaser whose purchase of Class A Units in this offering
would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than
4.99% (or, at the election of the holder, 9.99%) of our outstanding common stock immediately following the consummation of this
offering, the opportunity to purchase, if the purchaser so chooses, Class B Units, in lieu of Class A Units.&nbsp;&nbsp;Each Class
B Unit will consist of one share of our Series B Preferred, with a stated value of $1,000 and convertible into shares of our common
stock, at the public offering price of the Class A Units, together with an equivalent number of warrants as would have been issued
to such purchaser if they had purchased Class A Units based on the public offering price of the Class A Units. The Series B Preferred
do not generally have any voting rights but are convertible into shares of common stock.&nbsp;&nbsp;The Class B Units will not
be certificated and the shares of Series B Preferred and warrants that are part of such unit will be immediately separable and
will be issued separately in this offering.&nbsp;&nbsp;We are also offering the shares of common stock issuable upon exercise of
warrants sold in Class B Units and upon conversion of the Series B Preferred. For each Class B Unit we sell, the number of Class
A Units we are offering will be decreased on a dollar-for-dollar basis. Because we will issue a warrant as part of each Unit, the
number of warrants sold in this offering will not change as a result of a change in the mix of the Units sold.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0"><B>Public Offering Price Per</B><BR>
                                    <B>Class B Unit</B></P>


</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">$1,000 per Class B Unit.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>Warrants offered by us</B></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">Each warrant included in the Units will have an exercise price of 120% of the public offering price of
the Class A Units, or $1.38 per share, will be exercisable upon issuance and will expire five years from the date of issuance.
Each warrant will be exercisable to purchase one share of our common stock.&nbsp;&nbsp;No fractional shares of common stock will
be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will round up to the next whole share.
The warrants also provide that in the event of a fundamental transaction we are required to cause any successor entity to assume
our obligations under the warrants. In addition, the holder of the warrant will be entitled to receive upon exercise of the warrant
the kind and amount of securities, cash or property that the holder would have received had the holder exercised the warrant immediately
prior to such fundamental transaction. This prospectus also relates to the offering of the shares of common stock issuable upon
exercise of the warrants. Subject to certain exceptions, the warrants provide for adjustment of the exercise price, which initially
will be 120% of the public offering price of the Class A Units, or $1.38 per share, if we or any of our subsidiaries, as applicable,
sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase
or other disposition) any shares of our common stock or common stock equivalents, at an effective price per share that is less
than the exercise price then in effect (such lower price, the &ldquo;Base Share Price&rdquo; and such issuances collectively, a
 &ldquo;Dilutive Issuance&rdquo;). In the event a Dilutive Issuance occurs, the exercise price shall be reduced to equal the Base
Share Price.</P>



<P STYLE="margin: 0pt 0"></P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt"><B>Over-allotment option</B></FONT></TD>
    <TD STYLE="width: 70%; text-align: justify"><P STYLE="margin: 0pt 0">We have granted the underwriters a 45-day option to purchase up to&nbsp;2,428,825 additional shares of
common stock at a price of $1.15 per share and/or additional warrants to purchase up to an additional 2,248,825&nbsp;shares
of our common stock from us at a price of $0.01 per warrant, to cover over-allotments, if any, of the shares of common stock, shares
of common stock issuable upon conversion of the Series B Preferred and warrants comprising the Units.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Common stock to be outstanding after the offering</B></FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">23,400,493 shares of our common stock and assumes that all shares of Series B Preferred are converted
to shares of common stock and that none of the warrants are exercised. If the underwriters&rsquo; over-allotment option is exercised
in full, the total number of shares of common stock outstanding immediately after this offering would be&nbsp;25,829,318 assuming
all shares of Series B Preferred sold in this offering convert to common stock and that none of the warrants are exercised. This
prospectus also includes the shares of our common stock issuable upon conversion of the Series B Preferred and exercise of the
warrants.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Series B Convertible Preferred Stock</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Series B Preferred will be convertible into shares of our
    common stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations)
    at any time at the option of the holder, at a conversion price equal to the public offering price of the Class A Units. See
    &ldquo;Description of Securities We Are Offering&mdash; Preferred Stock &mdash; Series B Convertible Preferred Stock&rdquo;
    for a discussion of the terms of the Series B Preferred.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-top: 5pt; padding-bottom: 5pt; text-align: justify"><B>Use of Proceeds</B></TD>
    <TD STYLE="width: 70%; padding-top: 5pt; text-align: justify">We intend to use the net proceeds from the sales of
    securities offered by this prospectus to fund our and our subsidiaries&rsquo; preclinical and clinical programs, (including,
    but not limited to, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide approximately $5.0-$7.0
    million in funding for manufacturing scale-up activities to progress SYN-004 towards a potential Phase 3 clinical trial (broad
    indication) and/or initiate a Phase 1/2 clinical trial(s) in a specialty population, approximately $7.5 million in funding
    for preclinical development and related manufacturing activities for our IND and Phase 1 clinical trial for our SYN-020 program
    and required milestone payments) and for working capital and general corporate purposes, including, to acquire, license or
    invest in complementary businesses, technologies, product candidates or other intellectual property. We have broad discretion
    in determining how the proceeds of this offering will be used, and our discretion is not limited by the aforementioned possible
    uses. Our board of directors believes the flexibility in application of the net proceeds is prudent. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>Risk Factors</B></TD>
    <TD STYLE="text-align: justify">See the section entitled &ldquo;Risk Factors&rdquo; beginning on page 15 of this prospectus
    for a discussion of factors you should carefully consider before deciding to invest in our securities.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>Market symbol and trading</B></TD>
    <TD STYLE="text-align: justify">Our common stock is listed on the NYSE American under the symbol &ldquo;SYN&rdquo;. There
    is no established trading market for the Series B Preferred or warrants and we do not expect a market to develop. In addition,
    we do not intend to apply for the listing of the Series B Preferred or warrants on any national securities exchange or other
    trading market. Without an active trading market, the liquidity of the Series B Preferred and warrants will be limited.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock shown
above to be outstanding after this offering is based on 7,208,320 shares outstanding as of October 10, 2018, and assumes the issuance
and sale of 2,520,000 Class A Units in this offering, 15,723 Class B Units and that all Class B Units convert to an aggregate of
13,672,173 shares of common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we indicate otherwise, all information in this prospectus
is as of October 10, 2018 and:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">reflects
                                         a one-for-thirty-five reverse stock split of our issued and outstanding shares of common
                                         stock, options and warrants effected on August 10, 2018 and the corresponding adjustment
                                         of all common stock prices per share and stock option and warrant exercise prices per
                                         share and preferred stock conversion ratios</FONT> without taking into account fractional
                                         shares which are rounded up to the nearest whole number<FONT STYLE="font-family: Times New Roman, Times, Serif">;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">assumes
                                         no exercise by the <FONT STYLE="font-family: Times New Roman, Times, Serif">underwriters
                                         of their over-allotment option; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">excludes
                                         634,921 shares of our common stock issuable upon conversion of outstanding shares of
                                         preferred stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">excludes&nbsp;347,765
                                         shares of our common stock issuable upon exercise of outstanding options under our equity
                                         incentive plans at a weighted-average exercise price of $54.19 per share;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">excludes
                                         915,854&nbsp;shares of our common stock reserved for issuance upon the exercise of outstanding
                                         warrants with a weighted-average exercise price of $75.16 per share and assumes no exercise
                                         of the warrants issued in this offering;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">assumes all shares of Series B Preferred sold in this offering convert to shares of common stock; and</P>


</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">excludes&nbsp;170,674
                                         shares of our common stock that are reserved for equity awards that may be granted under
                                         our equity incentive plans.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent we sell any Class B Units
in this offering, the same aggregate number of common stock equivalents resulting from this offering would be convertible under
the Series B Preferred issued as part of the Class B Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>An investment in our securities involves
a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other
information contained or incorporated by reference in this prospectus, including our consolidated financial statements and the
related notes, before making a decision to invest in our securities. You should also consider the risks, uncertainties and assumptions
discussed under Item 1A, &ldquo;Risk Factors,&rdquo; in Part I of our Annual Report on Form 10-K for the year ended December 31,
2017 and Item 1A, &ldquo;Risk Factors,&rdquo; in Part II of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018
and any updates or other risks contained in other filings that we may make with the SEC after the date of this prospectus, all
of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports
we file with the SEC in the future and any additional prospectus supplement. If any of these risks actually occur, our business,
results of operations and financial condition could suffer. In that case, the market price of our common stock could decline,
and you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RISKS RELATED TO THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investors will experience immediate
and substantial dilution in the book value per share of the securities purchased in this offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors purchasing securities in this
offering will incur immediate and substantial dilution in net tangible book value per share of our common stock. After giving effect
to the sale of 2,520,000 Class A Units, at the public offering price of $1.15 per Class A Unit, and 15,723 Class B Units, assuming
that all Class B Units are converted into 13,672,173 shares of common stock, and after deducting the estimated underwriting discount
and estimated offering expenses payable by us, purchasers of our Class A units in this offering will incur an increase
of $0.23 per share in the net tangible book value of the common stock they acquire. For a further description of the dilution that
investors in this offering will experience, see &ldquo;Dilution&rdquo;.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that outstanding
stock options or warrants or preferred stock (including the exercise of any warrants) have been or may be exercised or converted
or other shares issued, you may experience further dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management will have broad discretion
over the use of proceeds from this offering and may not use the proceeds effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion
over the use of proceeds from this offering. The net proceeds from this offering will be used to fund our and our subsidiaries&rsquo;
preclinical and clinical programs (including, but not limited to, provide approximately $5.0-$7.0 in funding for manufacturing
scale-up activities to progress SYN-004 towards a potential Phase 3 (broad indication) clinical trial and/or initiate a Phase1/2
clinical trial(s) in a specialty population, approximately $7.5 million in funding for preclinical development and related manufacturing
activities in preparation for our IND and Phase 1 clinical trial for our SYN-020 program and required milestone payments) and
for working capital and general corporate purposes, including, to acquire, license or invest in complementary businesses, technologies,
product candidates or other intellectual property. Our management will have considerable discretion in the application of the
net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being
used appropriately. The net proceeds may be used for corporate purposes that do not improve our operating results or enhance the
value of our common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if this offering is successful,
we will need to raise additional capital in the future to continue operations, which may not be available on acceptable terms,
or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development
efforts or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have had recurring losses from operations,
negative operating cash flow and an accumulated deficit. We do not generate any cash from operations and must raise additional
funds in order to continue operating our business. We expect to continue to fund our operations primarily through equity and debt
financings in the future. Our cash requirements may vary from those now planned depending upon numerous factors, including the
result of future research and development activities. We expect our expenses to increase in connection with our ongoing activities,
particularly as we continue research and development activities and initiate and conduct clinical trials of, and seek marketing
approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect
to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We expect
that our existing cash together with the proceeds from this offering, will be sufficient to meet our anticipated cash requirements
for the next twelve months. We will, however, require additional financing in order to complete our planned Phase 3 clinical trial
for SYN-004 and/or our planned Phase 2b/3 clinical trial for SYN-010. Accordingly, we will need to obtain substantial additional
funding in connection with our continuing operations. There are no other commitments by any person for future financing. Our securities
may be offered to other investors at a price lower than the price per share offered to current stockholders, or upon terms which
may be deemed more favorable than those offered to current stockholders. In addition, the issuance of securities in any future
financing may dilute an investor's equity ownership and have the effect of depressing the market price for our securities. Moreover,
we may issue derivative securities, including options and/or warrants, from time to time, to procure qualified personnel or for
other business reasons. The issuance of any such derivative securities, which is at the discretion of our board of directors,
may further dilute the equity ownership of our stockholders. No assurance can be given as to our ability to procure additional
financing, if required, and on terms deemed favorable to us. To the extent additional capital is required and cannot be raised
successfully, we may then have to limit our then current operations and/or may have to curtail certain, if not all, of our business
objectives and plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no established market for
the Series B Preferred or warrants being offered in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established trading market
for the Series B Preferred or warrants and we do not expect a market to develop. In addition, we do not intend to apply for the
listing of the Series B Preferred or warrants on any national securities exchange or other trading market. Without an active trading
market, the liquidity of the Series B Preferred or warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of Series B Preferred will
have limited voting rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except with respect to certain material
changes in the terms of the Series B Preferred and certain other matters and except as may be required by Nevada law, holders
of Series B Preferred will have no voting rights. Holders of Series B Preferred will have no right to vote for any members of
our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants are speculative and
holders of the warrants will not have rights of common stockholders until such warrants are exercised.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants being offered do not
confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but
rather merely represent the right to acquire shares of common stock at a fixed price for a limited period of time.
Specifically, commencing on the date of issuance, holders of the warrants may exercise their right to acquire the common
stock and pay an exercise price per share equal to 120% of the public offering price, or $1.38 prior to five years from the
date of issuance, after which date any unexercised warrants will expire and have no further value. Moreover, there can also
be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the warrants, and
consequently, whether it will ever be profitable for holders of the warrants to exercise the warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The proceeds received from the exercise
of the warrants issued in this offering on a cash basis could be decreased upon the occurrence of certain events, which could
result in a decrease in our stock price and have a dilutive effect on our existing stockholders. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants being offered do not confer
any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely
represent the right to acquire shares of common stock at a fixed price for a limited period of time. Specifically, commencing on
the date of issuance, holders of the warrants may exercise their right to acquire the common stock and pay an exercise price per
share equal to 120% of the public offering price, or $1.38 per share prior to five years from the date of issuance, after which
date any unexercised warrants will expire and have no further value. Moreover, there can also be no assurance that the market price
of the common stock will ever equal or exceed the exercise price of the warrants, and consequently, whether it will ever be profitable
for holders of the warrants to exercise the warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 44pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to raise additional
capital to operate our business and our failure to obtain funding when needed may force us to delay, reduce or eliminate our development
programs or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2018,
our operating activities used net cash of approximately $10.4 million and as of June 30, 2018 our cash and cash equivalents were
$7.1 million. With the exception of the three months ended June 30, 2010, we have experienced significant losses since inception
and have a significant accumulated deficit. As of June 30, 2018, our accumulated deficit totaled approximately $200.8 million
on a consolidated basis. We expect to incur additional operating losses in the future and therefore expect our cumulative losses
to increase. With the exception of the quarter ended June 30, 2010, and limited laboratory revenues from Adeona Clinical Laboratory,
which we sold in March 2012, we have generated very minimal revenues. We do not expect to derive revenue from any source in the
near future until we or our potential partners successfully commercialize our products. We expect our expenses to increase in
connection with our anticipated activities, particularly as we continue research and development, initiate and conduct clinical
trials, and seek marketing approval for our product candidates. Until such time as we receive approval from the FDA and other
regulatory authorities for our product candidates, we will not be permitted to sell our products and therefore will not have product
revenues from the sale of products. For the foreseeable future we will have to fund all of our operations and capital expenditures
from equity and debt offerings, cash on hand, licensing and collaboration fees and grants, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to raise additional capital
to fund our operations and meet our current timelines and we cannot be certain that funding will be available on acceptable terms
on a timely basis, or at all. Based on our current plans, our cash and cash equivalents together with the proceeds of this offering
will not be sufficient to complete our planned Phase 3 clinical trial for SYN-004 or our planned Phase2b/3 clinical trial for
SYN-010. Any additional sources of financing will likely involve the issuance of our equity or debt securities, which will have
a dilutive effect on our stockholders. To the extent that we raise additional funds by issuing equity securities, our stockholders
may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability
to conduct our business. A failure otherwise to raise additional funds when needed in the future could result in us being unable
to complete planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory
authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego sales and marketing
efforts, and forego licensing in attractive business opportunities. Our ability to raise capital through the sale of securities
may be limited by the rules of the SEC and NYSE American that place limits on the number and dollar amount of securities that
may be sold. There can be no assurances that we will be able to raise the funds needed, especially in light of the fact that our
ability to sell securities registered on our registration statement on Form S-3 will be limited until such time the market value
of our voting securities held by non-affiliates is $75 million or more. We also may be required to seek collaborators for our
product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise
be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We expect to continue to incur significant
operating and capital expenditures.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than with respect to the three months
ended December 31, 2017 and June 30, 2010, we have a history of losses and we have incurred, and will continue to incur, substantial
losses and negative operating cash flow. Even if we succeed in developing and commercializing one or more of our product candidates,
we may still incur substantial losses for the foreseeable future and may not sustain profitability. We expect that our pivotal
Phase 2b/3 and Phase 3 clinical trials will enroll a greater number of patients than our prior clinical trials and will be more
costly than our prior clinical trials. In addition, we anticipate a need for additional employees as we undertake later stage
clinical trials. We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses
will substantially increase in the foreseeable future as we do the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">continue to undertake preclinical development and pivotal clinical trials for
    our product candidates, including SYN-010 and SYN-004 (ribaxamase);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">seek regulatory approvals for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">develop our product candidates for commercialization;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">implement additional internal systems and infrastructure;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">license or acquire additional technologies;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">lease additional or alternative office facilities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">manufacture product for clinical trials; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">hire additional personnel, including members of our management team.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience negative cash flow for
the foreseeable future as we fund our development and clinical programs with capital expenditures. As a result, we will need to
generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or
achieve profitability in the future. Our failure to achieve or maintain profitability could negatively impact the value of our
common stock and underlying securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We currently have no significant
source of revenue and may never generate significant revenue. Currently, we have no products approved for commercial sale.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to generate revenue depends
heavily on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">our ability to raise additional capital on a timely basis to continue to fund
    our clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">demonstration in current and future clinical trials that our lead product candidates,
    SYN-010 for the treatment of IBS-C and SYN-004 (ribaxamase) for the prevention of <I>C. difficile</I>, are safe and effective;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">our ability to seek and obtain regulatory approvals, including with respect to
    the indications we are seeking;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">successful manufacture and commercialization of our product candidates; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">market acceptance of our products.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our existing product candidates
are in various stages of development and will require extensive additional clinical evaluation, regulatory review and approval,
significant marketing efforts and substantial investment before they could provide us with any revenue. As a result, even if we
successfully develop, achieve regulatory approval and commercialize our products, we may be unable to generate revenue for many
years, if at all. We do not anticipate that we will generate revenue from product sales for at least several years, if at all.
If we are unable to generate revenue from product sales, we will not become profitable, and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our consolidated financial statements
have been prepared assuming that we will continue as a going concern.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our consolidated financial statements
as of December&nbsp;31, 2017 have been prepared under the assumption that we will continue as a going concern for the next twelve
months. In addition, our independent registered public accounting firm has issued a report that includes an explanatory paragraph
referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as a going concern
without additional capital becoming available. Our ability to continue as a going concern is dependent upon our ability to obtain
additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate
revenue. Our consolidated financial statements as of December&nbsp;31, 2017 did not include any adjustments that might result
from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our research and development efforts
may not succeed in developing commercially successful products and technologies, which may limit our ability to achieve profitability.
We are largely dependent on the success of our lead product candidates, SYN-004 (ribaxamase) and SYN-010, which require significant
additional clinical testing before we can seek regulatory approval and we cannot be certain that these product candidates will
receive regulatory approval or be successfully commercialized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We must continue to explore opportunities
that may lead to new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources
to research and development. A high rate of failure is inherent in the research and development of new products and technologies.
Any such expenditures that we make will be made without any assurance that our efforts will be successful. Failure can occur at
any point in the process, including after significant funds have been invested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The success of our business currently
depends on our development, approval and commercialization of our lead product candidates, SYN-004 and SYN-010, which are our
only two product candidates for which we have conducted clinical trials. Even though we are pursuing a registration pathway for
each of these product candidates based on specific FDA input, there are many uncertainties known and unknown that may affect the
outcome of future clinical trials. All of our product candidates, including SYN-004 and SYN-010, will require additional clinical
and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient
commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Regardless
of whether our clinical trials are deemed to be successful, promising new product candidates may fail to reach the market or may
only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability
to obtain necessary regulatory approvals or satisfy regulatory criteria, limited scope of approved uses, excessive costs to manufacture,
the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.
Failure to obtain regulatory approvals of SYN-004 or SYN-010 in a timely manner would have a material adverse impact on our business.
Even if we successfully develop SYN-010, SYN-004 or other new products or enhancements, they may be quickly rendered obsolete
by changing customer preferences, changing industry standards, or competitors&rsquo; innovations. Innovations may not be quickly
accepted in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party
reimbursement. We cannot state with certainty when or whether any of our products under development will be launched, whether
we will be able to develop, license, or otherwise acquire drug candidates or products, or whether any products will be commercially
successful. Failure to launch successful new products or new indications for existing products may cause our products to become
obsolete, which may limit our ability to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are actively seeking and may
form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits
of such alliances or licensing arrangements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are actively seeking and may form or
seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties
that we believe will complement or augment our development and commercialization efforts with respect to our product candidates
and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other
charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management
and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process
is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other
alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for
collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety
and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable
to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic
transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering
into new strategic partnership agreements related to our product candidates could delay the development and commercialization
of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to retain rights
licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need
to develop, manufacture, and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our own patent applications,
we also currently rely on licensing agreements with third party patent holders/licensors for our products. We have an exclusive
license agreement with CSMC relating to our IBS-C program. This agreement requires us or our sublicensee to use our best efforts
to commercialize each of the technologies as well as meet certain diligence requirements and timelines in order to keep the license
agreement in effect. In the event we or our sublicensee are not able to meet our diligence requirements, we may not be able to
retain the rights granted under our agreement or renegotiate our arrangement institution on reasonable terms, or at all. If the
license were to terminate and we were to lose the right to commercialize our products, our business opportunity would be adversely
affected. Furthermore, we currently have very limited product development capabilities, and limited marketing or sales capabilities.
For us to research, develop, and test our product candidates, we would need to contract with outside researchers, in most cases
those parties that did the original research and from whom we have licensed the technologies. Our ECC agreements with Intrexon
provide that Intrexon may terminate an agreement if we do not perform certain specified requirements, including developing therapies
considered superior. Our agreement with UT Austin allows the UT Austin to terminate its agreement if we fail to comply with the
terms of the agreement. Our agreement with CSMC allows CSMC to terminate its agreement if we fail to comply with the terms of
the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can give no assurances that any of
our issued patents licensed to us or any of our other patent applications will provide us with significant proprietary protection
or be of commercial benefit to us. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability,
nor does the issuance of a patent provide the patent holder with freedom to operate without infringing the patent rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur additional expenses
in connection with our arrangements with Intrexon, our development of SYN-004, SYN 010 and SYN-020, and our agreement with CSMC.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our ECC agreements with Intrexon,
we are responsible for future research and development expenses of product candidates developed under our collaboration, the effect
of which has and will continue to increase the level of our overall research and development expenses going forward. Our agreements
with CSMC requires that we initiate certain studies and file or have accepted an NDA within a certain amount of time, each of
which are costly and will require additional expenditures. Although all manufacturing, preclinical studies and human clinical
trials are expensive and difficult to design and implement, costs associated with the manufacturing, research and development
of biologic product candidates are generally greater in comparison to small molecule product candidates. We have added additional
personnel to support our ECC agreements with Intrexon, and research and development of our candidates, SYN-004, SYN-010 and SYN-020.
In addition, we have commenced or intend to commence manufacturing of SYN-004, SYN-010 and SYN-020 material to support our planned
preclinical and clinical studies which will require us to incur additional expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our biologic programs are relatively
new, we have only recently assumed development responsibility and costs associated with such programs. In addition, because development
activities in collaboration with Intrexon are determined pursuant to joint steering committees comprised of Intrexon and ourselves
and we have limited product development experience, future development costs associated with these programs may be difficult to
anticipate and exceed our expectations. Our actual cash requirements may vary materially from our current expectations for a number
of other factors that may include, but are not limited to, unanticipated technical challenges, changes in the focus and direction
of our development activities or adjustments necessitated by changes in the competitive landscape in which we operate. If we are
unable to continue to financially support such collaborations due to our own working capital constraints, we may be forced to
delay our activities. If we are unable to obtain additional financing on terms acceptable to us or at all, we may be forced to
seek licensing partners or discontinue development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Developments by competitors may
render our products or technologies obsolete or non-competitive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Companies that currently sell or are developing
proprietary products for the prevention and treatment of <I>C. difficile</I> infection include: Actelion Pharmaceutical Ltd.,
Merck &amp; Co. Inc., Merus B.V., Pfizer Inc., and Sanofi S.A. Companies that currently sell or are developing proprietary products
for IBS-C include: Actavis plc, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., and Takeda Pharmaceutical Company
Limited. Companies that currently sell or are developing proprietary products for pertussis include: GlaxoSmithKline plc, MitsubishiTanabe
Pharma Corporation and Sanofi S.A. Companies that sell or are developing products for the treatment of PKU include: BioMarin Pharmaceutical
Inc., Codexis, Inc. and Synlogic, Inc. Many of our competitors have significant financial and human resources. The infectious
disease market is highly competitive with many generic and proprietary intravenous and oral formulations available to physicians
and their patients. For our monoclonal antibodies, we currently do not expect to be able to deliver our infectious disease candidates
via the oral route and may thus be limited to the in-patient and/or acute treatment setting. In addition, academic research centers
may develop technologies that compete with our SYN-004, SYN-010, SYN-005, SYN-020 products and our other technologies. Should
clinicians or regulatory authorities view alternative therapeutic regiments as more effective than our products, this might delay
or prevent us from obtaining regulatory approval for our products, or it might prevent us from obtaining favorable reimbursement
rates from payers, such as Medicare, Medicaid, hospitals and private insurers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We operate in a highly competitive
environment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries,
including the monoclonal antibody industry, are characterized by rapidly evolving technology and intense competition. Our competitors
include major multi-national pharmaceutical companies and biotechnology companies developing both generic and proprietary therapies
to treat serious diseases. Many of our competitors have drugs that have already been commercialized and therefore benefit from
being first to market their products. Many of these companies are well-established and possess technical, human, research and
development, financial, and sales and marketing resources significantly greater than ours. In addition, many of our potential
competitors have formed strategic collaborations, partnerships and other types of joint ventures with larger, well established
industry competitors that afford these companies potential research and development and commercialization advantages in the therapeutic
areas we are currently pursuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Academic research centers, governmental
agencies and other public and private research organizations are also conducting and financing research activities which may produce
products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent
protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us. These competitors
will compete with us in product sales as well as recruitment and retention of qualified scientific and management personnel, establishment
of clinical trial sites and patient enrollment for clinical trials, as well as in the acquisition of technologies and technology
licenses complementary to our programs or advantageous to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Competitors could develop and/or
gain FDA approval of our product candidates for a different indication.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our competitors may have more
resources than us. We cannot provide any assurances that our products will be FDA approved prior to those of our competitors.
We are subject to the risk that products containing our active ingredients that are already marketed to treat other indications,
or future FDA approved products containing our active ingredients that are marketed to treat other indications, may be prescribed
by physicians, or that physicians may substitute a competitor&rsquo;s products, to treat the diseases for which we are intending
to commercialize; this is commonly referred to as &ldquo;off-label&rdquo; use. While under FDA regulations a competitor is not
allowed to promote off-label uses of its product, the FDA does not regulate the practice of medicine and, as a result, cannot
direct physicians to select certain products for their patients. Consequently, we might be limited in our ability to prevent off-label
use of a competitor&rsquo;s product to treat the diseases we are intending to commercialize, even if we have issued method of
use patents for that indication. If we are not able to obtain and enforce our patents, if any, or otherwise receive orphan drug
protection, a competitor could develop and commercialize similar products for the same indications that we are pursuing. We cannot
provide any assurances that a competitor will not obtain FDA approval for a product that contains the same active ingredients
as our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the parties we depend on for
supplying substance raw materials for our product candidates and certain manufacturing-related services do not timely supply these
products and services in sufficient quality or quantity, it may delay or impair our ability to develop, manufacture and market
our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on suppliers for the substance
raw materials of our product candidates and third parties for manufacturing-related services to produce material that meets appropriate
content, quality and stability standards and use in clinical trials of our products and, after approval, for commercial distribution.
To succeed, clinical trials require adequate supplies of study material, which may be difficult or uneconomical to procure or
manufacture and there can be no assurance that we will successfully procure such study material or even if procured, that we can
do so in quantities and in a timely manner to allow our clinical trials to proceed as planned. We and our suppliers and vendors
may not be able to (i) produce our study material to appropriate standards for use in clinical studies, (ii) perform under any
definitive manufacturing, supply or service agreements with us, or (iii) remain in business for a sufficient time to successfully
produce and market our product candidates. If we do not maintain important manufacturing and service relationships, we may fail
to find a replacement supplier or required vendor or manufacturer which could delay or impair our ability to obtain regulatory
approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers
and vendors, we may not be able to enter into agreements with them on terms and conditions favorable to us and, there could be
a substantial delay before a new facility could be qualified and registered with the FDA and foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third-party manufacturers of the active
pharmaceutical ingredient (API) and drug product for our lead product candidates, SYN-010 and SYN-004, are established cGMP manufacturers.
For all other therapeutic areas we have not yet established cGMP manufacturers for our biologic and drug candidates. We currently
have manufacturers for each of our lead product candidates as well as our SYN-020 program, however, we believe additional manufacturers
are available, if any of our manufacturers were to limit or terminate production or otherwise fail to meet the quality or delivery
requirements needed to satisfy the supply commitments, the process of locating and qualifying alternate sources could require
up to several months, during which time our production could be delayed. Any curtailment in the availability of SYN-004 or SYN-010
could have a material adverse effect on our business, financial position and results of operations. In addition, because regulatory
authorities must generally approve raw material sources for pharmaceutical products, changes in raw material suppliers may result
in production delays or higher raw material costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacture of our product candidates
requires significant expertise and manufacturers may encounter difficulties in production, particularly in scaling up production.
These problems include difficulties with production costs and yields, quality control, including stability of the product and
quality assurance testing, shortages of qualified personnel, as well as compliance with federal, state and foreign regulations.
We may experience longer than expected lead times with respect to the manufacture of SYN-004 (ribaxamase), which may result from
the increase in manufacturing scale necessary to conduct our anticipated Phase 3 clinical trial(s) and result in trial delays.
In addition, any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials,
increase the costs associated with conducting our clinical trials and, depending upon the period of delay, require us to commence
new clinical trials at significant additional expense or to terminate a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are responsible for ensuring that each
of our contract manufacturers comply with the cGMP requirements of the FDA and other regulatory authorities from which we seek
to obtain product approval. While we oversee compliance, we do not have control over our manufacturers and their compliance with
regulatory requirements. These requirements include, among other things, quality control, quality assurance and the maintenance
of records and documentation. The approval process for NDAs includes a review of the manufacturer&rsquo;s compliance with cGMP
requirements. We are responsible for regularly assessing a contract manufacturer&rsquo;s compliance with cGMP requirements through
record reviews and periodic audits and for ensuring that the contract manufacturer takes responsibility and corrective action
for any identified deviations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A failure to comply with these requirements
may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or
recall, or withdrawal of product approval. Furthermore, if our manufacturers fail to deliver the required commercial quantities
on a timely basis and at commercially reasonable prices, we may be unable to meet demand for any approved products and would lose
potential revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to manufacture
our product candidates in commercial quantities, which would prevent us from commercializing our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, our product candidates have been
manufactured in small quantities for preclinical studies and clinical trials. If any of our product candidates is approved by
the FDA or comparable regulatory authorities in other countries for commercial sale, we will need to manufacture such product
candidate in larger quantities. We may not be able to increase successfully the manufacturing capacity for any of our product
candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may require additional validation
studies, which the FDA must review and approve. If we are unable to increase successfully the manufacturing capacity for a product
candidate, the clinical trials as well as the regulatory approval or commercial launch of that product candidate may be delayed
or there may be a shortage in supply. Our product candidates require precise, high quality manufacturing. Our failure to achieve
and maintain these high quality manufacturing standards in collaboration with our third-party manufacturers, including the incidence
of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product
testing or delivery, cost overruns or other problems that could harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not obtain the necessary
regulatory approvals in the U.S. and/or other countries we will not be able to sell our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that we will receive
the approvals necessary to commercialize any of our product candidates or any product candidates we acquire or develop in the
future. We will need FDA approval to commercialize our product candidates in the U.S. and approvals from the FDA-equivalent regulatory
authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. We will be required to conduct
clinical trials that will be costly. We cannot predict whether our clinical trials will demonstrate the safety and efficacy of
our product candidates or if the results of any clinical trials will be sufficient to advance to the next phase of development
or for approval from the FDA. We also cannot predict whether our research and clinical approaches will result in drugs or therapeutics
that the FDA considers safe and effective for the proposed indications. The FDA has substantial discretion in the drug approval
process. The approval process may be delayed by changes in government regulation, future legislation or administrative action
or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may prevent
or delay commercialization of, and our ability to derive product revenues from our product candidates; and diminish any competitive
advantages that we may otherwise believe that we hold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we comply with all FDA requests,
the FDA may ultimately reject one or more of our NDAs or BLAs. We may never obtain regulatory clearance for any of our product
candidates. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by leaving us
without a saleable product, and therefore without any source of revenues, until another product candidate can be developed. There
is no guarantee that we will ever be able to develop or acquire another product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the FDA may require us to
conduct additional pre-clinical and clinical testing or to perform post-marketing studies, as a condition to granting marketing
approval of a product. The results generated after approval could result in loss of marketing approval, changes in product labeling,
and/or new or increased concerns about the side effects or efficacy of a product. The FDA has significant post-market authority,
including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information,
and compliance with FDA-approved risk evaluation and mitigation strategies. The FDA&rsquo;s exercise of its authority has in some
cases resulted, and in the future could result, in delays or increased costs during product development, clinical trials and regulatory
review, increased costs to comply with additional post-approval regulatory requirements and potential restrictions on sales of
approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In foreign jurisdictions, we must also
receive approval from the appropriate regulatory authorities before we can commercialize any products, which can be time consuming
and costly. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures
described above. There can be no assurance that we will receive the approvals necessary to commercialize our product candidate
for sale outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA approves any of our product
candidates, the labeling, manufacturing, packaging, adverse event reporting, storage, advertising, promotion and record-keeping
for our products will be subject to ongoing FDA requirements and continued regulatory oversight and review. Our drug manufacturers
and subcontractors that we retain will be required to comply with FDA and other regulations. We may also be subject to additional
FDA post-marketing obligations. If we are not able to maintain regulatory compliance, we may not be permitted to market our product
candidates and/or may be subject to product recalls, seizures, suspension of regulatory approval, suspension of production, injunctions
or civil or criminal sanctions. The subsequent discovery of previously unknown problems with any marketed product, including adverse
events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal
of the product from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical trials are very expensive,
time-consuming, and difficult to design and implement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials are very expensive
and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial
process is also time-consuming. We estimate that clinical trials for our product candidates would take at least several years
to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon
or repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">obtaining an IND application with the FDA to commence clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">identification of, and acceptable arrangements with, one or more clinical sites;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">obtaining IRB approval to commence clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">unforeseen safety issues;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">determination of dosing;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">lack of effectiveness during clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">slower than expected rates of patient recruitment;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">inability to monitor patients adequately during or after treatment;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">inability to obtain supply of our drug candidate in a timely manner;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">inability or unwillingness of medical investigators to follow our clinical protocols;
    and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">unwillingness of the FDA or IRBs to permit the clinical trials to be initiated.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we, IRBs or the FDA may suspend
our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs or the
FDA finds deficiencies in our submissions or conduct of our trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The results of our clinical trials
may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily
predictive of future results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, long-term safety and efficacy
have not yet been demonstrated in clinical trials for any of our product candidates. Favorable results in our early studies or
trials may not be repeated in later studies or trials. Even if our clinical trials are initiated and completed as planned, we
cannot be certain that the results will support our product candidate claims. Success in preclinical testing and early clinical
trials does not ensure that later clinical trials will be successful. Success of our predecessor P1A clinical product or positive
topline data from our previous SYN-004 Phase 1 and Phase 2 clinical trials, does not ensure success of SYN-004, and positive topline
data for our SYN-010 Phase 2 clinical trials does not ensure success of SYN-010. Furthermore, the FDA could determine that SYN-004
has not demonstrated safety and require additional clinical trials and safety data, despite positive results from our SYN-004
Phase 2b clinical trial and the determination by clinical sites investigators and an independent third party that the adverse
events that occurred in the group that received SYN-004 in our Phase 2b clinical trial were not drug related. We cannot be sure
that the results of later clinical trials would replicate the results of prior clinical trials and preclinical testing nor that
they would satisfy the requirements of the FDA or other regulatory agencies. Clinical trials may fail to demonstrate that our
product candidates are safe for humans and effective for indicated uses. A number of companies in the biopharmaceutical industry
have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding
promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products. Any
such failure could cause us or our sublicensee to abandon a product candidate and might delay development of other product candidates.
Preclinical and clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory
approvals or commercialization. Any delay in, or termination of, our clinical trials would delay our obtaining FDA approval for
the affected product candidate and, ultimately, our ability to commercialize that product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delays in patient enrollment may result
in increased cost or may adversely affect timing or outcome of planned clinical trials, which could prevent completion of these
trials and adversely affect our ability to advance the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delays in clinical testing could
result in increased costs to us and delay our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience delays in clinical testing
of our product candidates. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will
be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory
approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in
obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate
in a clinical trial or in obtaining sufficient supplies of clinical trial materials. Manufacturing considerations for SYN-004
(ribaxamase) and our other product candidates may include an expected several month lead time following a decision to commence
any clinical trial(s) and capacity considerations of our third-party contract manufacturers to provide clinical supply of SYN-004
or our other product candidates could cause delays in clinical trials. Many factors affect patient enrollment, including the size
of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, competing
clinical trials and new drugs approved for the conditions we are investigating. Clinical investigators will need to decide whether
to offer their patients enrollment in clinical trials of our product candidates versus treating these patients with commercially
available drugs that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase
our costs, slow down our product development and timeliness and approval process and delay our ability to generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patients who are administered our
product candidates may experience unexpected side effects or other safety risks that could cause a halt in their clinical development,
preclude approval of our product candidates or limit their commercial potential.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our clinical trials may be suspended at
any time for a number of reasons. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they
present an unacceptable risk to the clinical trial patients. In addition, the FDA or other regulatory agencies may order the temporary
or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted
in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the clinical trial patients.
For example, the FDA could determine that SYN-004 has not demonstrated safety and require additional clinical trials and safety
data, despite positive results from our SYN-004 Phase 2b clinical trial and the determination by clinical sites investigators
and an independent third party that the adverse events that occurred in the group that received SYN-004 in our Phase 2b clinical
trial were not drug related.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Administering any product candidate to
humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product
candidates and could result in the FDA or other regulatory authorities denying further development or approval of our product
candidates for any or all targeted indications. Ultimately, some or all of our product candidates may prove to be unsafe for human
use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse
health effects as a result of participating in our clinical trials. Any of these events could prevent us from achieving or maintaining
market acceptance of our product candidates and could substantially increase commercialization costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>An NDA submitted under Section 505(b)(2)
subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval
of our product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to submit SYN-010 to the FDA for
approval under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the submission of an NDA where at least some of the information
required for approval comes from studies that were not conducted by, or for, the applicant and on which the applicant has not
obtained a right of reference. The 505(b)(2) application would enable us to reference published literature and/or the FDA&rsquo;s
previous findings of safety and effectiveness for the branded reference drug. For NDAs submitted under Section 505(b)(2) of the
FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance with the Hatch-Waxman Act,
such NDAs may be required to include certifications, known as paragraph IV certifications, that certify that any patents listed
in the Patent and Exclusivity Information Addendum of the FDA&rsquo;s publication, Approved Drug Products with Therapeutic Equivalence
Evaluations, commonly known as the Orange Book, with respect to any product referenced in the 505(b)(2) application, are invalid,
unenforceable or will not be infringed by the manufacture, use or sale of the product that is the subject of the 505(b)(2) NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Hatch-Waxman Act, the holder
of patents that the 505(b)(2) application references may file a patent infringement lawsuit after receiving notice of the paragraph
IV certification. Filing of a patent infringement lawsuit against the filer of the 505(b)(2) applicant within 45 days of the patent
owner&rsquo;s receipt of notice triggers a one-time, automatic, 30-month stay of the FDA&rsquo;s ability to approve the 505(b)(2)
NDA, unless patent litigation is resolved in the favor of the paragraph IV filer or the patent expires before that time. Accordingly,
we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject
to significant delay and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2)
application will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical
entity, listed in the Orange Book for the referenced product has expired. The FDA may also require us to perform one or more additional
clinical studies or measurements to support the change from the branded reference drug, which could be time consuming and could
substantially delay our achievement of regulatory approvals for such product candidates. The FDA may also reject our future 505(b)(2)
submissions and require us to file such submissions under Section 505(b)(1) of the FDCA, which would require us to provide extensive
data to establish safety and effectiveness of the drug for the proposed use and could cause delay and be considerably more expensive
and time consuming. These factors, among others, may limit our ability to successfully commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates, if approved
for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate
revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If one of our product candidates is approved
for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of any approved product by physicians,
healthcare professionals and third-party payors and our profitability and growth will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">demonstration of safety and efficacy;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">changes in the practice guidelines and the standard of care for the targeted indication;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">relative convenience and ease of administration;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">the prevalence and severity of any adverse side effects;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">budget impact of adoption of our product on relevant drug formularies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">the availability, cost and potential advantages of alternative treatments, including
    less expensive generic drugs;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">pricing, reimbursement and cost effectiveness, which may be subject to regulatory
    control;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">effectiveness of our or any of our partners&rsquo; sales and marketing strategies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">the product labeling or product insert required by the FDA or regulatory authority
    in other countries; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">the availability of adequate third-party insurance coverage or reimbursement.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any product candidate that we develop
does not provide a treatment regimen that is as beneficial as, or is perceived as being as beneficial as, the current standard
of care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale by the FDA or other
regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any approved products
will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our
ability to obtain sufficient third-party coverage or reimbursement. If any product candidate is approved but does not achieve
an adequate level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product
would be substantially reduced. In addition, our efforts to educate the medical community and third-party payors on the benefits
of our product candidates may require significant resources, may be constrained by FDA rules and policies on product promotion,
and may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on third parties, including
researchers and sublicensees, who are not under our control. If these third parties do not successfully carry out their contractual
duties or meet expected deadlines, we may not be able to seek or obtain regulatory approval for or commercialize our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we have in-licensed some of our
product candidates, have sublicensed a product candidate and have collaboration agreements for the development of other product
candidates, we depend upon our sublicensee and independent investigators and scientific collaborators, such as universities and
medical institutions or private physician scientists, to advise us and to conduct our preclinical and clinical trials under agreements
with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to
our programs or the timing of their procurement of clinical-trial data or their compliance with applicable regulatory guidelines.
Should any of these scientific inventors/advisors or those of our sublicensee become disabled or die unexpectedly, or should they
fail to comply with applicable regulatory guidelines, we or our sublicensee may be forced to scale back or terminate development
of that program. They may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking
those programs ourselves. Failing to devote sufficient time and resources to our drug-development programs, or substandard performance
and failure to comply with regulatory guidelines, could result in delay of any FDA applications and our commercialization of the
drug candidate involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These collaborators may also have relationships
with other commercial entities, some of which may compete with us. Our collaborators assisting our competitors could harm our
competitive position. For example, we are highly dependent on scientific collaborators for our IBS-C development program, each
of whom are employed by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to our product candidates
in collaboration with Intrexon, we are dependent upon Intrexon&rsquo;s synthetic biology facilities and capabilities as we have
no such facilities and capabilities of our own. We are also reliant on their vectors, monoclonal antibody discovery, production
cell line development and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to our product candidate
for pertussis in collaboration with University of Texas at Austin, we are dependent on its research laboratories as we have no
such facilities or capabilities of our own. If any of the foregoing were to become inaccessible or terminated, it would be difficult
for us to develop and commercialize our synthetic biologic product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have in the past and expect to have
in the future agreements with third-party contract research organizations (CROs), under which we have delegated to the CROs the
responsibility to coordinate and monitor the conduct of our SYN-004 and SYN-010 clinical trials and to manage data for our clinical
programs. We, our CROs and our clinical sites are required to comply with current Good Clinical Practices, or cGCPs, regulations
and guidelines issued by the FDA and by similar governmental authorities in other countries where we are conducting clinical trials.
We have an ongoing obligation to monitor the activities conducted by our CROs and at our clinical sites to confirm compliance
with these requirements. In the future, if we, our CROs or our clinical sites fail to comply with applicable GCPs, the clinical
data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials
before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP
regulations, and will require a large number of test subjects. Our failure to comply with these regulations may require us to
repeat clinical trials, which would delay the regulatory approval process. If our CROs do not successfully carry out their contractual
duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data
they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons,
our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates
would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We currently have no marketing,
sales or distribution organization and have no experience in marketing products as a company. If we are unable to establish marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able
to generate product revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no marketing, sales
or distribution capabilities and have no experience in marketing products. We may develop an in-house marketing organization and
sales force, which will require significant capital expenditures, management resources and time. We will have to compete with
other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable or decide not to establish
internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing
of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements.
Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or
no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if
we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us
with the sales and marketing efforts of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that we will
be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators
to commercialize any product in the United States or overseas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if our products are approved,
if doctors decide not to prescribe SYN-010 or hospitals decide not to prescribe SYN-004, we may be unable to generate sufficient
revenue to sustain our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To increase awareness and adoption of
our products once approved, we and our collaborators will need to educate doctors and hospitals on the benefits and value of our
products through published papers, presentations at scientific conferences and one-on-one education sessions. In addition, we
and our collaborators will need to assure doctors of our ability to obtain and maintain adequate reimbursement coverage from third-party
payors. We and our collaborators may need to hire additional commercial, scientific, technical, sales and marketing and other
personnel to support this process. If our educational efforts fail and medical practitioners do not decide to prescribe our products
in sufficient volume, we may be unable to generate sufficient revenue to sustain our business. In addition, factors outside of
our control, such as insurance reimbursement are expected to influence market acceptance of our products. Accordingly, even if
we receive regulatory approval for the use of our products, we may not be successful in generating revenue from the sale of our
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reimbursement may not be available
for our product candidates, which would impede sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market acceptance and sales of our product
candidates may depend on coverage and reimbursement policies and health care reform measures. Decisions about formulary coverage
as well as levels at which government authorities and third-party payers, such as private health insurers and health maintenance
organizations, reimburse patients for the price they pay for our products as well as levels at which these payors pay directly
for our products, where applicable, could affect whether we are able to commercialize these products. We cannot be sure that reimbursement
will be available for any of our products. Also, we cannot be sure that coverage or reimbursement amounts will not reduce the
demand for, or the price of, our products. If coverage and reimbursement are not available or are available only at limited levels,
we may not be able to commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In recent years, officials have made numerous
proposals to change the health care system in the United States. These proposals include measures that would limit or prohibit
payments for certain medical treatments or subject the pricing of drugs to government control. In addition, in many foreign countries,
particularly the countries of the European Union, the pricing of prescription drugs is subject to government control. If our products
are or become subject to government regulation that limits or prohibits payment for our products, or that subjects the price of
our products to governmental control, we may not be able to generate revenue, attain profitability or commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of legislative proposals and
the trend towards managed health care in the United States, third-party payors are increasingly attempting to contain health care
costs by limiting both coverage and the level of reimbursement of new drugs. They may also impose strict prior authorization requirements
and/or refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA
has granted market approvals. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse
patients for their use of newly-approved drugs, which in turn will put pressure on the pricing of drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare reform measures could
hinder or prevent our product candidates&rsquo; commercial success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. government and other governments
have shown significant interest in pursuing continued healthcare reform. Any government-adopted reform measures could adversely
impact the pricing of healthcare products and services in the United States or internationally and the amount of reimbursement
available from governmental agencies or other third party payors. The continuing efforts of the U.S. and foreign governments,
insurance companies, managed care organizations and other payors of health care services to contain or reduce health care costs
may adversely affect our ability to set prices for our products which we believe are fair, and our ability to generate revenues
and achieve and maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New laws, regulations and judicial decisions,
or new interpretations of existing laws, regulations and decisions, that relate to healthcare availability, methods of delivery
or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and we may need to revise
our research and development programs. The pricing and reimbursement environment may change in the future and become more challenging
due to several reasons, including policies advanced by the current executive administration in the United States, new healthcare
legislation or fiscal challenges faced by government health administration authorities. Specifically, in both the United States
and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system
in ways that could affect our ability to sell our products profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If product liability lawsuits are
successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product
candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent risk of product liability
lawsuits related to the testing of our product candidates, and will face an even greater risk if we sell our product candidates
commercially. Currently, we are not aware of any anticipated product liability claims with respect to our product candidates.
In the future, an individual may bring a liability claim against us if one of our product candidates causes, or merely appears
to have caused, an injury. If we cannot successfully defend ourselves against the product liability claim, we may incur substantial
liabilities. Regardless of merit or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">decreased demand for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">injury to our reputation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">withdrawal of clinical trial participants;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">costs of related litigation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">initiation of investigations by regulators;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">substantial monetary awards to patients or other claimants;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">distraction of management&rsquo;s attention from our primary business;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">product recalls;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">loss of revenue; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">the inability to commercialize our product candidates.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have clinical trial liability insurance.
We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for our
product candidates. Our current insurance coverage may prove insufficient to cover any liability claims brought against us. In
addition, because of the increasing costs of insurance coverage, we may not be able to maintain insurance coverage at a reasonable
cost or obtain insurance coverage that will be adequate to satisfy liabilities that may arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on patent applications and
various regulatory exclusivities to protect some of our product candidates and our ability to compete may be limited or eliminated
if we are not able to protect our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent positions of pharmaceutical
companies are uncertain and may involve complex legal and factual questions. We may incur significant expenses in protecting our
intellectual property and defending or assessing claims with respect to intellectual property owned by others. Any patent or other
infringement litigation by or against us could cause us to incur significant expenses and divert the attention of our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Others may file patent applications or
obtain patents on similar technologies or compounds that compete with our products. We cannot predict how broad the claims in
any such patents or applications will be, and whether they will be allowed. Once claims have been issued, we cannot predict how
they will be construed or enforced. We may infringe intellectual property rights of others without being aware of it. If another
party claims we are infringing their technology, we could have to defend an expensive and time consuming lawsuit, pay a large
sum if we are found to be infringing, or be prohibited from selling or licensing our products unless we obtain a license or redesign
our product, which may not be possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trade secrets and proprietary
know-how to develop and maintain our competitive position. Some of our current or former employees, consultants, scientific advisors,
current or prospective corporate collaborators, may unintentionally or willfully disclose our confidential information to competitors
or use our proprietary technology for their own benefit. Furthermore, enforcing a claim alleging the infringement of our trade
secrets would be expensive and difficult to prove, making the outcome uncertain. Our competitors may also independently develop
similar knowledge, methods, and know-how or gain access to our proprietary information through some other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may incur substantial costs as
a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated
with lawsuits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any other person files patent applications,
or is issued patents, claiming technology also claimed by us in pending applications, we may be required to participate in interference
proceedings in the U.S. Patent and Trademark Office to determine priority of invention. We, or our licensors, may also need to
participate in interference proceedings involving our issued patents and pending applications of another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The intellectual property environment
in the monoclonal antibody field is particularly complex, constantly evolving and highly fragmented. We have not conducted freedom-to-use
patent searches on all aspects of our product candidates or potential product candidates, and we may be unaware of relevant patents
and patent applications of third parties. In addition, the freedom-to-use patent searches that have been conducted may not have
identified all relevant issued patents or pending patents. We cannot provide assurance that our proposed products in this area
will not ultimately be held to infringe one or more valid claims owned by third parties which may exist or come to exist in the
future or that in such case we will be able to obtain a license from such parties on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot guarantee that the practice
of our technologies will not conflict with the rights of others. In some foreign jurisdictions, we could become involved in opposition
proceedings, either by opposing the validity of another&rsquo;s foreign patent or by persons opposing the validity of our foreign
patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also face frivolous litigation
or lawsuits from various competitors or from litigious securities attorneys. The cost to us of any litigation or other proceeding
relating to these areas, even if deemed frivolous or resolved in our favor, could be substantial and could distract management
from our business. Uncertainties resulting from initiation and continuation of any litigation could have a material adverse effect
on our ability to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we infringe the rights of others
we could be prevented from selling products or forced to pay damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our products, methods, processes, and
other technologies are found to infringe the proprietary rights of other parties, we could be required to pay damages, or we may
be required to cease using the technology or to license rights from the prevailing party. Any prevailing party may be unwilling
to offer us a license on commercially acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not have a guarantee of patent
term restoration and marketing exclusivity of the ingredients for our drugs even if we are granted FDA approval of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Drug Price Competition and Patent
Term Restoration Act of 1984 (Hatch-Waxman) permits the FDA to approve Abbreviated New Drug Applications (ANDAs) for generic versions
of innovator drugs, as well as NDAs with less original clinical data, and provides patent restoration and exclusivity protections
to innovator drug manufacturers. The ANDA process permits competitor companies to obtain marketing approval for drugs with the
same active ingredient and for the same uses as innovator drugs, but does not require the conduct and submission of clinical studies
demonstrating safety and efficacy. As a result, a competitor could copy any of our drugs and only need to submit data demonstrating
that the copy is bioequivalent to gain marketing approval from the FDA. Hatch-Waxman requires a competitor that submits an ANDA,
or otherwise relies on safety and efficacy data for one of our drugs, to notify us and/or our business partners of potential infringement
of our patent rights. We and/or our business partners may sue the company for patent infringement, which would result in a 30-month
stay of approval of the competitor&rsquo;s application. The discovery, trial and appeals process in such suits can take several
years. If the litigation is resolved in favor of the generic applicant or the challenged patent expires during the 30-month period,
the stay is lifted and the FDA may approve the application. Hatch-Waxman also allows competitors to market copies of innovator
products by submitting significantly less clinical data outside the ANDA context. Such applications, known as Section 505(b)(2)
NDAs may rely on clinical investigations not conducted by or for the applicant and for which the applicant has not obtained a
right of reference or use and are subject to the ANDA notification procedures described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law also permits restoration of a
portion of a product&rsquo;s patent term that is lost during clinical development and NDA review, and provides statutory protection,
known as exclusivity, against FDA approval or acceptance of certain competitor applications. Restoration can return up to five
years of patent term for a patent covering a new product or its use to compensate for time lost during product development and
regulatory review. The restoration period is generally one-half the time between the effective date of an IND and submission of
an NDA, plus the time between NDA submission and its approval (subject to the five-year limit), and no extension can extend total
patent life beyond 14 years after the drug approval date. Applications for patent term extension are subject to U.S. Patent and
Trademark Office (USPTO) approval, in conjunction with FDA. Approval of these applications takes at least nine months, and there
can be no guarantee that it will be given at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hatch-Waxman also provides for differing
periods of statutory protection for new drugs approved under an NDA. Among the types of exclusivity are those for a &ldquo;new
chemical entity&rdquo; and those for a new formulation or indication for a previously-approved drug. If granted, marketing exclusivity
for the types of products that we are developing, which include only drugs with innovative changes to previously-approved products
using the same active ingredient, would prohibit the FDA from approving an ANDA or 505(b)(2) NDA relying on our safety and efficacy
data for three years. This three-year exclusivity, however, covers only the innovation associated with the original NDA. It does
not prohibit the FDA from approving applications for drugs with the same active ingredient but without our new innovative change.
These marketing exclusivity protections do not prohibit the FDA from approving a full NDA, even if it contains the innovative
change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The technology on which our channel
partnering arrangements with Intrexon are based on early stage technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2012, we announced an exclusive
channel collaboration with Intrexon relating to the design, production, testing and commercialization of human recombinant monoclonal
antibodies for the treatment of certain infectious diseases. Although monoclonal antibody therapeutics are well established in
the biotechnology and pharmaceutical sectors, their use for the treatment of infectious disease is extremely limited. In order
for monoclonal antibodies to be effective for infectious diseases, they must not only properly target the organism of interest
(or its toxins), but may also need to overcome defenses and forms of resistance of such organisms. To accomplish this may require
the use of more than one specific monoclonal antibody, and mixtures of different monoclonal antibodies, which may create additional
unforeseen complications, including increased manufacturing complexity and expense. In order to be competitive, monoclonal antibodies
will be required to be produced at a low enough cost of goods in order to be profitably marketed. We have very limited development
and manufacturing experience in the field of monoclonal antibodies and infectious disease. We cannot assure that any monoclonal
antibody candidates will provide satisfactory <I>in vitro</I> and <I>in vivo</I> nonclinical results sufficient to warrant the
expense of cGMP manufacture and clinical testing in human clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2015, we expanded our relationship
with Intrexon and entered into an ECC that governs a &ldquo;channel collaboration&rdquo; arrangement in which we intend to use
Intrexon&rsquo;s technology for development of biotherapeutic products for the treatment of PKU in humans. The strategy is to
orally deliver a bacterium, <I>Lactococcus lactis</I>, that has been engineered to efficiently degrade phenylalanine in the GI
tract to prevent phenylalanine absorption into the blood. The strategy is supported by data from rodent studies. The extent to
which the data translate to large animal models and to a human therapeutic remains unknown. While genetically-modified versions
of <I>Lactococcus lactis</I> have been tested in human clinical trials for other indications, the regulatory paths for recombinant
bacterial products have not been fully established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not expect to generate any
additional revenue from our sublicense with Meda AB due to recent developments in Europe.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, we entered into a sublicense
agreement with Meda AB whereby we were given the right to receive certain milestone payments totaling $17.5 million (including
an upfront payment of $2.5 million that was received in 2010), plus certain royalties on our flupirtine program. Meda AB informed
us that due to the decision of the European Medicines Agency (EMA) to limit the use of flupirtine for long-term pill and systemic
use, it has postponed its planned fibromyalgia clinical trials in the U.S. Therefore, we do not expect that the various milestones
set forth in the sublicense agreement will be achieved by Meda AB, or that Meda AB will develop flupirtine for fibromyalgia in
the U.S., Canada or Japan and accordingly we do not expect to receive any additional milestone payments or royalties on sales
in connection with the sublicense agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may fail to retain or recruit
necessary personnel, and we may be unable to secure the services of consultants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2018, we employed
25 individuals, 24 of whom are full-time employees. We have also engaged clinical consultants to advise us on our clinical programs
and regulatory consultants to advise us on our dealings with the FDA and other foreign regulatory authorities. We have been and
will be required to retain additional consultants and employees in order to fulfill our obligations under the ECC agreements with
Intrexon, our development of SYN 010 and SYN-004 and our agreement with CSMC. Our future performance will depend in part on our
ability to successfully integrate newly hired officers into our management team and our ability to develop an effective working
relationship among senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of our directors, scientific advisors,
and consultants serve as officers, directors, scientific advisors, or consultants of other biopharmaceutical or biotechnology
companies that might be developing competitive products to ours. Other than corporate opportunities, none of our directors are
obligated under any agreement or understanding with us to make any additional products or technologies available to us. Similarly,
we can give no assurances, and we do not expect and stockholders should not expect, that any biomedical or pharmaceutical product
or technology identified by any of our directors or affiliates in the future would be made available to us other than corporate
opportunities. We can give no assurances that any such other companies will not have interests that are in conflict with our interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Losing key personnel or failing to recruit
necessary additional personnel would impede our ability to attain our development objectives. There is intense competition for
qualified personnel in the drug and biologic development areas, and we may not be able to attract and retain the qualified personnel
we would need to develop our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on independent organizations,
advisors, and consultants to perform certain services for us, including handling substantially all aspects of regulatory approval,
clinical management, manufacturing, marketing, and sales. We expect that this will continue to be the case. Such services may
not always be available to us on a timely basis when we need them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We expect to increase the size of
our organization, and we may experience difficulties in managing growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a small company with 25 employees
as of September 30, 2018. To continue our clinical trials and commercialize our product candidates, we will need to expand our
employee base for managerial, operational, financial and other resources. Future growth will impose significant added responsibilities
on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial
performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability
to manage any future growth effectively. To that end, we must be able to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%">manage development efforts effectively;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>manage our commercialization activities effectively;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>integrate additional management, administrative, manufacturing and sales and marketing personnel;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>maintain sufficient administrative, accounting and management information systems and controls; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>hire and train additional qualified personnel.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be able to accomplish these tasks, and our failure
to accomplish any of them could harm our financial results and impact our ability to achieve development milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management team may invest or
spend the proceeds of our prior offerings and future offerings in ways with which you may not agree or in ways which may not yield
a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion
over the use of proceeds from our offerings. The net proceeds from our offerings, including sales made under the sales agreement
that we entered into on August 5, 2016 with FBR Capital Markets &amp; Co. now known as B. Riley FBR, Inc. (the &ldquo;B. Riley
FBR Sales Agreement&rdquo;), will be used primarily for general corporate purposes, which may include, among other things, for
clinical trials for our product candidates, paying general and administrative expenses and accounts payable, increasing our working
capital, funding research and development and funding capital expenditures. We may also use a portion of the net proceeds for
licensing or acquiring intellectual property to incorporate into our products and product candidates or our research and development
programs and to in-license, acquire or invest in complementary businesses or products, although we have no commitments or agreements
with respect to any such licenses, acquisitions or investments as of the date of this filing supplement. Our management will have
considerable discretion in the application of the net proceeds, and investors will not have the opportunity, as part of their
investment decision, to assess whether the proceeds are being used appropriately. The net proceeds may be used for corporate purposes
that do not increase our operating results or enhance the value of our common stock. The failure of our management to use funds
effectively could have a material adverse effect on our business, cause the market price of our common stock to decline and impair
the commercialization of our products and/or delay the development of our product candidates. Pending their use, we may invest
the net proceeds from this offering in short-term, investment-grade, interest-bearing instruments and U.S. government securities.
These investments may not yield a favorable return to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot assure you that our common
stock will be liquid or that it will remain listed on the NYSE American. A failure to regain compliance with the NYSE American
stockholders equity listing requirements or failure to continue to meet the other listing requirements could result in a de-listing
of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the NYSE
American. The NYSE American&rsquo;s listing standards generally mandate that we meet certain requirements relating to stockholders&rsquo;
equity, stock price, market capitalization, aggregate market value of publicly held shares and distribution requirements. We cannot
assure you that we will be able to maintain the continued listing standards of the NYSE American. The NYSE American requires companies
to meet certain continued listing criteria including a minimum stockholders&rsquo; equity of $6.0 million if an issuer has sustained
losses from continuing operations and/or net losses in its five most recent years, as outlined in the NYSE American Company Guide.
At June 30, 2018, we had stockholders&rsquo; deficit of $208.8 million. The NYSE American Company Guide also states that the NYSE
normally will not consider removing from listing securities of an issuer with total value of market capitalization of at least
$50.0 million and 1,100,000 shares publicly held, a market value of publicly held shares of at least $15.0 million and 400 round
lot shareholders. Although we have more than 1,100,000 shares publicly held and 400 round lot shareholders, our stock price is
volatile and, during the first two quarters of 2018, the price of our common stock experienced a sustained decrease resulting
in a period where our market capitalization fell below $50.0 million. Our market capitalization is currently below $50.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2018, we announced that we
received written communication from the NYSE American stating we were no longer in compliance with certain continued listing standards
as set forth in the NYSE American Company Guide. Specifically, based on our annual report on Form 10-K for the year ended December
31, 2017, and filed with the SEC on February 22, 2018, we are below compliance with Part 10, Section 1003(iii) of the NYSE American
Company Guide since we reported a stockholders&rsquo; deficit of $1.5 million and net losses in five of our most recent fiscal
years as of December 31, 2017. On April 3, 2018, we submitted a plan of compliance to the NYSE American outlining our plan to
regain compliance with certain continued listing standards as set forth in Part 10, Section 1003(iii) of the NYSE American Company
Guide by September 2, 2018, the conclusion of the compliance plan period. There can be no assurance that we can regain compliance
with the listing standard of the NYSE American, or that the NYSE American will continue to list our common stock if we regain
compliance, or if we continue to fail to maintain the minimum stockholders&rsquo; equity. In addition, in the future we may not
be able to maintain such minimum stockholders&rsquo; equity and/or issue additional equity securities in exchange for cash or
other assets, if available, to maintain certain minimum stockholders&rsquo; equity required by the NYSE American. If we are delisted
from the NYSE American then our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin
Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation requirements.
If our common stock is delisted from the NYSE American due to our failure to regain compliance with the listing standards by the
end of the compliance period or for any other reason, and the market value of our shares of common stock held by non-affiliates
remains below $15 million, we will likely no longer be eligible to sell common stock pursuant to the B. Riley FBR Sales Agreement
or otherwise utilize our shelf registration statement. In addition, delisting of our common stock could depress our stock price,
substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable
to us, or at all. Delisting from the NYSE American could also have other negative results, including the potential loss of confidence
by suppliers and employees, the loss of institutional investor interest and fewer business development opportunities. On May 18,
2018 we received notification from the NYSE American that NYSE Regulation has reviewed our plan of compliance and determined to
accept the plan and grant a plan period through September 2, 2019. NYSE Regulation staff will review our company periodically
for compliance with the initiatives outlined in the plan. If we are not in compliance with the continued listing standards by
September 2, 2019 or if we do not make progress consistent with the plan during the plan period, NYSE Regulation staff will initiate
delisting proceeding as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our common stock falls below $0.20
per share on a 30-trading-day average it will become subject to the continued listing evaluation and follow-up procedures set
forth in Section 1009 of the NYSE American Company Guide which could, among other things, result in initiation of immediate delisting
procedures. In the event that we were to fail to meet the requirements of NYSE American per share price requirement or stockholders
equity requirement and we could not timely cure such deficiency, our listing could become subject to NYSE American continued listing
evaluation and follow-up procedures, which could result in delisting procedures. Based on the low stock price on July&nbsp;28,
2018, our board of directors approved a <FONT STYLE="font-family: Times New Roman, Times, Serif">one-for-thirty-five </FONT>proportionate
reverse stock split of our authorized number of shares of common stock and our outstanding number of shares of common stock that
we effected on August 10, 2018. However, there can be no assurance that the reverse stock split will result in a sustained higher
stock price that will allow us to meet the NYSE American stock price listing requirements or that the reverse stock split will
not inhibit our ability to seek equity financing as a remedy to regain compliance with NYSE American stockholders&rsquo; equity
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of our warrants issued in
our October 2014 offering, and our November 2016 offering, and our Series A Preferred Stock have no rights as common stockholders
until they exercise their warrants or convert their Series A Preferred Stock and acquire our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until the holders of the warrants we issued
in our October 2014 offering and our November 2016 offering and the holders of our Series A Preferred Stock acquire shares of
our common stock by exercising their warrants or converting their Series A Preferred Stock, respectively, the holders have no
rights as a stockholder with respect to the shares of common stock underlying their securities. Upon exercise of the warrants
or conversion of the Series A Preferred Stock, the holders will be entitled to exercise the rights of a common stockholder only
as to matters for which the record date occurs after the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because there is no established public
trading market for the October 2014 or November 2016 warrants or the Series A Preferred Stock we issued, the liquidity of each
such security is limited. We do not expect a market to develop, nor do we intend to apply to list the October 2014 or November
2016 warrants or the Series A Preferred Stock on any securities exchange. Upon exercise of the October 2014 or November 2016 warrants
and conversion of the Series A Preferred Stock, our stockholders will experience dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 32; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The fundamental change purchase
feature of the warrants we issued in our November 2016 offering may delay or prevent an otherwise beneficial attempt to take over
our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the November 2016 warrants
require us to offer to purchase the warrants for cash in the event of a fundamental change, as defined. This feature may have
the effect of delaying or preventing a takeover of our company that would otherwise be beneficial to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrants are a risky investment.
Holders of outstanding warrants may not be able to recover the investment in the warrants, and the warrants may expire worthless.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether our outstanding warrants will
have any value will depend on the market conditions for, and the price of, our common stock, which conditions will depend on factors
related and unrelated to the success of our clinical development program, and cannot be predicted at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our common stock price does not increase
to an amount sufficiently above the exercise prices of the warrants during the periods the warrants are exercisable, holders of
warrants will be unable to recover any of their investment in the warrants. In fact, the warrants issued in November 2016 that
had an exercise price of $60.20 (post reverse stock split) expired unexercised because their exercise price was above the common
stock trading price. There can be no assurance that any of the factors that could impact the trading price of our common stock
will result in the trading price increasing to an amount that will exceed the exercise price or the price required for holders
of warrants to achieve a positive return on their investment in the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not have the funds necessary
to fulfill our obligation to repurchase the November 2016 warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under certain circumstances, if an extraordinary
transaction (as defined in the warrant agreement) occurs, holders of the warrants issued in November 2016 may require us to repurchase
the remaining unexercised portion of such warrants for an amount of cash equal to the value of the warrant as determined in accordance
with the Black Scholes option pricing model and the terms of the warrants. Our ability to repurchase the warrants depends on our
ability to generate cash flow in the future. To some extent, this is subject to general economic, financial, competitive, legislative
and regulatory factors and other factors that are beyond our control. We cannot assure you that we will maintain sufficient cash
reserves or that our business will generate cash flow from operations at levels sufficient to permit us to repurchase the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The issuance of shares of common
stock upon conversion of the Series A Preferred Stock would reduce the relative voting power of holders of our common stock, would
dilute the ownership of such holders and may adversely affect the market price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The conversion of the Series A Preferred
Stock to common stock would dilute the ownership interest of existing holders of our common stock, and any sales in the public
market of the common stock issuable upon conversion of the Series A Preferred Stock could adversely affect prevailing market prices
of our common stock. Sales by such holders of a substantial number of shares of our common stock in the public market, or the
perception that such sales might occur, could have a material adverse effect on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The holders of shares of the Series A Preferred Stock
may exercise significant influence over us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Series A Preferred
Stock will own approximately 9% (without taking into account the securities offered in the offering) of our shares of common
stock on a fully diluted as-converted basis based on the number of shares of common stock outstanding as of the date hereof.
 &nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under the terms of the Certificate
of Designation that governs the Series A Preferred Stock, the Series A Preferred Stock generally ranks, with respect to liquidation,
dividends and redemption, senior to other securities (including our common stock and Series B Preferred) and, so long as any shares
of Series A Preferred Stock remain outstanding, the approval of the holders of a majority of the Series A Preferred Stock outstanding
at the time of approval is required in order for us to, among other things, (i) alter or change adversely the powers, preferences
or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation; (ii) amend our Articles of Incorporation
or bylaws in any manner that adversely affects any powers, preferences or rights of the Series A Preferred Stock; (iii) authorize
or create any series or class of stock ranking as to redemption, distribution of assets upon a Liquidation Event (as defined in
the Certificate of Designation) or dividends senior to, or otherwise <I>pari passu</I> with, the Series A Preferred Stock; (iv)
declare or make any dividends other than dividend payments on the Series A Preferred Stock or other distributions payable solely
in common stock; (v) authorize any increase in the number of shares of Series A Preferred Stock or issue any additional shares
of Series A Preferred Stock; or (vi) enter into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The holders of Series A Preferred
Stock have rights, preferences and privileges that are not held by, and are preferential to, the rights of our common stockholders
and holders of our Series B Preferred Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon our liquidation, dissolution or winding
up, the holders of the Series A Preferred Stock will be entitled to receive out of our assets, in preference to the holders of
the common stock and any junior preferred stock (including the Series B Preferred offered hereby), an amount per share equal to
the greater of (i) the sum of the Accreted Value (as defined in the Certificate of Designation) plus an amount equal to all accrued
or declared and unpaid dividends on the Series A Preferred Stock that have not previously been added to the Accrued Value, or
(ii) the amount that such shares would have been entitled to receive if they had converted into common stock immediately prior
to such liquidation, dissolution or winding up. In addition, upon consummation of a specified change of control transaction, each
holder of Series A Preferred Stock will be entitled to have us redeem the Series A Preferred Stock at a price specified in the
Certificate of Designation. These provisions may make it more costly for a potential acquirer to engage in a business combination
transaction with us. Provisions that have the effect of discouraging, delaying or preventing a change in control could limit the
opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that
some investors are willing to pay for our common stock. If there are insufficient assets to pay in full such amounts, then the
available assets will be ratably distributed to the holders of the Series A Preferred Stock in accordance with the respective
amounts that would be payable on such shares if all amounts payable thereon were paid in full. This will reduce the remaining
amount of our assets, if any, available to distribute to holders of our common stock. The holders of Series A Preferred Stock
also have a preferential right to receive cumulative dividends on the Accreted Value of each share of Series A Preferred Stock
at an initial rate of 2% per annum, compounded quarterly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the holders of the Series
A Preferred Stock also have certain redemption and conversion rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our obligations to the holders of Series
A Preferred Stock could limit our ability to obtain additional financing or increase our borrowing costs, which could have an
adverse effect on our financial condition. These preferential rights could also result in divergent interests between the holders
of shares of the Series A Preferred Stock and holders of our common stock and Series B Preferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The redemption right of the holders
of the Series A Preferred Stock may delay or prevent an otherwise beneficial change of control transaction or result in a depletion
of our cash in order to satisfy the redemption right of the holders Series A Preferred Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the Series A Preferred Stock
provide the holders with the right to require us to redeem the stock upon a change of control for cash in the event of a fundamental
change, as defined. This feature may have the effect of delaying or preventing a change of control that would otherwise be beneficial
to investors or depleting our cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market price of our common stock
has been and may continue to be volatile and adversely affected by various factors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our common stock could
fluctuate significantly in response to various factors and events, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">our ability to execute our business plan;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">operating results below expectations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">announcements concerning product development results, including clinical trial
    results, or intellectual property rights of others;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">litigation or public concern about the safety of our potential products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">our issuance of additional securities, including debt or equity or a combination
    thereof, necessary to fund our operating expenses;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">announcements of technological innovations or new products by us or our competitors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">loss of any strategic relationship;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">industry developments, including, without limitation, changes in healthcare policies
    or practices or third-party reimbursement policies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">economic and other external factors effecting U.S. or Global equity markets;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">period-to-period fluctuations in our financial results; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">whether an active trading market in our common stock develops and is maintained.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the securities markets have
from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular
companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our articles of incorporation and
bylaws and Nevada law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause
our stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our articles of incorporation, as amended,
our amended and restated bylaws and Nevada law could make it more difficult for a third party to acquire us, even if closing such
a transaction would be beneficial to our stockholders. The board of directors could authorize the issuance of an additional series
of preferred stock that would grant holders preferred rights to our assets upon liquidation, special voting rights, the right
to receive dividends before dividends would be declared to common stockholders, and the right to the redemption of such shares,
possibly together with a premium, prior to the redemption of the common stock. To the extent that we do issue additional preferred
stock, the rights of holders of common stock could be impaired thereby, including without limitation, with respect to liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions of our articles of incorporation,
as amended and our amended and restated bylaws may also prevent or frustrate attempts by our stockholders to replace or remove
our management. In particular, our articles of incorporation, as amended, and amended and restated bylaws, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">provide the board of directors with the ability to alter the bylaws without stockholder
    approval; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.65pt; text-align: justify; text-indent: -17.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">provide that vacancies on the board of directors may be filled by a majority of
    directors in office, although less than a quorum.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to fulfill all of our
registration requirements may cause us to suffer liquidated damages, which may be very costly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the registration
rights agreement that we entered into with Intrexon and an affiliated entity, we were required to file a registration statement
with respect to securities issued and are required to maintain the effectiveness of such registration statement. The failure to
do so could result in the payment of damages by us. There can be no assurance that we will be able to maintain the effectiveness
of any registration statement, and therefore there can be no assurance that we will not incur damages with respect to such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the registration
rights agreement that we entered into with holders of our Series A Preferred Stock, we are required to file a registration statement
with respect to the securities issued to them upon their request within certain time periods and are required to maintain the
effectiveness of such registration statement. The failure to do so could result in the payment of damages by us. There can be
no assurance that we will be able to meet the required filing deadlines or maintain the effectiveness of any registration statement,
and therefore there can be no assurance that we will not incur damages with respect to such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay dividends
in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid cash dividends on our
common stock. We currently intend to retain our future earnings, if any, to finance the operation and growth of our business and
currently do not plan to pay any cash dividends in the foreseeable future. If we do not pay dividends, our common stock may be
less valuable because a return on your investment will only occur if the market price of our common stock price appreciates. Our
Series A Preferred Stockholders rank senior to our common stockholders with respect to dividends and, subject to any senior rights
of the Series A Preferred Stock, the holders of the Series B Preferred will participate, on an as-if-converted-to-common stock
basis, in any dividends to the holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Resales of our common stock in the
public market by our stockholders may cause the market price of our common stock to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue common stock from time to
time in connection with future offerings. Any issuance from time to time of new shares of our common stock, or our ability to
issue shares of common stock in future offerings, could result in resales of our common stock by our current stockholders concerned
about the potential dilution of their holdings. In turn, these resales could have the effect of depressing the market price for
our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The shares of common stock offered under the B. Riley
FBR Sales Agreement may be sold in &ldquo;at the market&rdquo; offerings, and investors who buy shares at different times will
likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors who purchase shares that are
sold under the B. Riley FBR Sales Agreement at different times will likely pay different prices, and so may experience different
outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers
of shares sold, and there is no minimum or maximum sales price. Investors may experience declines in the value of their shares
as a result of share sales made at prices lower than the prices they paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the documents incorporated
by reference herein contain forward-looking statements, including statements regarding the progress and timing of our product
development, the goals of our development activities, estimates of the potential markets for our product candidates, estimates
of the capacity of manufacturing and other facilities to support our products, our expected future revenues, operations and expenditures
and projected cash needs. The forward-looking statements are contained principally in the sections entitled &ldquo;Prospectus
Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo; and &ldquo;Business&rdquo; of this prospectus and the documents incorporated by reference. These statements
relate to future events of our financial performance and involve known and unknown risks, uncertainties and other factors that
could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied
by these forward-looking statements. Those risks and uncertainties include, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to implement our business plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to raise additional capital to meet our liquidity needs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to generate sufficient proceeds from this offering;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to generate product revenues;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to achieve profitability;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to satisfy U.S. (including the FDA), and international regulatory requirements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to obtain market acceptance of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to compete in the market;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to advance our clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to fund, design and implement clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to demonstrate that our product candidates are safe for human use and effective
                                         for indicated uses;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to gain acceptance of physicians and patients for use of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         dependency on third-party researchers and manufacturers and licensors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to establish and maintain strategic partnerships, including for the distribution
                                         of products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to attract and retain sufficient, qualified personnel;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to obtain or maintain patents or other appropriate protection for the intellectual
                                         property;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         dependency on the intellectual property licensed to us or possessed by third parties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to adequately support future growth;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to maintain our NYSE American listing; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">potential
                                         product liability or intellectual property infringement claims.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements include all
statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo;
 &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
 &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
or the negative of those terms, and similar expressions and comparable terminology intended to identify forward-looking statements.
These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and
uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking
statements represent our estimates and assumptions only as of the date of this prospectus and, except as required by law, we undertake
no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events
or otherwise after the date of this prospectus. You should read this prospectus, the documents incorporated by reference in this
prospectus, the documents referenced in this prospectus and the documents filed as exhibits to the registration statement, of
which this prospectus is a part, completely and with the understanding that our actual future results may be materially different
from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 36; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds of this
offering will be approximately $16.7 million, or approximately $19.3 million if the underwriters exercise in full their over-allotment
option, based on a public offering price of $1.15&nbsp;per Class A Unit and $1,000 per Class B Unit, after deducting the estimated
underwriting discount and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the
warrants. The public offering price per Class A Unit was determined between us, the underwriters and investors based on market
conditions at the time of pricing, and was at a discount to the  market price of our common stock. We will only receive
additional proceeds from the exercise of the warrants issuable in connection with this offering if such warrants are exercised
at their exercise price of 120% of the public offering price of the Class A Units, or $1.38 per share, and the holders of such
warrants pay the exercise price in cash upon such exercise and do not utilize the cashless exercise provision of the warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds, if
any, from the sales of securities offered by this prospectus to fund our and our subsidiaries&rsquo; preclinical and clinical
programs (including, but not limited to, provide approximately $5.0-$7.0 million in funding for manufacturing scale-up activities
to progress SYN-004 towards a potential Phase 3 clinical trial (broad indication) and/or initiate a Phase 1/2 clinical trial(s)
in a specialty population, approximately $7.5 million in funding for preclinical development and related manufacturing activities
in preparation for our IND and Phase 1 clinical trial for our SYN-020 program and required milestone payments) and for working
capital and general corporate purposes, including, to acquire, license or invest in complementary businesses, technologies, product
candidates or other intellectual property. We have broad discretion in determining how the proceeds of this offering will be used,
and our discretion is not limited by the aforementioned possible uses. Our board of directors believes the flexibility in application
of the net proceeds is prudent.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected use of proceeds from this
offering represent our current intentions based on present plans and business conditions. The amounts and timing of our actual
expenditures will depend on numerous factors, including our development and commercialization efforts, as well as the amount of
cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes
described above. We may find it necessary or advisable to reallocate the net proceeds of this offering within the categories listed
above or to use the net proceeds for other purposes. Accordingly, we will have broad discretion in the application of the net proceeds.
Pending the uses described above, we plan to invest the net proceeds from this offering in short-term, investment-grade, interest-bearing
securities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our capitalization
as of June 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">on
                                         an actual basis, adjusted to reflect the reverse stock split of one-for-thirty-five effective
                                         August 10, 2018;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">on
                                         a pro forma basis to give effect to the issuance of 3,485,483 shares of common stock
                                         for which we received net proceeds of $11.8 million from July 1, 2018 through and immediately
                                         prior to the date of this prospectus but does not reflect reductions in cash subsequent
                                         to June 30, 2018 as a result of expenses incurred in the ordinary course of business;
                                         and</P>


</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma as adjusted basis to give effect to (i) the issuance of&nbsp;3,485,483 shares of common stock for which we received net proceeds of $11.8 million from July 1, 2018 through and immediately prior to the date of this prospectus but does not reflect reductions in cash subsequent to June 30, 2018 as a result of expenses incurred in the ordinary course of business and (ii) the sale of 2,520,000 Class A Units in this offering at the public offering price of $1.15 per Class A Unit, and 15,723 Class B Units, at the public offering price of $1,000 per Class B Unit, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The pro forma as adjusted basis assumes that all of the Class B Units convert to 13,672,173 shares of common stock and excludes the proceeds, if any, from the exercise of any warrants issued in this offering.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Capitalization table should be read
in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our historical financial statements and notes to those financial statements that are incorporated by reference in this prospectus.
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30, 2018<BR> (in thousands)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma As <BR> Adjusted</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -6pt; padding-left: 6pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,129</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">18,886</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">35,604</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -6pt; padding-left: 6pt">Series A convertible preferred stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,173</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,173</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,173</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -6pt; padding-left: 6pt">Common stock, $0.001 par value; 35,000,000 shares authorized, 3,722,837, shares issued and outstanding actual; Preferred Stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">130</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -6pt; padding-left: 6pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">194,186</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">205,940</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">222,642</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -6pt; padding-left: 6pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(200,803</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(200,803</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(200,803</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -6pt; padding-left: 6pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -6pt; padding-left: 6pt">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,487</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,144</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,862</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -6pt; padding-left: 6pt">Non-controlling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,940</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,940</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,940</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -6pt; padding-left: 6pt">Total Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,427</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,204</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,922</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -6pt; padding-left: 6pt">Total Capitalization</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,427</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,204</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">19,922</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we indicate otherwise, all information
in this Capitalization section&nbsp;is as of June 30, 2018 and:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">reflects
                                         a one-for-thirty-five reverse stock split of our issued and outstanding shares of common
                                         stock, options and warrants effected on </FONT>August 10<FONT STYLE="font-family: Times New Roman, Times, Serif">,
                                         2018 and the corresponding adjustment of all common stock prices per share and stock
                                         option and warrant exercise prices per share and conversion ratios</FONT> without taking
                                         into account fractional shares which are rounded up to the nearest whole number<FONT STYLE="font-family: Times New Roman, Times, Serif">;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">assumes
                                         no exercise by the <FONT STYLE="font-family: Times New Roman, Times, Serif">underwriters
                                         of their over-allotment option; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">excludes
                                         shares of our common stock issuable upon conversion of outstanding shares of Series A
                                         preferred stock;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24pt">&nbsp;</TD>
    <TD STYLE="width: 24pt; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">excludes 347,765    shares of our common
    stock issuable     upon     exercise of outstanding options under our equity incentive plans at a weighted-average exercise
    price     of $54.19 per     share;</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">excludes
                                         915,854 shares of our common stock reserved for issuance upon the exercise of outstanding
                                         warrants with a weighted-average exercise price of $75.16 per share&nbsp;and assumes
                                         no exercise of the warrants issued in this offering;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">assumes all shares of Series B Preferred sold in this offering convert to 13,672,173 shares of common stock; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24pt">&nbsp;</TD>
    <TD STYLE="width: 24pt; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">excludes 170,674 shares of our common stock that are reserved for equity awards that may be granted under our equity incentive plans.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If you invest in
our securities in this offering, you will experience dilution to the extent of the difference between the public offering price
per Class A Unit in this offering and our as adjusted net tangible book value per share immediately after this offering assuming
no value is attributed to the warrants, and the warrants are accounted for and classified as equity. This calculation does not
reflect any dilution associated with the sale and exercise of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net tangible book value on June 30,
2018 was approximately $3.7 million, or $1.01 per share. &ldquo;Net tangible book value&rdquo; is total assets minus the sum of
liabilities and intangible assets. &ldquo;Net tangible book value per share&rdquo; is net tangible book value divided by the total
number of shares outstanding.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pro forma net tangible book value as
of June 30, 2018 was $15.5 million or $2.15 per share of common stock, based upon 7,208,320 shares outstanding, after giving effect
to issuances of 3,485,483 shares of common stock for which we received net proceeds of $11.8 million from July 1, 2018 through
and immediately prior to the date of this prospectus but does not reflect reductions in cash subsequent to June 30, 2018 as a result
of expenses incurred in the ordinary course of business. After giving effect to the sale by us of 2,520,000 Class A units in this
offering at a public offering price of $1.15 per Class A Unit, 15,723 Class B Units at a public offering price of $1,000 per Class
B Unit and assuming that all Class B Units convert to 13,672,173 shares of common stock, and after deducting the estimated underwriting
discount and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2018 would
have been approximately $32.2 million, or approximately $1.38&nbsp;per share. This represents an immediate decrease in pro forma
as adjusted net tangible book value of $0.77 per share to existing stockholders and an increase of $0.23 per share to new investors
purchasing Class A Units in this offering. The following table illustrates this per share dilution:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Public offering price per Class A Unit</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1.15</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Pro forma net tangible book value per share as of June 30, 2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Decrease in pro forma net tangible book value per share after this offering</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(0.77</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Pro forma as adjusted net tangible book value per share after giving effect to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1.38</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Immediate increase in pro forma as adjusted net tangible book value &nbsp;per share to investors purchasing our common stock in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.23</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
information above and below assumes that all shares of Series B Preferred that are sold in this offering convert to 13,672,173
shares of common stock. The information above assumes that the underwriters do not exercise their over-allotment option. If the
underwriters exercise their over-allotment option in full, the pro forma as adjusted net tangible book value would be $1.35 per
share, representing an immediate decrease to existing stockholders of $0.80 per share and an immediate</FONT> increase in pro forma
as adjusted net tangible book value <FONT STYLE="background-color: white">of $0.20 per share to new investors. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing discussion and table do
not take into account further dilution to new investors that could occur upon the exercise of outstanding options or warrants
or conversion of our outstanding Series A Preferred Stock. In addition, we may choose to raise additional capital due to market
conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><FONT STYLE="text-transform: uppercase"><B>MARKET
FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has traded on the NYSE
American under the symbol &ldquo;SYN&rdquo; since February 16, 2012. Prior to February 16, 2012, our common stock traded under
the symbol &ldquo;AEN&rdquo; since October 16, 2008. The following table states the range of the high and low sales prices of our
common stock for the year ended December 31, 2016, and the year ended December 31, 2017 and the first and second fiscal quarter
of 2018 and for the third quarter through October 10, 2018 (as adjusted to reflect the one-for-thirty-five reverse stock split
effective August 10, 2018). These quotations represent inter-dealer prices, without retail mark-up, markdown, or commission, and
may not represent actual transactions. The last price of our common stock as reported on the NYSE American on October 8, 2018 was
$2.10 per share. As of October 10, 2018, there were approximately 347 stockholders of record of our common stock. This number does
not include beneficial owners from whom shares are held by nominees in street name.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2018, we announced a reverse
stock split of our shares of common stock at a ratio of one-for-thirty-five. The reverse stock split took effect at 11 p.m. (Eastern
Time) on August 10, 2018, and our common stock began to trade on a post-split basis at the market open on August 13, 2018. When
the reverse stock split became effective, every 35 shares of our issued and outstanding common stock were combined into one share
of common stock. Effecting the reverse stock split reduced the number of issued and outstanding common stock from approximately
132,969,743 shares to approximately 3,799,136. It also subsequently adjusted outstanding options issued under our equity incentive
plan, outstanding warrants to purchase common stock and our outstanding preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">YEAR ENDED DECEMBER 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">82.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">35.35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">95.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">57.40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">66.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">61.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26.60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">YEAR ENDED DECEMBER 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14.35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">YEAR ENDED DECEMBER 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Third Quarter (through October 10, 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 40; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid cash dividends on our
common stock. Moreover, we do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. We
intend to use all available cash and liquid assets in the operation and growth of our business, subject to terms of any preferred
stock or debt securities. Any future determination about the payment of dividends will be made at the discretion of our board
of directors and will be subject to the rights of any outstanding preferred stock and will depend upon our earnings, if any, capital
requirements, operating and financial conditions and on such other factors as our board of directors deems relevant. The Series
A Preferred Stock ranks senior to the shares of our common stock with respect to dividend rights and holders of Series A Preferred
Stock are entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears, as set forth in the Certificate
of Designation of Series A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>DESCRIPTION OF OUR
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital currently consists
of 200 million shares of common stock, par value $0.001 per share, and 10 million shares of preferred stock, par value $0.001 per
share. As of October 10, 2018, 7,208,320 shares of common stock were issued and outstanding, and 120,000 shares of preferred stock
were issued and outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue shares of our common stock
from time to time. We currently have authorized 200,000,000 million shares of common stock, par value $.001 per share. We may
offer shares of common stock alone or underlying the registered securities convertible into or exercisable for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting.</I> The holders of our common
stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including
the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our
common stock entitled to vote in any election of directors can elect all of the directors standing for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividends.</I> Subject to preferences
that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends,
if any, as may be declared from time to time by our board of directors out of legally available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation.</I> In the event of our
liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction
of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rights and Preferences.</I> The holders
of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and
may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and
issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fully Paid and Nonassessable</I>. All
of our outstanding shares of common stock are, and the shares of common stock to be issued under this prospectus will be, fully
paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus, we have summarized
certain general features of our common stock under &ldquo;Description of Our Securities&mdash;Common Stock&rdquo;. We urge you,
however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided
to you) related to any common stock being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has the authority,
without action by our stockholders, to designate and issue up to 10 million shares of preferred stock in one or more series or
classes and to designate the rights, preferences and privileges of each series or class, which may be greater than the rights
of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights
of holders of our common stock until our board of directors determines the specific rights of the holders of the preferred stock.
However, the effects might include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 2%">&#9679;</TD>
    <TD STYLE="width: 96%; text-align: justify">restricting dividends on our common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 2%">&#9679;</TD>
    <TD STYLE="width: 96%; text-align: justify">diluting the voting power of our common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 2%">&#9679;</TD>
    <TD STYLE="width: 96%; text-align: justify">impairing liquidation rights of our common stock; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 2%">&#9679;</TD>
    <TD STYLE="width: 96%; text-align: justify">delaying or preventing a change in control of us without further action by our
    stockholders.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors&rsquo; authority
to issue preferred stock without stockholder approval could make it more difficult for a third-party to acquire control of our
company, and could discourage such attempt. We have no present plans to issue any shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series A Preferred</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had 120,000 shares of Series A Preferred
Stock outstanding as of October 10, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Stock ranks senior
to the shares of our common stock, and any other class or series of stock issued by us with respect to dividend rights, redemption
rights and rights on the distribution of assets on our voluntary or involuntary liquidation, dissolution or winding up. Holders
of Series A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears,
as set forth in the Certificate of Designation of Series A Preferred Stock classifying the Series A Preferred Stock. The Series
A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at a conversion price of
$18.90 per share (as adjusted to reflect the 1-for-35 reverse stock split effected August 10, 2018), subject to certain customary
anti-dilution adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any conversion of Series A Preferred Stock
may be settled by us in shares of common stock only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holder&rsquo;s ability to convert
the Series A Preferred Stock into common stock is subject to (i) a 19.99% blocker provision to comply with NYSE American Listing
Rules, (ii) if so elected by the holder, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99%
of our outstanding shares common stock or voting power at any time, and (iii) applicable regulatory restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of our liquidation, dissolution
or winding-up, holders of the Series A Preferred Stock are entitled to a preference on liquidation equal to the greater of (i)
an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series A Preferred Stock
(the &ldquo;Accreted Value&rdquo;), and (ii) the amount such holders would receive in such liquidation if they converted their
shares of Series A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of
the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i) and (ii), is referred
to as the &ldquo;Liquidation Value&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise required by law, the
holders of Series A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance
of <I>pari passu</I> or senior preferred stock. Upon certain change of control events involving our company, we will be required
to repurchase all of the Series A Preferred Stock at a redemption price equal to the greater of (i) the Accreted Value and (ii)
the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common
stock issuable upon conversion of such share of Series A Preferred Stock if all outstanding shares of Series A Preferred Stock
were converted into common stock immediately prior to the change of control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On or at any time after (i) the VWAP (as
defined in the Certificate of Designation) for at least 20 trading days in any 30 trading day period is greater than $70.00 (as
adjusted to reflect the 1-for-35 reverse stock split effected August 10, 2018), subject to adjustment in the case of stock split,
stock dividends or the like we have the right, after providing notice not less than 6 months prior to the redemption date, to
redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Preferred
Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share of Series A Preferred Stock
of $7,875.00 (as adjusted to reflect the 1-for-35 reverse stock split effected August 10, 2018), subject to appropriate adjustment
in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred
Stock, or (ii) the five year anniversary of the issue date, we have the right to redeem, in whole or in part, on a pro rata basis
from all holders thereof based on the number of shares of Series A Preferred Stock then held, the outstanding Series A Preferred
Stock, for cash, at a redemption price per share equal to the Liquidation Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 10, 2018, we had issued and
outstanding warrants to purchase a total of 915,857 shares of our common stock outstanding at a weighted-average price of $75.16
(as adjusted to reflect the 1-for-35 reverse stock split effected August 10, 2018 without taking into account fractional shares
which are rounded up to the nearest whole number).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2016, we completed a public
offering of 714,286 shares of common stock (as adjusted to reflect the 1-for-35 reverse stock split effected August 10, 2018)
in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of the common stock(as adjusted to reflect
the 1-for-35 reverse stock split effected August 10, 2018), of which warrants to purchase 714,286 (as adjusted to reflect the
1-for-35 reverse stock split effected August 10, 2018 without taking into account fractional shares) shares of common stock are
outstanding (the &ldquo;Series A Warrants&rdquo;). The per share exercise price of the Series A Warrants is $50.05 (as adjusted
to reflect the 1-for-35 reverse stock split effected August 10, 2018) subject to further adjustment as specified in the warrant
agreements. The Series A Warrants may be exercised at any time until the four-year anniversary of the issuance date. The warrants
include a provision that if we were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased
from the holder for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 10, 2014, we issued 14,059,616
units at a price of $1.47 per unit to certain institutional investors in a registered direct offering, each unit consisted of
one share of our common stock and a warrant to purchase 0.5 shares of common stock. The warrants, exercisable for an aggregate
of 200,852 (as adjusted to reflect the 1-for-35 reverse stock split effected August 10, 2018 without taking into account fractional
shares) shares of common stock, have an exercise price of $61.25 per share (as adjusted to reflect the 1-for-35 reverse stock
split effected August 10, 2018) and a life of five years. The warrants vested immediately and expire on October 10, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 10, 2018, options to purchase
an aggregate of 347,765&nbsp;(as adjusted to reflect the 1-for-35 reverse stock split effected August 10, 2018 without taking
into account fractional shares) shares of common stock were outstanding under our equity incentive plans.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stockholder Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are party to a registration rights
agreement (the &ldquo;Registration Rights Agreement&rdquo;) that provides the holder of the Series A Preferred Stock with certain
registration rights. Pursuant to the terms of the Registration Rights Agreement, we agreed to file a registration statement covering
resales of the shares of common stock issuable upon conversion of the Series A Preferred Stock with the SEC within 60 days following
receipt of a request at any time (as long as the requestor beneficially owns at least ten percent (10%) of our common stock then
outstanding or is otherwise deemed our affiliate) and to use reasonable best efforts to have the registration statement declared
effective within 120 days following receipt of such request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay certain penalties
if the registration statement is not declared effective by the SEC on or before the required deadline. After that deadline and
until such time as the registration statement is declared effective (or until we are no longer required to cause the registration
statement to be declared effective), we will be required to pay additional liquidated damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the registration
rights agreement that we entered into with Intrexon and an affiliated entity, we were required to file a registration statement
with respect to securities issued and are required to maintain the effectiveness of such registration statement. The failure to
do so could result in the payment of damages by us. The registration statement was declared effective on April 29, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Certain Provisions
of our Articles of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation, as amended,
and amended and restated bylaws contain certain provisions that may have anti-takeover effects, making it more difficult for or
preventing a third party from acquiring control of the Company or changing its board of directors and management. According to
our Amended and Restated Bylaws and Articles of Incorporation, neither the holders of our common stock nor the holders of any
preferred stock we may issue in the future have cumulative voting rights in the election of our directors. The lack of cumulative
voting makes it more difficult for other stockholders to replace our board of directors or for a third party to obtain control
of our company by replacing its board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Authorized but Unissued Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized but unissued shares of
common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares
for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee
compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult
or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;business combination&rdquo;
provisions of Sections 78.411 to 78.444, inclusive, of the Nevada Revised Statute (the &ldquo;NRS&rdquo;) generally prohibit a
Nevada corporation with at least 200 stockholders from engaging in various &ldquo;combination&rdquo; transactions with any interested
stockholder for a period of two years after the date of the transaction in which the person became an interested stockholder,
unless the transaction is approved by the board of directors prior to the date the interested stockholder obtained such status
or the combination is approved by the board of directors and thereafter is approved at a meeting of the stockholders by the affirmative
vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders, and extends
beyond the expiration of the two-year period, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol"><B>&middot;</B></FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">the combination was approved by the board of directors prior to the person becoming
    an interested stockholder or the transaction by which the person first became an interested stockholder was approved by the
    board of directors before the person became an interested stockholder or the combination is later approved by a majority of
    the voting power held by disinterested stockholders; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol"><B>&middot;</B></FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">if the consideration to be paid by the interested stockholder is at least equal
    to the highest of: (a) the highest price per share paid by the interested stockholder within the two years immediately preceding
    the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever
    is higher, (b) the market value per share of common stock on the date of announcement of the combination and the date the
    interested stockholder acquired the shares, whichever is higher, or (c) for holders of preferred stock, the highest liquidation
    value of the preferred stock, if it is higher.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;combination&rdquo; is generally
defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in
one transaction or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a) an aggregate market value
equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal to 5%
or more of the aggregate market value of all outstanding shares of the corporation, (c) 10% or more of the earning power or net
income of the corporation, and (d) certain other transactions with an interested stockholder or an affiliate or associate of an
interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, an &ldquo;interested stockholder&rdquo;
is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s
voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may
discourage attempts to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their
stock at a price above the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Control Share Acquisitions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;control share&rdquo; provisions
of Sections 78.378 to 78.3793, inclusive, of the NRS apply to &ldquo;issuing corporations&rdquo; that are Nevada corporations
with at least 200 stockholders, including at least 100 stockholders of record who are Nevada residents, and that conduct business
directly or indirectly in Nevada. The control share statute prohibits an acquirer, under certain circumstances, from voting its
shares of a target corporation&rsquo;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains
approval of the target corporation&rsquo;s disinterested stockholders. The statute specifies three thresholds: one-fifth or more
but less than one-third, one-third but less than a majority, and a majority or more, of the outstanding voting power. Generally,
once an acquirer crosses one of the above thresholds, those shares in an offer or acquisition and acquired within 90 days thereof
become &ldquo;control shares&rdquo; and such control shares are deprived of the right to vote until disinterested stockholders
restore the right. These provisions also provide that if control shares are accorded full voting rights and the acquiring person
has acquired a majority or more of all voting power, all other stockholders who do not vote in favor of authorizing voting rights
to the control shares are entitled to demand payment for the fair value of their shares in accordance with statutory procedures
established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A corporation may elect to not be governed
by, or &ldquo;opt out&rdquo; of, the control share provisions by making an election in its articles of incorporation or bylaws,
provided that the opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling
interest, that is, crossing any of the three thresholds described above. We have not opted out of the control share statutes,
and will be subject to these statutes if we are an &ldquo;issuing corporation&rdquo; as defined in such statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effect of the Nevada control share
statutes is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting
rights in the control shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada
control share law, if applicable, could have the effect of discouraging takeovers of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our
common stock is Corporate Stock Transfer, Inc. The transfer agent&rsquo;s address is 3200 Cherry Creek South Drive, Suite 430,
Denver, Colorado 80209. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named
and described in the prospectus supplement for that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing on the NYSE American</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NYSE American under the symbol
 &ldquo;SYN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>DESCRIPTION OF SECURITIES
WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering 2,520,000 Class A Units,
assuming no exercise of the over-allotment option. We are also offering to each purchaser whose purchase of Class A Units in this
offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning
more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation
of this offering, the opportunity in lieu of purchasing Class A Units, to purchase Class B Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also offering 15,723 Class B Units
consisting of 15,723 shares of Series B Preferred, which is convertible into an aggregate of 13,672,173 shares of our common stock,
and warrants to purchase 13,672,173 shares of our common stock. Each Class B Unit consists of one share of Series B Preferred with
a stated value of $1,000 and is convertible into shares of our common stock at the public offering price of the Class A Units,
or $1.15 per share, together with the equivalent number of warrants as would have been issued to such purchaser of Class B Units
if they had purchased Class A Units based on the public offering price. For each Class B Unit we sell, the number of Class A Units
we are offering will be decreased on a dollar-for-dollar basis. Because we will issue a warrant as part of each Unit, the number
of warrants sold in this offering will not change as a result of a change in the mix of the Units sold. The number of shares of
our common stock outstanding after this offering will fluctuate depending on how many Class B Units are sold in this offering and
whether and to what extent holders of Series B Preferred shares convert their shares to common stock. We are also offering the
shares of common stock issuable upon exercise of warrants sold in Class B Units and upon conversion of the Series B Preferred.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The material terms and provisions of our
common stock and each other class of our securities which qualifies or limits our common stock are described under the caption
 &ldquo;Description of Our Securities&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of our articles
of incorporation, our board of directors has the authority to issue preferred stock in one or more classes or series and to fix
the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, including dividend
rights, conversion right, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any
class or series, without further vote or action by the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series B Convertible Preferred Stock
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following is a summary of the material
terms of the Series B Preferred. This summary is not complete. The following summary of the terms and provisions of the Series
B Preferred is qualified in its entirety by reference to the Certificate of Designation of the Series B Preferred, the form of
which has been filed as an exhibit to the registration statement of which this prospectus is a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General. </I>Our board of directors
has designated up to 15,723 shares of the 10,000,000 authorized shares of preferred stock as Series B Convertible Preferred Stock.
When issued, the shares of Series B Preferred will be validly issued, fully paid and non-assessable. Each share of Series B Preferred
will have a stated value of $1,000 per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rank. </I>The Series B Preferred will
rank junior to the Series A Preferred Stock and on parity to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conversion. </I>Each share of Series
B Preferred is convertible into shares of our common stock (subject to adjustment as provided in the related certificate of designation
of preferences, rights and limitations) at any time at the option of the holder at a conversion price equal to the stated value
of the Series B Preferred of $1,000 divided by the public offering price of the Class A Units in this offering. Holders of Series
B Preferred will be prohibited from converting Series B Preferred into shares of our common stock if, as a result of such conversion,
the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our common stock then issued
and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon
at least 61 days&rsquo; prior notice from the holder to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Preference.</I> Subject
to the senior rights of the Series A Preferred Stock, in the event of our liquidation, dissolution or winding-up, holders of Series
B Preferred will be entitled to receive if the Series B Preferred were fully converted into shares of our common stock at the
conversion price (disregarding for such purposes any conversion limitations) which amounts shall be paid <I>pari passu</I> with
all holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights.</I> Shares of Series
B Preferred will generally have no voting rights, except as required by law and except that the affirmative vote of the holders
of a majority of the then outstanding shares of Series B Preferred is required to, (a) alter or change adversely the powers, preferences
or rights given to the Series B Preferred, (b) amend our articles of incorporation or other charter documents in any manner that
materially adversely affects any rights of the holders, (c) increase the number of authorized shares of Series B Preferred, or
(d) enter into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividends. </I>Shares of Series B Preferred
will not be entitled to receive any dividends, unless and until specifically declared by our board of directors. Subject to any
senior rights of the Series A Preferred Stock, the holders of the Series B Preferred will participate, on an as-if-converted-to-common
stock basis, in any dividends to the holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Redemption. </I>We are not obligated
to redeem or repurchase any shares of Series B Preferred. Shares of Series B Preferred are not otherwise entitled to any redemption
rights or mandatory sinking fund or analogous fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exchange Listing.</I> We do not plan
on making an application to list the Series B Preferred on the NYSE American, any other national securities exchange or other
nationally recognized trading system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary of certain terms
and provisions of the warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety
by, the provisions of the warrant agent agreement, the form of which is filed as an exhibit to the registration statement of which
this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of warrant agent
agreement for a complete description of the terms and conditions of the common warrants.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Form.</I> The warrants will be issued in electronic book
entry form. The form of warrant is filed as an exhibit to the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercisability.</I> The warrants
are exercisable at any time after their original issuance and will expire on the fifth anniversary of the original issuance date.
The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise.
If at the time of exercise, there is no effective registration statement registering, or no current prospectus available for,
the issuance of the shares of common stock to the holder, then the common warrant may only be exercised through a cashless exercise,
in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the
formula set forth in the warrant. No fractional shares of common stock will be issued in connection with the exercise of a warrant.
In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the fair market
value of any such fractional shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercise Limitations.</I> Under the
warrants, we may not effect the exercise of any warrant, and a holder will not be entitled to exercise any portion of any warrant,
which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned
by the holder (together with its affiliates) to exceed [4.99%/9.99%] of the number of shares of our common stock outstanding immediately
after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together
with its affiliates) to exceed [4.99%/9.99%] of the combined voting power of all of our securities then outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants.
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days&rsquo;
prior notice from the holder to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercise Price.</I> The exercise price
per whole share of our common stock purchasable upon the exercise of the warrants is 120% of the public offering price of the Class
A Units, or $1.38 per share. The exercise price of the warrants is subject to appropriate adjustment in the event of certain stock
dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and
also upon any distributions of assets, including cash, stock or other property to our stockholders. Subject to certain exceptions,
the warrants provide for adjustment of the exercise price if we or any of our subsidiaries, as applicable, sell or grant any right
to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition)
any shares of our common stock or common stock equivalents, at an effective price per share that is less than the exercise price
then in effect (such lower price, the &ldquo;Base Share Price&rdquo; and such issuances collectively, a &ldquo;Dilutive Issuance&rdquo;).
In the event a Dilutive Issuance occurs, the exercise price shall be reduced to equal the Base Share Price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Transferability</I>. Subject to applicable
laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exchange Listing</I>. We do not plan
on applying to list the warrants on the NYSE American, any other national securities exchange or any other nationally recognized
trading system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fundamental Transactions.</I> In the
event of a fundamental transaction, as described in the warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common
stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock,
the holders of the common warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities,
cash or other property that the holders would have received had they exercised the warrants immediately prior to such fundamental
transaction without regard to any limitations on exercise contained in the warrants. In the event of a fundamental transaction,
we are required to cause any successor entity to assume all of our obligations under the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Right as a Stockholder</I>. Except
by virtue of such holder&rsquo;s ownership of shares of our common stock, the holder of a warrant does not have the rights or
privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into an underwriting agreement,
dated October 10, 2018, with A.G.P., acting as the representative of the several underwriters named below. Subject to the terms
and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and the underwriters have severally agreed
to purchase, the number of Units, provided below opposite their respective names.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Underwriters</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class A Units</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class B Units</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-bottom: 1pt; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">A.G.P./Alliance Global Partners</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,520,000</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">15,723</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 24.15pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>2,520,000</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>15,723</B></P></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The underwriters are
offering the Units subject to their acceptance of the Units from us and subject to prior sale. The underwriting agreement provides
that the obligations of the several underwriters to pay for and accept delivery of the Units offered by this prospectus are subject
to the approval of certain legal matters by their counsel and to certain other conditions. The underwriter is obligated to purchase
all of the Units if any of the securities are purchased, other than those shares covered by the over-allotment option to purchase
additional securities described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discount, Commissions and Expenses
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters have advised us that they
propose to offer the Units to the public at the public offering price set forth on the cover page of this prospectus and to certain
dealers at that price less a concession not in excess of $0.04025 per Unit. After this offering, the public offering price, concession and reallowance to dealers may be changed by the
representative. No such change shall change the amount of proceeds to be received by us as set forth on the cover page of this
prospectus. The Units are offered by the underwriters as stated herein, subject to receipt and acceptance by them and subject to
their right to reject any order in whole or in part. The underwriters have informed us that they do not intend to confirm sales
to any accounts over which they exercise discretionary authority.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows the underwriting discount payable
to the underwriters by us in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Class A Unit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Class B Unit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Without Over-</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Allotment</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>With Over-</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Allotment</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1.15&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">18,621,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">21,414,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Underwriting discount<SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.0805&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,303,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,499,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.0695&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">930&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,318,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19,915,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to reimburse the underwriters
for certain out-of-pocket expenses not to exceed $150,000 in the aggregate without our consent which shall not be unreasonably
withheld. We estimate that expenses payable by us in connection with this offering, including reimbursement of the underwriters
out-of-pocket expenses, but excluding the underwriting discount referred to above, will be approximately $600,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">The underwriter will receive a discount of 7% to the public offering price with respect to any Class A
Units or Class B Units purchased in this offering by investors. The underwriters have agreed to credit us $105,000 at the closing
with respect to sales made to a certain investor.</P>


</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Option To Purchase Additional Shares and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted to the underwriters an
over-allotment option exercisable not later than 45 days after the date of this prospectus to purchase up to 2,428,825 additional
shares of common stock (15% of the shares included in the Class A Units sold in this offering and the shares of common stock issuable
upon conversion of the Series B Preferred included in Class B Units sold in the offering) and/or warrants to purchase a maximum
of up to 2,428,825 additional shares of common stock from us to cover over-allotments, if any. If the underwriters exercise all
or part of this option, they will purchase such common stock covered by the option at the public offering price per Class A Unit,
minus once cent and the warrants covered by this option at a price of one cent per warrant, in each case less the underwriting
discounts and commissions. If this option is exercised in full, the total offering price to the public will be approximately $21.4
million and the total net proceeds, after expenses, to us will be approximately $19.9&nbsp;million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have agreed to indemnify
the underwriters against certain liabilities, including liabilities under the Securities Act and liabilities arising from breaches
of representations and warranties contained in the underwriting agreement, or to contribute to payments that the underwriters
may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Determination of Offering Price </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The actual offering price of the securities we are offering
will be negotiated between us and the underwriter based on the trading of our shares of common stock prior to the offering, among
other things, and may be at a discount to the current market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-up Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We, our officers and
directors have agreed, subject to limited exceptions, for a period of 90 days after the date of the underwriting agreement, not
to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly
or indirectly any shares of common stock or any securities convertible into or exchangeable for our common stock either owned
as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the representative. The
representative may, in its sole discretion and at any time or from time to time before the termination of the lock-up period,
without notice, release all or any portion of the securities subject to lock-up agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Price Stabilization, Short Positions and Penalty Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter may engage in syndicate
covering transactions, stabilizing transactions and penalty bids or purchases for the purpose of pegging, fixing or maintaining
the price of our shares of common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Syndicate
                                         covering transactions involve purchases of securities in the open market after the distribution
                                         has been completed in order to cover syndicate short positions. Such a naked short position
                                         would be closed out by buying securities in the open market. A naked short position is
                                         more likely to be created if the underwriter is concerned that there could be downward
                                         pressure on the price of the securities in the open market after pricing that could adversely
                                         affect investors who purchase in the offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Stabilizing
                                         transactions permit bids to purchase the underlying security so long as the stabilizing
                                         bids do not exceed a specific maximum.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Penalty
                                         bids permit the underwriter to reclaim a selling concession from a syndicate member when
                                         the securities originally sold by the syndicate member are purchased in a stabilizing
                                         or syndicate covering transaction to cover syndicate short positions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These syndicate covering transactions,
stabilizing transactions and penalty bids may have the effect of raising or maintaining the market prices of our securities or
preventing or retarding a decline in the market prices of our securities. As a result, the price of our shares of common stock
may be higher than the price that might otherwise exist in the open market. Neither we nor the underwriter make any representation
or prediction as to the effect that the transactions described above may have on the price of our shares of common stock. These
transactions may be effected on the NYSE American, in the over-the-counter market or on any other trading market and, if commenced,
may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this offering, the
underwriter also may engage in passive market making transactions in our shares of common stock in accordance with Regulation&nbsp;M
during a period before the commencement of offers or sales of our shares of common stock in this offering and extending through
the completion of the distribution. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for that security. However, if all independent bids are lowered below the passive market maker&rsquo;s bid that
bid must then be lowered when specific purchase limits are exceeded. Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriter make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on
the prices of our securities. In addition, neither we nor the underwriter make any representation that the underwriter will engage
in these transactions or that any transactions, once commenced, will not be discontinued without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Electronic Distribution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus in electronic format may
be made available on websites or through other online services maintained by one or more of the underwriters, or by their affiliates.
Other than this prospectus in electronic format, the information on any underwriter&rsquo;s website and any information contained
in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus
forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter, and should not be
relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, certain of the underwriters
and/or their affiliates have provided, and may in the future provide, various investment banking and other financial services
for us for which services they have received and, may in the future receive, customary fees. In the course of their businesses,
the underwriters and their affiliates may actively trade our securities or loans for their own account or for the accounts of
customers, and, accordingly, the underwriters and their affiliates may at any time hold long or short positions in such securities
or loans. Except for services provided in connection with this offering, no underwriter has provided any investment banking or
other financial services to us during the 180-day period preceding the date of this prospectus and we do not expect to retain
any underwriter to perform any investment banking or other financial services for at least 90 days after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>NOTICE TO INVESTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notice to Investors in Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus
Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale securities must be made in accordance
with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities legislation in certain provinces
or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment
thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within
the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer
to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these
rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section 3A.3 (or, in the case
of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105
Underwriting Conflicts (&ldquo;NI 33-105&rdquo;), the underwriters are not required to comply with the disclosure requirements
of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Notice to Investors
in the United Kingdom </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In relation to each Member State of the
European Economic Area which has implemented the Prospectus Directive (each, a &ldquo;Relevant Member State&rdquo;) an offer to
the public of any securities which are the subject of the offering contemplated by this prospectus may not be made in that Relevant
Member State except that an offer to the public in that Relevant Member State of any such securities may be made at any time under
the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose
corporate purpose is solely to invest in securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
any legal entity which has two or more of: (1) an average of at least 250 employees during the last financial year; (2) a total
balance sheet of more than &euro;43,000,000; and (3) an annual net turnover of more than &euro;50,000,000, as shown in its last
annual or consolidated accounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
the underwriters to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus Directive);
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of these securities
shall result in a requirement for the publication by the issuer or the underwriters of a prospectus pursuant to Article 3 of the
Prospectus Directive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of this provision, the
expression an &ldquo;offer to the public&rdquo; in relation to any of the securities in any Relevant Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and any such securities to be offered so as to
enable an investor to decide to purchase any such securities, as the same may be varied in that Member State by any measure implementing
the Prospectus Directive in that Member State and the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC
and includes any relevant implementing measure in each Relevant Member State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each underwriter has represented, warranted
and agreed that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement
to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 (the FSMA))
received by it in connection with the issue or sale of any of the securities in circumstances in which section 21(1) of the FSMA
does not apply to the issuer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has complied with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to
the securities in, from or otherwise involving the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>European Economic Area</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In particular, this document does not
constitute an approved prospectus in accordance with European Commission&rsquo;s Regulation on Prospectuses no. 809/2004 and no
such prospectus is to be prepared and approved in connection with this offering. Accordingly, in relation to each Member State
of the European Economic Area which has implemented the Prospectus Directive (being the Directive of the European Parliament and
of the Council 2003/71/EC and including any relevant implementing measure in each Relevant Member State) (each, a Relevant Member
State), with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State
(the Relevant Implementation Date) an offer of securities to the public may not be made in that Relevant Member State prior to
the publication of a prospectus in relation to such securities which has been approved by the competent authority in that Relevant
Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that
Relevant Member State, all in accordance with the Prospectus Directive, except that it may, with effect from and including the
Relevant Implementation Date, make an offer of securities to the public in that Relevant Member State at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to
                                         legal entities which are authorized or regulated to operate in the financial markets
                                         or, if not so authorized or regulated, whose corporate purpose is solely to invest in
                                         securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to
                                         any legal entity which has two or more of: (1) an average of at least 250 employees during
                                         the last financial year; (2) a total balance sheet of more than &euro;43,000,000; and
                                         (3) an annual net turnover of more than &euro;50,000,000, as shown in the last annual
                                         or consolidated accounts; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in
                                         any other circumstances which do not require the publication by the Issuer of a prospectus
                                         pursuant to Article 3 of the Prospectus Directive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of this provision, the
expression an &ldquo;offer of securities to the public&rdquo; in relation to any of the securities in any Relevant Member State
means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to
be offered so as to enable an investor to decide to purchase or subscribe for the securities, as the same may be varied in that
Member State by any measure implementing the Prospectus Directive in that Member State. For these purposes the securities offered
hereby are &ldquo;securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gracin &amp; Marlow, LLP, New York, New
York will pass upon certain legal matters related to the issuance and sale of the warrants offered on our behalf and Parsons Behle
 &amp; Latimer, Reno, Nevada will pass upon certain legal matters relating to the issuance and sale of the common stock offered
hereby on our behalf. Zysman, Aharoni, Gayer and Sullivan &amp; Worcester LLP, is acting as counsel to the underwriters in this
offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements as of December
31, 2017 and 2016 and for the years then ended and management&rsquo;s assessment of the effectiveness of internal control over
financial reporting as of December 31, 2017 incorporated by reference in this Prospectus and in the Registration Statement have
been so incorporated in reliance on the reports of BDO USA, LLP, an independent registered public accounting firm (the reports
on the financial statements contain an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going concern),
incorporated by reference in this Prospectus and in the Registration Statement, given on the authority of said firm as experts
in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016"></A><B>WHERE YOU CAN FIND
ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the Securities and
Exchange Commission (the &ldquo;SEC&rdquo;) a registration statement on Form S-1 under the Securities Act with respect to the
securities offered by this prospectus. This prospectus, which is part of the registration statement, omits certain information,
exhibits, schedules and undertakings set forth in the registration statement. For further information pertaining to us and the
securities offered hereby, reference is made to the registration statement and the exhibits and schedules to the registration
statement. Statements contained in this prospectus as to the contents or provisions of any documents referred to in this prospectus
are not necessarily complete, and in each instance where a copy of the document has been filed as an exhibit to the registration
statement, reference is made to the exhibit for a more complete description of the matters involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read and copy all or any portion
of the registration statement without charge at the public reference room of the SEC at 100 F Street, N.E., Washington, D.C. 20549.
Copies of the registration statement may be obtained from the SEC at prescribed rates from the public reference room of the SEC
at such address. You may obtain information regarding the operation of the public reference room by calling 1-800-SEC-0330. In
addition, registration statements and certain other filings made with the SEC electronically are publicly available through the
SEC&rsquo;s website at <I>www.sec.gov</I>. The registration statement, including all exhibits and amendments to the registration
statement, has been filed electronically with the SEC. You may also read all or any portion of the registration statement and
certain other filings made with the SEC on our website at <I>www.syntheticbiologics.com</I>. The information contained in, and
that can be accessed through, our website is not incorporated into and is not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the information and
periodic reporting requirements of the Exchange Act and, accordingly, are required to file annual reports containing financial
statements audited by an independent public accounting firm, quarterly reports containing unaudited financial data, current reports,
proxy statements and other information with the SEC. You will be able to inspect and copy such periodic reports, proxy statements
and other information at the SEC&rsquo;s public reference room, the website of the SEC referred to above, and our website at <I>www.syntheticbiologics.com</I>.
Except for the specific incorporated reports and documents listed above, no information available on or through our website shall
be deemed to be incorporated in this prospectus or the registration statement of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_017"></A><B>INCORPORATION OF
CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
SEC allows us to &ldquo;incorporate by reference&rdquo; certain information that we will file with it which means that we can
disclose important information to you by referring you to those documents instead of having to repeat the information in this
prospectus. The later information that we file with the SEC will automatically update and supersede this information. We incorporate
by reference </FONT>the documents listed below and any future filings made <FONT STYLE="font-family: Times New Roman, Times, Serif">with
the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act </FONT>(Commission File No. 001-35994)) after (i) the date
of this initial registration statement and prior to effectiveness of this registration statement and (ii) the date of this prospectus
and before the completion of the offering of the securities included in this prospectus, <FONT STYLE="font-family: Times New Roman, Times, Serif">however,
we will not incorporate by reference any documents or portions thereof that are not deemed &ldquo;filed&rdquo; with the SEC, or
any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form
8-K:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">Our annual report on Form 10-K for the fiscal year ended December 31, 2017 filed
    with the SEC on February 22, 2018 (File No. 001-12584);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">Our quarterly reports on Form 10-Q for the quarters ended March 31, 2018 and June
    30, 2018 filed with the SEC on May 8, 2018 and August 8, 2018, respectively (File No. 001-12584);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><P STYLE="margin: 0pt 0">Our current reports on Form 8-K (File No. 001-12584)
                                         filed with the SEC on January 8, 2018, March 7, 2018; April 23, 2018, May 7, 2018, May
                                         22, 2018; August 1, 2018, August 13, 2018, September 6, 2018, September 6, 2018, September
                                         26, 2018, October 2, 2018 and October 10, 2018;</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">Our definitive proxy statement on Schedule 14A filed with the SEC on August 14,
    2018 (File No. 001-12584); and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">The description of our common stock set forth in our registration statement on
    Form 8-A12B, filed with the SEC on June 20, 2007 (File No. 000-12584).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide to each person, including
any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the reports or documents that we incorporate
by reference in this prospectus contained in the registration statement (except exhibits to the documents that are not specifically
incorporated by reference) at no cost to you, by writing or calling us at the following address and telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270, Suite
12<BR>
Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information about us is available at our
website at <I>www.syntheticbiologics.com. </I> Except for the specific incorporated reports and documents listed above, no information
available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which
it forms a part. Any statement contained in this registration statement or in a document incorporated or deemed to be incorporated
by reference in this registration statement shall be deemed to be modified or superseded for purposes of this registration statement
to the extent that a statement contained in this registration statement or in any other subsequently filed document which also
is or is deemed to be incorporated by reference in this registration statement modifies or supersedes that statement. Any statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>2,520,000 Class
A Units Consisting of Shares of Common Stock and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>15,723 Class B Units
Consisting of Series B Convertible Preferred Stock and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>13,672,173 Shares of Common Stock Underlying
the Series B Convertible Preferred Stock and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>13,672,173
Shares of Common Stock Underlying the Warrants</B></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>A.G.P.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October 10, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Through and including November 5, 2018
(25 days after commencement of this offering), all dealers that effect transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This is in addition to the dealer&rsquo;s obligation to deliver a prospectus
when acting as an underwriter and with respect to their unsold allotments or subscriptions.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Options: NewSection Last; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ + "1 P$1  (1 0,1 ?_$ +T   (!! ,!
M      @)!P($!@H  0,% 0 ! P4!               %!@@)  (#! <!$
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MQ5 2' /:&MJKMRJ)D)7[V/JX]D:M+=O.U14G\,R]OMAK)%#"<Q1IOIU !':
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6]'FM>/XGVLHO_N_T:3W\CN@CX8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $I MD# 2(  A$! Q$!_\0
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M;_@HQ_T37]B?_P -)\=O_HHJ/^(G;_@HQ_T37]B?_P -)\=O_HHJ_-_X??\
M!++]NKXG_!;1/V@?"7P12/X9^)_"NO\ CGP?<^)_B+\,O!WB;QMX*\,:,NOZ
MOXG\(>"_%GC#1/%>NZ/+X>-UK&DZA9Z7>IJ^G1V6LZ:US9W>GSW/HG[</_!*
M3XS?L0?"CX,_&/Q)XX\&>/O"GQ%^&_@'Q-XV&F:GX!T6[^''Q"\>69F?X=:/
M9:3\3O'&J?%K0=&GL]12+XP>%=*TWP9K,,MK<V%O96UNAD /MS_B)V_X*,?]
M$U_8G_\ #2?';_Z**C_B)V_X*,?]$U_8G_\ #2?';_Z**OB']F/]ACX'^(/V
M0_'/[=W[8_QR\:_"+X"Z3\3A\%?AGX3^$'@G1/&?Q>^,?Q+BT0:KJ5GX<B\1
M:HGAO3K&T$&K"T@NHPM[#H'BC5K_ %;PSHFB6MQ?\M/^P)'\>/BEXXTC_@GE
M\0X_VC?@[X)\#?#WQOXF\?\ Q:U+P'^SUJGP^U#XCZSKGAW3OASXWA^(OB?P
MQI-YXLM-<\/RV<5WH1L;#5)+V-=+M)X#&\H!^@__ !$[?\%&/^B:_L3_ /AI
M/CM_]%%1_P 1.W_!1C_HFO[$_P#X:3X[?_115^;>E?\ !+3]NO5_C?\ %']G
M2R^"J#XO_!_X;V'Q>\7>&+_QW\.K"VG^'.J3+;Z7XF\.>)KSQ3:>#_$]AJ%V
MYLK==$UF^FBN;+4(=16VFWQ+2\:_\$Q/VX_A_P#''X._LYZY\#[V\^*GQ^T:
M_P!?^$>F^%O%G@GQIX?\7:)HPE;7]83QUX?U^[\$Z9I_AFTMX]3\3W/B#7])
M32=+U.QU2>6UMK_1?[1 /TQ_XB=O^"C'_1-?V)__  TGQV_^BBH_XB=_^"C'
M?X:_L3CW/PD^.V!]?^,HOP^M<!XQ_P""1UK\#?@;^Q%K'QJ\(?$36?VB?C]^
MW!>?LX?$7X8_#GXS_!F]TK5?!]U8>/KCPSI/@'Q/;1:EX)\*>.M2GT#0K'4-
M8\5^++[3]!U!M5M]6TBTN9(X[3YITO\ X)9?M'?&/]H7]H'PA\#_ ('>*= ^
M$/P$^-5A\./'5Y\5OB]\'=.U;P2+K4]-@E\*7_Q FUO1OAYXS\;6VFW7GR'P
M/-J5A%+?Z2+R"/4+ZTLI@#[4'_!SO_P49.?^+:?L3C!Q_P DD^.O(]?^3H_Y
M\Y!!I?\ B)V_X*,?]$U_8G_\-)\=O_HHJ^=_VM/^"3GB_1?VZ?VC?V9OV-M,
MN?%'@'X#>%_@QXFUK7_C/\7/AGX2N])C^*7@K2=5M(M3\3^+[OX=:-<C4O$,
M^LVVG6FD6D]^L.G^5+OD1V.?^S/_ ,$5?VEOC-\>?CY^SY\8-2@_9O\ &OP%
M^$/A_P"*-['K>F>"OB#!XQD\:SZFOPZTSP[<6'Q;\$Z9>^%_%)\,^+[?5/B9
MX=UKQ5X:\):WHG_".^)[33I[A;:V /IC_B)V_P""C'_1-?V)_P#PTGQV_P#H
MHJ/^(G;_ (*,?]$U_8G_ /#2?';_ .BBK\\?AI_P29_;V^+6I>.]+\$?!_0;
MY/AWX\B^%^L>(+[XN_";2_!NK_$%["VNI/"7@7Q9J?C2T\/_ !*U6P3*ZTW@
MG6M?@L-1O8--O!I6KQ7^D0_!?B_P?XI^'7B[Q1X \=:#JOA7QKX)UW5O"_BW
MPUKML]IJ^A>(=!O[C3-6TS4+=E58[FSO+:6"1H0;>8I]HMY)H)8YY0#^@+_B
M)V_X*,?]$U_8G_\ #2?';_Z**C_B)V_X*,?]$U_8G_\ #2?';_Z**OYW:* /
MZ(O^(G;_ (*,?]$U_8G_ /#2?';_ .BBH_XB=O\ @HQ_T37]B?\ \-)\=O\
MZ**OYW:* /ZSOV'O^#@/]N?]IG]JGX5_ [Q_X#_9-TOPAXVM/BG/K%_X/^&G
MQCTOQ+ ? _P9^(WQ#TI-,OM7_:)\0Z;;K<Z[X1TRUU'[5H][YVD3W\%O]EO)
M;>]MODJS_P"#GC_@HN]K;R#X9?L2Q^;!!+L7X2?'<A!+#'(B;F_:CW.8T98S
M(0I?9NV("$7\]O\ @DOG_AX9^SYC.?[/_:#QC_LV+XV9Z\8VYS[=.<5;_P""
M5G[$GP\_;L^*/Q4\ ?$SQI\1O!/A[X6?LU>*_CFM[\+=*\/ZYXMUBY\'>)/
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M+.6YBBF5+N>.VA /TF_XB=O^"C'_ $37]B?_ ,-)\=O_ ***C_B)V_X*,?\
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M.N0V,DT^C:A'  ?JQ_Q$[?\ !1C_ *)K^Q/_ .&D^.W_ -%%7H'PD_X.1_\
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M5LK6X'B2#PS#;75GKWVU+-?#]\T(!^DG_$3M_P %&/\ HFO[$_\ X:3X[?\
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M1C_HFO[$_P#X:3X[<>__ "=%T'>OS%_:*_X)I_MI_LI?#L?%GXW_  AA\/\
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MO^BMX8_\/^4?_-YK_P 0H\4F[+PT\0K_ /9$\5?_ #B/FSX\_P#!1O\ 9_\
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M!_\ $)XI_P#G&?GQ_P $ECC_ (*&?L]D8S_9_P"T& #WS^S%\;%Q]>>*I_\
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M5"L=ZJJJXW D_P!#O_#G3]A/_I+=X9_\1M\1_P#SPZ/^'.?["?\ TEM\,_\
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M^WO]3O?>?^'.O["7_26WPU_XC9XE_P#GA>Y_.C_ASK^PE_TEM\-?^(V>)?\
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MJ/VE/BA\?=;?QI)<?$76/#DMS)XQO? $OCM[#PUX1\->";-M9U+X<^ ?AQX
M.NMI'AJU+7&A?#_1-/MKC8L]OK4L,^NZQ^@WQ/\ V^/V*_$7[(*_L;_!;X$_
MM5_L]_"R/[?XJU_3_!OQC^"-W-\=OBM:0Q:EX*\<_M+:UX@^"OB'QSXLTC1M
M?TC2]6G\+>%?$7@SP[;JNBV.C:1IQT3P6_AOZ#_X<Z?L)?\ 26WPU_XC9XE_
M^>%2_P##G7]A/_I+;X;..?\ DVSQ*?\ WH77)_.G_KQP5_T6'"W_ (D63?\
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M/"K,N%N(<&\0J4*$ZCH^WR>G[10AB</*3AS)1K4W?WT?RG_M-'9^T?\ M 9
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MV\N/W5M:6<$UQ.X/EQL!D=;XR^$7Q8^'%K:W_P 1_A1\4?AY97\YM+&Z\?\
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MC?OXX'AW^PF/AY;06L.EFX&DR+8Q7SW:6\81 S?H-^V1^VIX#\$^/?C[\+/
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MO2PV75:SCE^+5*O0<Z3/SWTGX<?$/Q!J_B+P]X?^'7CSQ!XA\'6VI7OBW0-
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MO_8]VJ:;MI=NVEC[:=X3E!2J-0E*"O7Q=^6$IPC>V+6T816W0C\M/0_]\_\
MV-'EIZ'_ +Y_^QJ3(]1^8HR/4?F*GGEWJ_\ @4/_ )C%S/\ FG_X/Q?_ ,V$
M?EIZ'_OG_P"QH\M/0_\ ?/\ ]C4F1ZC\Q1D>H_,4<\N]7_P*'_S&',_YI_\
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M &;<8'./[/N@NXYRQ'V<[F.3N8X+9.??^ZGRHATCC7/7:B#/U&VE\M/[J?\
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M/636K\DK^M#]I964(*7@WAG*,8Q;7'.+@FTFKJ$.%G&*VTBVE\V?PL?8K_\
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MG4X8C*,(RS&4X\J:C*,GJY:?PI?8K\<?8-0X_P"G&[_K;4?8K_\ Y\-0_P#
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M-B9YGFLLS<ZG'E7#.+GE>0Y<Z<(4^&)*4%+)ISC.7+)^VY'%>SN_X6?L5_\
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M&_A-?>%8WTM+GQIX?^+>LVFIZ)\+/$OA%==\/?$+Q'IMYH_A#5=9U&SOK2V
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M&V&X:P?"V>X3)L#@_P"PJ.9Q@YX;ZQ*O]9DZ<IQJPN^647J[VC;E/[AS?*?
MCPH\.? +.N*O"+,>-\Z\0>%,7Q/GV-AQWBLLI5Z>&S3^S%AEA84(JC.2E'%N
M=+EO2BX6YI67X<?\/L?%.,?\,[>#?_#KZK^)Y\$YY]^1TH_X?8^*?^C=?!O_
M (=?5/\ YB:_;S_A3_PB' ^$?PM(_P"R>>#?_E+^7M[T?\*@^$?_ $2/X6_^
M&\\&?_*6O7?!'C4G9^,6#;ZN'"-'E>B^&[VU^],^9CXO?1:48K_B6+.U9?\
M1S<5WE_T[?EU>EC\0_\ A]CXI_Z-U\&_^'7U3_YB:/\ A]CXI_Z-U\&_^'7U
M3_YB:_;S_A4'PC_Z)'\+?_#>>#/_ )2T?\*@^$?_ $2/X6_^&\\&?_*6E_J1
MXT_]'APO_B)4/\RO^(O_ $6O^D8\[_\ %FXK_P"5'XA_\/L?%/\ T;KX-_\
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M=?!O_AU]4_\ F)K]O/\ A4'PC_Z)'\+?_#>>#/\ Y2T?\*@^$?\ T2/X6_\
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MQ^O_ !)!W]*;_P *@^$?_1(_A;_X;SP9_P#*6G_J1XU?]'APO_B)4/\ ,?\
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M-U9:K;0W37,\@8GGY_V%?V.[G1=+T"X_9R^&,UEHWQ,\:?&6QO9-)NF\4/\
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M/[:O[6W[6OAC]A+X\?M>2_"KXA?L>_$O]B+XY^!_'V@>"Y_&;^+_ (8?MB?
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MN#&VN&9%2-7,+[BL2)$A).6.Y(TSDY9=J,-J* "TNAC%M.!@ @1/G !"CD=
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M,_B!X:M)KBZT?P_HKZMXJU[1-!U  ]SWV_\ SYQ?^!%W_P#':-]O_P ^</\
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M]@ENK2VNEN+>!EDNK6%[JWP"LML/-5L@K7J:(LCI&RAE=E1E)8!E8A2I*E6
M(."58,.H(/->Q0Q.'Q6'ABL+B*&)PU6#J4L1AJM+$4*D%S>_3JT9U:=2/NO6
M,Y)V:UN?,X_+\PRK&XC+<TP.-RO,<'4C2Q> S/!8K XW"590IU(PQ6"QM#"X
MJC+DJ4ZCIU:-*;A)72YDT_SX^,VT?'R\7%Y@G'O<$@ G/!'(P>]/MY(?/M\6
MD*M]I@!?SKD/S+&"<B;AAG.[UX.1D'\ OAM_P5E\8^ OB%XP\%?M >&CXW\*
MZ3XV\6Z/9^,_!5G'8^---T_2-<O-,L1J.C33)H.NI:V\$4;36#>'[V6W@5Y8
MM1O2\Q_9?X*_'_X._'O3[/7?A+\0="\86L<VG/?:=9R3V?B#1R989!'K'AS4
MTM]<TM_,$EL@O+55FGBD$$DT(6>3XKA/Q'X.XO3PF49S3GF$,1C,-6RK&O#X
M3$*KA,5B*<_J.'J5:=6M1K_5JV,]E35648P=6<::2@_U/Q'\!_%/POH87'<5
M<)YE3R#'X'+\?@N(<GPN,S+AS%4<SPM#,:=6KC,#AJE/*<4H8BE3G@<7[-TX
M2Y7C:TKT3V:1[<22[K*%OWLOS/-=Y^^1C)F/&><9QDG'6H_,MQ_RYP^V;BZP
M?SEY_P#KBO*M>^+7A_PW\0HOA]KFGZGH\DW@3Q)\39?&VK7/A;3O >G^$?"=
M_9:=XDO-3U>_\3VNIV#:3>:OH<5TUQH@M(TUFVOC=_V=;:G>6'5>'?%WACQC
M#=W?A#Q%H/BFQL;K[!>W?AS7-*UN'3]16*":73]2GTV\N+>SO88[F!C;2RB2
M;S8VMA,LJ.WVE+%X6O6G0I8FC.M3E.%2G&I!3C.G2C5G'EDZ>L*;4GRIK244
MW.%2$/RS$8#&X>A3Q5?#U:6%KT:6(IXODY\,Z%:%:=&K+$4/;4*<:L<-64/:
MU*+E.#I\OMIPIU>L\VW/_+E >>GGW)S^'F]/7\Z7S+<=+& ?2:ZQ]>9:X"W^
M)/P[N?$-]X3M_'W@RX\4Z4NI/JGAJ'Q3HDVOZ<NC6JWFL_;=&BOGU&W.D021
MOJBO;[M.5T:_%J)8/.XCQ!^T=\$]!\,#QA_PLCP9KOAY?$O@SPK=ZCX8\6^%
M]<MM-U3QWJMMI>@G4KRTUIK&RM2DMWJUW-+="6'1=(U>_@M[AK":%9GB\'24
MJL\5AX1C&7-.6(@K1@XJ7_+UOW74A=J+:YE?K;3#Y5FM:M2P]#+\PJUJ_LG1
M@L'BHNJL1356BZ?M</2C*-6DU.G-/DG%OEFVG%>Z^;;=K*W'TGN?_CM&^W/_
M "YP\_\ 3>Z_^._R^E>16WQL^&3Z;K.N7_C+P[X:\/Z-XJ_X1!_$/BGQ+X;T
MG0M5U-M%T3Q#!-H>IS:X]O?6=WH^OV-]8M(UI>7D'FRP64D4EA+?;ES\3OAS
M8ZU<>&;_ ,?^![3Q1;K?27'AN?QAX<37HO[-TB/Q#?\ G:5)J:WUN;3P[+!X
M@N5>%5M-%N;;4;PV]G<V\LJ6-P4[6Q="5ISBK5X_'3]HIQLJBYG'V-32TE[D
MFKZ-DLKS.FVI9=CDTKNV#Q$THWI1YFX8>K%1YL11CSN2A>K!<]VTO0=\'_/E
M%_W_ +KZ?\]?\]>M&^W_ .?*'_O_ '7?_MK7F_PQ^*'@KXP^"](\>^ ]:M-5
M\/ZS8Q7L;)/;/J&FSS6-OJ7]D:]96<]XVEZQ;6MS;27NF3.UQ:).JS!2PK?\
M,^+_  GXRLSJ/@_Q1X<\66$=W_9T]_X7U[1_$MA!J'D1W9L7N]!OM1@2Y%G-
M;W?DF8N8+JQ8+_I]B)W1Q6$KPH5J.(I5(8O#_6L/.-2T:V&E"+]K33<+P<)I
M_!%VE?E6MLJV$QF&J8B&(PU>A4PLXX?%*K2E2^KU7-P5&M*<(0I5%-.#ISE"
MHI+EE%-I/M5D@-E.WV2, 36:[//NRK9AF"DYG/*]1@8SVJF9+?I]B@&<<>=<
M\GL<&7!Y_ ]*Y'2?B'X&US5=1\):)XW\':WXETUGFU/PYH_BG0M4U[31I]P]
MI=MJ&CV%_=7]DMA+<6MK>_:8(GM;FY@BN$B:6'S;7B#Q1X=\)Z=+J_BKQ#H/
MA?1HF2.;5?$FL6&AZ8L\@EV6SW^I7%K;1SS10RRQ!I K0P7<QD1+.=DTA6H*
ME*M"M3]C17+*I[6+A37-M+FF[/F>MTY+K96,_98E5'2=#$*M%1G[%X>M]8E%
MN7+4IT'0]O6@W":C4HT:U-RIU(J;E3J1I]&&@R?]#@QG@"6Y&!SQD2Y/)ZGD
M4F^$'FRB;C',UQ@D?Q8\T#GTP![5Q=MX_P# ]U:"^M_&?A.>T:?P]:)<P^(]
M%GMY+WQ:;./PKIT,MK?3Q3WGB22_LD\/Q1LUQK9N8O[/BN2R!\H_%_X4K:W-
M\WQ/^'"Z?9W46GW5^WCKPH+*#4[EKM;339KH:NT$%]>?8+TVT$[QM(+6<X @
MN6@FI7PS<*<L5ATW[D(K$47?FJQERKDG/>K.,KMJ\I7YGJEHLNQSIS7U''2I
MJ5;"R3PN-J1<\17J1K4(_N*KG4K8BE42A3O.<H2]E>,7;TH/;C.;&#).1F6X
M!QZ<2\_4Y/&*=OM^@L8!])KH?CQ+^G3VK@D^(_@&6]T#3(/'?@F6_P#%UC'J
MGA73XO%WAZ6^\4:7<)-]EU/PY9PZG+<ZYIUX\<<%O?:5%>6ADES+-&L,_EPZ
M+\4OAOXEO'TWPW\0? OB/4H[";57T[P_XQ\-:U?1Z7;2P17.I2VNG:K<RP:?
M US;F2]F6.U_TFU F_TB(MFLQP4KR6-H5+T>=RC64HRI1Y/>44^6]ZE-+E@J
MLG**49-V#ZGCI2;^I8Y-3<&Y8+&049TY>R<92J82DH.$Z;@W/D5Z<U=^SJ<O
MH0>#&/L4)^L]T?\ VKC_ #]* ]N!S8P$^OFW(_+$O'I[=1@\UFZ=J6GZOI]A
MJVDW]EJFE:K8VFIZ7J>G7,5[I^IZ;J%O'=V&HV%[;O);W=A?6LT5S9W4$CPW
M-O)'-#(Z.I-VNM-24)1:DE:<)1:DK3BG&<91<E*,X2C*$TY0G!QG"4HM2.>:
MFIR=3VBG:I3FI.<9*\N2K"<.:/+-3I.G5C*G&I"=*=.HH3ISA"0S6R @V46X
MJ^T?:+SJ$.3Q.O*\$9)'M7J>/]I_^_C_ /Q5>3/]QO\ =;^1KUJF2>87V1?7
MN00#>W>#V/\ I$I_E7QK^V-^RK:_M:^#?!_@761\$;OPWH'B;4-?UC1?CE\!
M=0^.6D7C7GAK6]$M-3\$W?A3XR_ /XB_"OXAZ8=1NK6T^(7@WXCV<LGA/7?%
M7@36M \0Z3XFL=1\,_:5]%&U[>#[=9K_ *9=-L9I5=,R%MKD1.I;,A& H& #
MG.157[/'_P _]E_W\E_^1J /SYT;]A'2HM _8!MO'7Q,U/XP>-_V%_C-XI^,
M5O\ $_XK^&Y?'_CCXB_\)5\*?CGX"G\"6?BGQGXL\0^,/!/AG0_$GQ5^'GC'
MPA?:WXN^*OB/2K']G3X3Z%XBUWQIXKT>R^*6D>>:E_P35L9_&7PO^(&C?&J]
M\/>*_!?[9_Q$_::\?7UG\.+6:T^,OPF\8?M3?$C]KOPG^S?XIL?^$^@%B?A1
M\6/'-OJ_P]^,EN^J:SX>OKCXGSZ-X&\/Z/\ &7QQX=D_4G[/'_S_ -E_W\E_
M^1J/L\?_ #_V7_?R7_Y&H ^&/BI^QHWB+5?@AXS^#?Q@\9_#/XE? 3XN>(/B
MIX5\0_&#6?BQ^UYX9UV'QEX;NO"WC'P'XET+XP_&C3_&UCX/U>S&DZAI4/P[
M^)_PU;PMKV@65_8VTFCZUK6E2_-^I_\ !+J]F^'_ (Q^'OA_]H&VT2P_:"^"
M_P 6/@A^U[J.J?!,Z]=?%3PS\=?VA_C%^TM\2M6^"L-K\8/#L'[._B+_ (3#
M]I?]HC0/"3^(1\?]'\.>&_&/@V#4=*\4W_P[;4?%GZ[_ &>/_G_LO^_DO_R-
M1]GC_P"?^R_[^2__ "-0!\C/^RAX/LOVA/AE^T%X4NT\/:CX,\0?M.^,/'6A
M7%EJ_B#5/C#XU_:5T?X;Z1<^*=<\;:UXL-]H9^'FC?#'PYX4\&Z3=:5XGM--
M\"Z3X0^'WA>+P-X;\&:996O!?&;]GOQYXZ^+WQUBT7RX_AS^V+^Q5J7[+GQ#
M\>-/HFI:C\"O&7PWA^-$WPH\:GP;J/BCPKJ_CSPEXXTK]I7XEZ7X@TOP_K-S
MJ>B^)O /@'3KI;?POXZ\1>+?AW][?9X_^?\ LO\ OY+_ /(U+]GBQ_Q^V.?[
MWFSAOS$ QCMB@#\R?C;_ ,$\Y?BI'X*E\-?%GPQX,O/ /P)_9;^"FA6^N_!*
M3QUX68_LO_M6?!K]J'2==U#PWI'Q>^'MP_AKQA)\)!X$O_AYI^MV3:)9:['K
MEOXPO3H5MX:U3S7XU?\ !,CXD?&'P+\4_"K_ +7M]X3U'X]K^U!J/QOC\-?#
M'XG^%/AQXC\5_M&>#OAS\/\ 3_$'@_X??#']K'X7Z]I6G?#_ ,$_"[3=)N/
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M^!OBUJ/@;X1_"^X_X2'5M:L=6\(:MK'QP^'FK_#[QUX)\7:/XZU#]3?L\?\
MS_V7_?R7_P"1J/L\8&!?675C_K9?XB"1_P >W3(X[^] 'Y%^"/\ @F5XO\!^
M$OAO\.-"_:3T@?#SPY_P[(UWXA:9K/P"N=1\7>-?B!_P34U[X376B>(?"GB_
M2OC[HUA\./#OQC\._!+P)I6M^&+OPI\2M8\&:S'J^N6'C_Q'I6IV_A6Q1O\
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M53\-_$&G:+X1_:,UO0_$'A+P;X'U/PO=7P\>_!R]^)FJZSI&M>-O"5W:^%O
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M:?B^V\53_ ;QN/&=KXT?Q:W[(G[2L?\ P2);5H_&K>)K7X[O^V[^TZ?V7W^
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MPQ^?/)';VYFBMEN+ATB@:ZN'6.VMO.D=(HYKF5DAMUFDC$T\D,$3/+*J!^X
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M^*WBC7/#OP^^'.G^'OVEO'?QU\ ZSX$T3Q'X>NM2\2@'Z*44#H/_ -7Z=J*
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M"_X=>*H%^#'@73O"VLZ!\;-!T?QA\%YOV@/B3I/BKP?+J_B^#XDOXKL?AO\
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M (*WID+\0/C.@))P/VRKY1D]\#XJK],\].O8._X93_X*X_\ 10OC/_XF9?\
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ME2+'++"CJR,,?*0HP,95>>6_B=2?E5FRH<94)D221J_YC?$@6,-E^T&=7BU
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M-Y>O6]QJ4]GJD%R/XL_'Z;2O$WB"#QS%>OX'^$/P?\:6UMX,\,>']7\+^/\
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M5+_SSM?_  !LO_C5 %?$O]U?_'O_ (FCYQ]\*!T!&>OX@#IFK'VJ7_GG:_\
M@#9?_&J!=SC[J6JGIDV-F./PB]A^M "&.22S"A=P>^QM#.FX?V=;\%T.Y0?X
MR,$)N/(%?EA\8OV2OVE]8\.?MV_!OX577P(N?A'^W[KOB#6O$_Q&^(?CCXA>
M&?BA\$T^-'P/^'_[-OQQM/#_ ,)_!_P7\9>#OBS)HO@+X>CXC?"F^O\ XO\
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M'NN'2G\+:'XT;2?AC\3_ (5?M"_LU>,/#7C7Q!;^(O%&G^/-%^"?P[TCQO\
MM5]JF_YYVO\ X V7T_YY>G%+]KF_YYVW/7_0;+_XU0!459!N"A2NYF4[1&3'
M(QEB+0Q@Q0,8Y$+0PA84.?*\Q"L\KL2_W5_\>_\ B:L?:IO^>=K_ . -E_\
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MQ+J>BZ/X<U#7&CVZG>:%X>U'6=6T32IKJ-(V-GI>I>(-:O+".,1_9+C4;B6
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MP">UN6T^_M]2L7EB18E$EI>VEK/!)$(FCEMTD7Y]Q;H/M4O_ #SM?_ &R_\
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M#PR_]I:+9V7C'QC\4OCK\,([+Q#<+J>E>'_ &D>.)AHUYJVH:!JFE?'&G_\
M!2S3]2^,WP]OF^'?CO1?V6OB=^S;X$^+7P]\<ZUH'@2/Q5\8M3^-W[5_P!_9
MV^#/Q%\"6%I\8[K6_!_PAU[3/COIWB;5K#XQ>"?AC\0[+1K[1-=@\/V>IZ#X
MB\*O]O?$KX1:SXC^-7P$^-GA+6M(T?Q#\*Q\3_ 'C'3=8M;V]T_XB? OXSV&
MAWGC[P9(T+Q)I/B73OB#\-OA'\1?"^NM9:_;W%SX1USP;J-MHVF_$/6/$UG\
M[6O_  36^ 5KHMOH,_BGXW7^D>%_@WH?P"^#UG?_ !"TMA\ /A9X(^)?P]^+
M?PAT+X33V'A"TG_MKX)_$#X2?#O7_ ?C3XK7OQ6\>:PGA70M%^*GB7XF:%H\
M6F1 '9ZO^W%\/;3Q[XK^$?@_X9?'#XQ?&/P9X[^*7@S4_A5\.= ^'L/BK4]/
M^#/@SX&^-_B;\1M+N_&WQ-\#^&C\./#-K^T=\'?#%FUQK>D>/_$GC#QSHN@>
M'? NHW4.H3S>%>,O^"COA_QC-^SY??LP:/J?Q'^%OQ&_:9_9:^$_C_\ :'O=
M-\(Z=\(]%\,?M#>!O#7QAB\*:59^(?B7X0^+,GQ%F^#GQ'^%/BVU\0:1\+?&
MG@'PY+XSCT77O$<WBS3/%WASP=[+!^P-\,=-U#4O%WA[XJ_M$^'/B[KWCCXF
M^-_$OQYT'XB>&++XKZY=_&KPA\)_!_QA\.2SW/P\N?A]I'@OQ_;? [X4:\WA
M_P )_#WP^/A_XR\!^%O$_P 'KWX<7_A_1S8IH_\ P3T_9V\+ZCX)@\$I\0/
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M$USXK>$?B=K.H^*8/A?J^E:WX-\$^$M8\1Z+J.M:#!=3QZ7J$OB+3_9_'O\
MP4*^&/PTT+QM>>./AC\4_!/BCX<_$SPO\+O&'P[\?^-_V2?AKXBT6\^('PYN
M?B9\/?%W_":?$O\ :G\'_ WQ#X:\7Z':2Z9H5GX:^+FJ^,+CQ9%<>']6\%Z=
M<V^MS:3N:7_P3[_9RT?X-?$+X&Z7!\0AX!^)G[+'P6_8^\1K/XTG?Q /@W\
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M_'W:_P#7>P_]*$IE/M_^/NU_Z[V'_I0E [KNOO7^8C_ZR7_KM-_Z->FTY_\
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M\_:?W2_R/[*/^(A3]B3_ *)Y^TG_ .$5X!_^>E1_Q$*?L2?]$\_:3_\ "*\
M_P#STJ_C7V#U/Z?X4;!ZG]/\*/\ 5/)?^?53_P E#_6+-O\ G[3^Z7^1_91_
MQ$*?L2?]$\_:3_\ "*\ _P#STJ/^(A3]B3_HGG[2?_A%> ?_ )Z5?QK[!ZG]
M/\*-@]3^G^%'^J>2_P#/JI_Y*'^L6;?\_:?W2_R/[+V_X.&/V(_LP@_X5_\
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M8D_Z)Y^TG_X17@'_ .>E7\:^P>I_3_"C8/4_I_A1_JGDO_/JI_Y*'^L6;?\
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M _\ STJ/^(A3]B3_ *)Y^TG_ .$5X!_^>E7\:P4-G/8#I@=1GTQ2[!ZG]/\
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M_(_LG/\ P<*_L1_]$\_:4X]/!/@+Z?\ 14??^O:NWN/^"\7['<'PPT7XD/X
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M ,]*C_B(4_8D_P"B>?M)_P#A%> ?_GI5_&OL'J?T_P *-@]3^G^%7_JGDO\
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M)M1U/6A;K=Z?+JVGR+\?_P#!.;XN^!?!7[,W[4GA/P'\:?A-^S7^VAXN\:?
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MR=K6TLY-Z63:ULFT?T??L'_&_P"!GPB_99_9/^'^M_M"?\$Y[CQI^S_^U?\
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MA_G9/[//[0Q^]\ OCHP'"@_"'X@G:O.%'_%.]!EB..":4_L\_M",Y<_ +XZ
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M]C5_Y]5/_ )?_(GD=%>OG]G?]H@()3^S[\=!&76,2?\ "G_B(4,C+(_EA_\
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MU>MC]GK]H0#CX _'(_\ =(?B%V '_0O^V?QI?^&>_P!H7_H@'QR_\-!\0O\
MYGZZ77PLO>5:BT]4_:0U^^2?3LB94JMW^ZJ;O[$O_D3R.BO7/^&>_P!H7_H@
M'QR_\-!\0O\ YGZ/^&>_VA?^B ?'+_PT'Q"_^9^CVV&_Y^T?_!L/_DQ>QJ_\
M^JG_ (!/_P"1/(Z*]<_X9[_:%_Z(!\<O_#0?$+_YGZ/^&>_VA?\ H@'QR_\
M#0?$+_YGZ/;8;_G[1_\ !L/_ ),/8U?^?53_ , G_P#(GD=%>N?\,]_M"_\
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M\_\ J/\ X'7?_P <H_M/4_\ G_U'_P #KO\ ^.56HIZ]Y?\ @RK_ /)A[O\
M)#_P%?Y%G^T]3_Y_]1_\#KO_ ..4?VGJ?_/_ *C_ .!UW_\ '*K44:]Y?^#*
MO_R8>[_)#_P%?Y%G^T]3_P"?_4?_  .N_P#XY1_:>I_\_P#J/_@==_\ QRJU
M%&O>7_@RK_\ )A[O\D/_  %?Y%G^T]3_ .?_ %'_ ,#KO_XY1_:>I_\ /_J/
M_@==_P#QRJU%&O>7_@RK_P#)A[O\D/\ P%?Y%G^T]3_Y_P#4?_ Z[_\ CE']
MIZG_ ,_^H_\ @==__'*K44:]Y?\ @RK_ /)A[O\ )#_P%?Y%G^T]3_Y_]1_\
M#KO_ ..4?VGJ?_/_ *C_ .!UW_\ '*K44:]Y?^#*O_R8>[_)#_P%?Y%G^T]3
M_P"?_4?_  .N_P#XY1_:>I_\_P#J/_@==_\ QRJU%&O>7_@RK_\ )A[O\D/_
M  %?Y'3>&;^_FUVP22]OW1OMNY7OKIE)33;KJIEQE=JXXX8 CD9K 75-2*K_
M ,3'4G)56YO[UR Z-*#_ *UB ZAF0?Q,0B@R.JMJ^%N-=T\^G]I_^F^[KX6_
M:,\9?$-OC-^R%\!O _Q(UOX.Z?\ 'CQ!\:+KQ7\0_">@?#K7O&]Q9_!+X7Q^
M/]-^%_@<_%KP5\2/ &DZ[\0I5N=?UC4=2\!^*=<_X5_\-_'5MX6T_2;^:;QW
MX%75ZS]?:5+]?[P>[_)#_P !7^1]K?VIJ7_00U \9&+^[.0"%."),<,=IYX;
M*'#JR@&IZDQ 74-08EUC 6_NF_>.&*1G$I =PC%$)#,!D Y7/Y)?";]KKXY6
MGQQG_9:U.?P5\6'\._%W]M7PYJW[27Q4UJS^'NIR_"S]E+1?V.?&;7>H>#/A
M'\,H/ GB?XEZ+#^U?X@^%/C:30;?X2>"K37_ ('ZIK]Q_8=W<ZIX9?RW5_V]
M?B_\4-$\(^'IO!?_  J*]UGXI_\ !+#XI>#?B+X%\2^*X_#WQ8^ 7[4'[<6A
M?![Q9H^F6'Q%\+>!?B.?!?C'0/#NIV=AJ_B7P7X+U3XB>"?$;:EJ_@7X?7,7
M]C7Y\Y_^#*G_ ,D+W?Y(?^ K_(_;\:GJ1!87^HE1U?[9>^7G!.T2;_++G&U4
M#%W=DC16DDC5C^T]3Y_T_4" 2N1?71&0<$ B7!P>#M) /!.<BOD+XH>)/$6L
M_M5_LU_"6R\3:[X9\#P_#S]H+]I[Q_9^&]8N]'U+XDI\&M7^!OPK\#_"V\U#
M2[G3M2;P=_PDW[0K?$KQ)H5EJNC0>+-9^'GA#P]XENM0\#ZQXY\.^(OS^L_V
MZ_C;+\2/@#\=]6\*:!:?!O\ :$_8J^!7Q6^&/P@TOXAZ_<QQ:)^U-^V]^R%\
M(/ GC;XFZA/X1BT6+XM>!?AC\>HKW5-/\)6FN^&UOI->\*6/C35M'?3_ !3.
M?.?_ (,J?_)#]W^2'_@*_P C]OO[4U+_ )_]1_\  Z[_ /CGZ]#@XS2C4M4(
M)%]J. 0#_IUV2">@P)"<G#$ #E4D;[L;E?SOA_:[^*_CKX^_$#]F+X1_"GX;
MR?%7PCX]_:.T_3-;^+/Q%\9>#?AYJ/P\_9V^'W['VLWVMZK?^&/AGXSUK3?%
MWBWXA_ME> O#5OX7L-,U32O"W@KPWXY\<7?BC7=8\/6G@7Q'\O']OWQ_^TMX
M8_9O^,OP7\/7WPG^ -[^V1^PSX \=7.O:_J:?&[Q$WQR^ OPW_:<\0>";KPG
MHND/X/M?ATG@+X[_  \\(ZD=?\42:AXK\5:)XAU4^&M.\,-X1O-<+^<O_!E3
M_P"2L'N_R0_\!7^1^V!U341C.H7X##*DZA=#(SCC,H_+K[4O]IZF"0;_ %$$
M=0U]=J1QD9#2#&>P.#VQFOQM\#_\%-/BYX[^%WPV^*^C_LIZOIWASX_:I^QS
M_P *4UGQC8_M!?#CP1I]I^V'^T5\.O@MH'A'XC?$'XB_L[^&_"WB'QWX5\'_
M !=\'?$M;WX!3?&#P!XLBT/XBV&E>)K/1=)\%>*_'WJ-A^WWXMM[+XE:;X@^
M$/AJ#Q?\(/V?O^"FWQ9\5V_A_P"(%]?:#JGBW_@GC\9?A;\*;;P_X4N-7\+:
M?K-QX2^+=A\2HO$T^LZSI6FZKX&O[-_#*Z?XCMDLO%&M%U_-/_P94]/Y@]W^
M2G_X"O\ (_4#^T]2Y_XF&H< $YOKL8!95'60#EF5>,\GT!(/[4U+K_:&H8]?
MMUWC_P!&9'XC-?E/'^W?\;-:\7Q:7X6^"GP<7PU>?M4? C]D>+4O$OQ?^(5G
MKZ^-_CY^Q=\*_P!JW2?&$^CZ9\&M3M5\,^%]0^*5GX-DTE+]-9\66^FM?;_!
M=XEW#!]L?LT?%_4OCQ\(=+^)6L^&['PIKR>-/B[\./%VA:/JMUK_ (<L_&/P
M5^,/CWX*>++OPUK6HZ7H&H:IX5U?Q'\/]2U;PO-J>D:;K9T2_P!-_MO3].U1
MKC3X'\Y_^#*G_P D+W?Y(?\ @"_R/H :GJ1Z7^H=Q_Q_W789/_+7L.M*-3U(
MD :AJ&6.U0;^[!9\9V)F0;W ()1-S@%3M^9<_G[\6_VP?&/PSMOVSOB-8_#+
MPOK_ ,"OV"--U;_A=MY=^.->TGXL^+M?T[]EGP-^U5+;?#/18/ FK>!+726\
M.?%GX8>%!>^-_%FD$ZQ/\1-3NVT[2O!WAH_$3YR^/_[97Q;^#GQI^%G@?XSZ
M%8^$=<^"'Q)U+XD?'70?V?O&'B?QIX+^+?P1US_@G#_P4?\ C7I7@J!O&'A'
MP%K=SXKT[XE?LLZG<Q>$]3M$L=4BTGX5>.=,U*#4_$6H>$_!B^<__!E3_P"2
M#W?Y(?\ @*_R/V._M/4O^@AJ!^E_=D?@1(0?H"3WQBE.I:FN,ZA?@D @'4+D
M,002"JF4,V% =MH.U'BD;$<T+/\ EEJ?[<'QT\/>*? OPEU_X*_!S_A</Q,U
MC]BV;PV=#^,'Q#O/ACHW@K]LV']HFTTO4]8\23?!*'Q)>>+?ASKG[.'BA(M*
ML_!]EH/Q.TO6=(NM,U[P<^G^,X_!_1>$_P!H/QSX]U3]B?XR(L_@B3XL_M'_
M +4G[%7QE^$-AXQU3Q1\--5N/A'#^U?&WQ$\(1W^E:0\GB73/B9^QY:Z[X)\
M32:/H6L7OP@^*7C30?&MGJFH:?X6'AL^<_\ P94_^2'[O\E/_P !7^1^E7]I
MZG_S_P"H_P#@==__ !RC^U-3[:AJ8_W=0O%_/;*,U5!SR.5(5E(.X$$=F 4.
M,Y^90%ZJ,E22M%O.7_@RK_\ )A[O\D/_  %?Y&W_ &GJ?]D[CJ.I,1?M][4;
MS)_T=$"LS3@E%!XC9BBMAE4/@UF?VKJ1ZW^H(=NX*U]=JQ7.-ZJ9MS+G.2%P
MH1R2 CE9F(&CY(! U(G!SCB.(\D$$?52K+U1E8!A_/\ ?M*_M=_MU> O$7_!
M2G0OAAK>MZSI.B>)/$W@S]E[Q_:_"'P!XE\)?L@:O^SO^Q-^SS^UC\;-4^*%
M^_@^8>)]/^*WP[^+'C:Y^#[_ !.MOB)%<_&7P5I7@R_AAT7Q5%;79\Y;_P#/
MRIY?WNO];![O\D/_  %?Y'[^G4]2!8'4+\;,^8QU"Y"1!7=&:9_-V0HICF+2
M2LD:QP7$Q80VT\D8=2U,$*;[4022,&]NP=RD*R[3)NWHQ"2)C?')^Z=5D!0?
MD9IW[>WQD\5:EXN\&?#OX'^)O%7_  @J:)\*O$GQ(M/A]\;]3M]!^)>I?LF:
M!\>+GXM:OXBT'X$Z[^S9H'PU\->,/&?@3POJ7@[6?BWI_CC5M-O]7\86VDQH
M?"/@GQ9X#HW[9?[77@3P1\'/C[XXA^'_ ,3XM%_X(S:5^V=\9/ Z>-_$7@W1
MO&<VGZE\-/$6I>,/#FB:5\-9_#%A\:_%FBWGBK3?*2'PSX)T!=2CL]%M[K2+
MR4Z$?.?_ (,J?_)"]W^2G_X"C]\!JFI'IJ&H'Z7]T<8)!SB4X((((Z@@C&:/
M[4U+./[0U#(Y*_;[K< >A*F7< >Q(&>U?E;\6/\ @H?XH^&7Q*^(NC:?\'M+
M\>_"CP_=_M6^#O"GQ2T7Q!XKTC3+WXK_ +*W[.'Q _: \0^ -=G\3>#]-LM5
MNT;X7^+OAYXQO_AO#XI\'^$O%-E%867C;Q3XB@\8>'_"-W1?VZ?BO-XG\.?"
M/6O@M\-K/XR_$_4?V/W^&)\/?$_Q9K7PGM=+_:U^'_[2'Q*'_">^(KSX<:)X
MOM-3^&?A_P#92^*NG)'X>\#7&G_$O7M<^%T-I?>!HO$7BA/!1\Y_^#*G_P D
M'N_R0_\  5_D?J+_ &IJ7_/_ *C^-]=#_P!J]^WJ>*/[4U+I_:&H9!P0;^Z!
MSZ8,N:_'[Q1_P4F^)L'PN^./CCPA\#?A[=ZY^RM\*O%?Q"^/.E^*_B?XNT[P
M]JFL^&/VIOVD?V4H]!^#&NZ3\,;^]\0:)J/BS]E'XH^*T\6^,='\,G3](UGP
M'H%YH!\27'BRU\-:'CO_ (*3?$'PMI_[3WC?P_\ LR^,O%'PM_9_M/V]-/A\
M32^%_CUH&F_\)5^PUHWQ)^U7WQ'^*NI_ 9?V?M'\%_%_QS\'/''@'P\_PY^*
MGQ'\9>&]2UGX:K>^&-7UK7O%V@>!CYR_\&5/_DA^[_)#_P !7^1^N(U343TU
M'4#DX&+Z[Y)!( 'F9)(!QC.<$#)P"JZGJ3' U&^X.&)U&Y"I\H?=(QEVQH$.
M\R2%8P@=BV(Y"OYG>*/VR?COX4OOB#X1OOV>+'Q!XH^&_P 1_A;H/C7Q9\*K
M?XX?'#P%X)^%GQ8_9\UGXT:3\0];\'_"KX1>(/CMJ[:?XIT)_A+=6'@OX<Z[
MIEM=^(?"OC/6O$_A?1M5U&RT7U7XF?'C5C\/_P!A[Q_X0\2:8]I^T1^T#^S9
MX:U/5?AEXA\+>*? OB?P3\6/ _C+Q/>6?A_Q%\1OA?J6H>)_AGJ]QI-O+X>U
MK0/"GP:\>:_I5O'K4/B7P-KNI^+_  \QZ.?_ (,J?_)"]W^2'_@*_P C[;_M
M/4^GV_40<LI4WUVKJT;%)$9&D#))%(K12Q.%DCE22)U62-U4_M34O^?_ % Y
MSTOKL].#_P M.Q_/J,CFOSO_ &-/VQ/B%^T@GP=E^(GPO\"_#UOC[^Q+\)/V
MV/AY-X!^(7B#Q];Z-X:^(EUHVDZGX#\=WWBKP/X",?B/1[GQ5X2O=*U?2TU#
M2IEN/&&AW-S<2>%;'5-9YCQQ^W3X^\-:G8^(]%^$O@K4?A#K/[1G[2O[,6CZ
MIK7Q \0:7\1&\7?LN?L^?M,_%7Q7XLU?1+7P-?\ AC3/#6O>./V:/%?@G0=*
MC\07.L)X1NK+QOK$VFZNT_@VT/G/_P &5/\ Y(?N_P E/_P%?Y'Z<#4]2X_X
MF%^,@L VH72E@ S'8&E!<X5CM3<Q R 01D.I:F,9O]0Y4,,7]T?E894\2G@C
MD>H(/0BOQY^-O[;GQSU75O@!X-^!_A[PGX+U_P ?6'_!)CXUZ[J_B[4SJ^E:
MMX._;N^/7QP^&/C'X/G_ (H;7;K2]-T^'X,:24\>:0^G^)9K'QKK.I:&WAS7
M?#_AFWUK]=+07HMK==2C@AU%+>&/4(K8RM;QZA'&%OT@>X5+F2$7HN#%)=1Q
MW4D962X5I6:1SYS_ /!E3_Y(/=_DA_X"O\C1_M34QTU#4AU'%_>#.?7$HS^/
M3M6@=1OUTN%QJ.HK.=5O=SB_OA(84T[2B=S>=DQ">= "3L\V1@I,@D QJ_#S
M_@IQ^VE^W?\ LY_'/P3X _9:^'\_BKX<ZO\ !G0/'&M:C#\!?$GQ1B@^(.H^
M/_B=X;UJV;Q-HSFUT^5/#/A3PA)_8,L?G1-<3ZE(3_:42P]6#P<L=B*>'BX7
MGS?QL5*BM$WI*<G%N]KJVVIAB<13PU&565)2M9148QW;UO=/2VUNO='[G'4]
M48Y.HZBQ]3?WKGVY\P_E1_:.I_\ /_J/_@;>_P#Q=?R*_P##T?\ X*^G[WP;
MNB?4_LA>.#QU_N] 21^M'_#T;_@KW_T1NY_\1!\<?_$U['^JV:+2,L'RW=K9
MG';IW.!YS@HOEEAZMUH[0I6O9/MYG]=7]HZG_P _^H_^!M[_ /%T?VCJ?_/_
M *C_ .!M[_\ %U_(K_P]&_X*]_\ 1&[G_P 1!\<?_$T?\/1O^"O?_1&[G_Q$
M'QQ_\31_JOFO\V#_ /#G'_(7]MX'_H'J_P#@%(_KJ_M'4_\ G_U'_P #;W_X
MNC^T=3_Y_P#4?_ V]_\ BZ_D5_X>C?\ !7O_ *(W<_\ B(/CC_XFC_AZ-_P5
M[_Z(W<_^(@^./_B:/]5\U_FP?_ASC_D']MX'_H'J_P#@%(_KJ_M'4_\ G_U'
M_P #;W_XNC^T=3_Y_P#4?_ V]_\ BZ_D5_X>C?\ !7O_ *(W<_\ B(/CC_XF
MC_AZ-_P5[_Z(W<_^(@^./_B:/]5\U_FP?_ASC_D']MX'_H'J_P#@%(_KJ_M+
M5!_R_P"HC_M]O?\ XNK[ZCJ TE'.HWZ.=0OHW8W=T'95T^SE@4N958JDJM)&
M.0DF67#'G^08_P#!4;_@KYV^#=SGW_9!\<?_ !-2G_@J?_P6!^S+;-\&KDVZ
M7'VGY/V/_'Y8RLUI'*"1!Y(7[/G_ );!\C+*J@!T^%<R>LJN71?:IF3<GOM9
MI6?32]P_MK ]*%3_ , I?Y,_KE_M'4_^?_4?_ V]_P#BZ/[1U/\ Y_\ 4?\
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M^"O?_1&[G_Q$'QQ_\31_JOFO\V#_ /#G'_(/[;P/_0/5_P# *1_75_:.I_\
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M5_(K_P /1O\ @KX.GP;N<_\ 9H/C@?\ LM(?^"HW_!7XGGX-W'X_LA>.2?\
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M-45_/+_P]F_:9_Z%#X#_ /A%>./_ )YE'_#V;]ID_P#,H_ ;[P7_ )$KQO\
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M1#::3<?$SQ6OQ$^)-CJ'C"]6YNX[#XD?$!;.WMM0\:>(-3O/Q$_X>S?M,_\
M0H? ?_PBO''_ ,\RC_A[-^TS_P!"A\!__"*\<?\ SS*.>/9_A_F!_0U17\\O
M_#V;]IG_ *%#X#_^$5XX_P#GF4?\/9OVF?\ H4/@/_X17CC_ .>91SKL_P /
M\P/Z*#DZ.V ,C4'*@G&[]U%C#8< '(^8HX7[QCD V-YU)\-OA]<:3\3-"NO
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M6_"4D^@:@+C0II-&;\5_^'LW[3/_ $*'P'_\(KQQ_P#/,H_X>S?M,_\ 0H?
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MG0?V?H^CJZF74=0UB]L=+M'5+O5;NPAF@>7TG_A[-^TS_P!"A\!__"*\<?\
MSS*0?\%9/VF%D>5?"?P(1WAB@81^"/&JL4B>61%>6/XFK)MCDGN98%??Y$MW
M>-%Y;W=TTO;E^/>!Q,<1#1Q3Z*^O;;\T<V+PRQ5&5%SE",FF^7JD]G^GF>5?
MLI?\$$M0NAI_BW]LCQQ)I,02*]_X4Q\*]4L[K4'VJKMIOC?XF&WO+"-7D=;6
M^T_P%#>7,*"1])\>V%Q 5N/WW^!/[,7[/O[,FF:GI7P#^$WA7X;0ZUA=;U'2
M(KV^\2ZY'^XQ;:UXPUR[U3Q3JEA";>*6UTV\U:?2[&:*W-CIUO%;1QG\7O\
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MOA3\+O#MMI-GH/P]\&:-:Z#XOU;X@Z)#IGAO2+1-+\>:]I.J>'M8\:VHCLU
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M_P!"A\!__"*\<?\ SS*.>/9_A_6]QV2T6RV]#^AJBOYY?^'LW[3/_0H? ?\
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M]G]FCN=5\1:]H6B:MJ%QI^H66K:+I^DZG<W>O:=>Z3=V-OY>O:.;GZ#\3_\
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M@DFE/_!(/]J<DD^*O@.Q.<EO&?BYF;)S\Q/PV)89Y 8D \C%?TFT4 ?S8_\
M#H+]J?=N_P"$J^!)88//C7Q>1D'(.#\-R,@@'..O/6D_X=!?M38 _P"$I^!
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M>S+D;0< '\V7_#H+]J;.?^$J^!'X^-/%Y_/_ (MOS^/]*4?\$@_VIP=P\5?
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M7_\ SMZ_I/(()!X(.#]?ZCN** /YL/\ AT#^U-_T-/P(_P#"T\7_ /SMZ/\
MAT#^U-_T-/P(_P#"T\7_ /SMZ_I/HH _FP_X= _M3?\ 0T_ C_PM/%__ ,[>
MC_AT#^U-_P!#3\"/_"T\7_\ SMZ_I/HH _FP_P"'0/[4W_0T_ C_ ,+3Q?\
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M@M[NWN+:1Q-#(B6=W(QDAF9$/&688^4\8W$$2*>!Y9&03S0!_-DW_!(+]J<
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MNB7#Z]=R)H<<&L:7*^L_V+=8UE-)1+PSZK/I0BNAJ4%A;SC3#87SZA-;^28
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MW#+ %LH=K J P8 $CR\[B0"-R EHQAG+9VA'8J,_[HZ _>)'=E[@ >I.#U%
M'\VO_#GW]JK:TG_"5? 4QJ4#$>,_&.09?,\L'/PVQD^7)TX^1LD<9;_PZ!_:
MF_Z&GX$?^%IXO_\ G;U_1J_BOPO L%K-XCT.*75?%:^#=/675K />^+M.M-:
MO[_PU:I'-+YNNV-E9W]W?:4,7EI;V4[S1+)!?0V&OD],KN5F5P'5BK)(Z%2F
MU6#C;ADY)8'! (  /YL_^'0/[4W_ $-/P(_\+3Q?_P#.WH_X= _M3?\ 0T_
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M>"=<UCX<72IK\VC:3X2OK]+K^BQOO7'_ &$)O_3]H%68?^0E8?6__P#2G1Z
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M"L?Q/?X?IJ'BA8M2\17J6'CJ"?6M0:?QQ>/+XIC\(ZFGBWQ2)M2^R&_U;?\
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MZCX,\7CXV^)_!.F>/I?B=;RII6LZQ;:3KQ\,0ZIH\O@2QDNM/^YKC_CYL_\
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M%W<ZZEE=6/@_2]0\52:5(?TLCZ)]8_YV-<;IW_(W>+/^P-\-?_2CQ#0!\_?
MN'QY=?$3XE:3KWB?7-9\&_ _5-<^%WA/47\33ZM'X]U7QCJNE?$ZXUKQ*_G.
M^I>(_A+X6O/AW\)6N=4>^D?6S\0[J]>*]NM4EB^M!C QTQQ]*Y'PG_QYZE_V
K-7B3_P!.]Y76KT'T'\J %HHHH :_W&_W6_D:]:KR5_N-_NM_(UZU0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1P#I P$1  (1 0,1 ?_$ +X   $"!P$!
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MVO347BV>]J2'/>;N,.,YL"WYYF5@Q^;>74,PF+E*2RMXN*2A*0E1%:E8U=Y
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M"%5!ZC2KD</],ZR47(<)!]E!/&>3Y*6N2VN.E*62+'77KU^JNB#VL_>HQ'W
M\EN_&>08LSQ[R?880E3,9DJ=9/927 HQTR7EOJ<3V55!'H--68X9';QW\P#C
MA-A<6%A>C_!\SF29[<%;3:6U7%P3V%ZTGW"O?HP7Q+Y.C<%<2X!<N6N7''%,
MR;%%97(CLO)4X@HK"D)?_$CXCXZP\<X8SD$K+CCJ=NHL!2SD_+Y.,"4L-MKW
M&QN32'^)7\Q!"Y2YAMW#'D7Q)<>%\IO I 8EQY,9B3)6MM#$="KA(WJ[O<'H
M*Z<X7'67XKSGF+#[2K)38:^VF23R>6B4TRIE%G0+ZG2_A0(?>O\ ,_D'GKR/
MQQ,[ <DX_P ?P*_M)QZ;!<N<6/F$9N8PMMU95*"%)<2RFG;I^/3Z[QN#&B!W
MSU%W:"00.MM1]%"F?YOD\;,5&CQFU( ZDFNC#PD]S'F?,?!S*>09?C5E N'"
MN)X_8<8MC]ON1D9;$@M_ERYP"I!<?87'9#B%)/U ]="*VFTO!M*[ JHTC2I+
MN-1.=;LI;(7;6P)%[4D/@9[WP\H_*^Q\ WGQKLF 9/>GW&)-\DVUV+=+?/:1
M(<D-S77%*6TD(9-#ZE1ZZ(Y''HJ\4N8'E;P/RV%JP8/(F2W^J4 '$K(M3D/<
M6]]'"/#?D!7"/&6'N\H\P-S!:W,9CI<>;1<5HWI92(;R9&VA'J*]=#>/PC4D
M'SEJ0;^RLN8YA+QJPEAI#@/6Y-,9XR_F4,_LO(F,X=Y-^-T_C&+EURB6^!.7
M&N32P_,>2U'$<3I"4K:4%U)/6NG-WC$%"=P?5T]E8L9R_(SE;5,( ]A-=86*
M92QFF)XYE5K:4(F1VBVWJ*F0-JOL[C%:EH)VE74-.CXZ$766VG%(4JP!-&GZ
MB46PL-ZFU"J]RC//M9&-X8V\I+<FLA48&B2HMI7W*5J:E'\-<N/G1YLN'F,?
M"@[' AY=[*.F@&H%;P_*SP@<G9GRP7//;;02E*0;:GK?QI6_#6Z+RKQ[R+'Q
M*[DV(Q,:;14%24IBI"12E?74K>@\U[,^D,@RFPA16H::FVT&^M"GK6E& ]28
MT61\.UE/YM#;<1>@WY"J59+U?K7)23*M]\D!Q*ZA2F^XXHJ(]?56N7?K J2W
MSC(1E-?X*7[!1'46&M="O2)Q+G!X:L?9Y!9M<:^-6QO"83T>;"<6EUA]A^.Z
MFF^J:*<2?@ %Z8'(&-XQE,?(QTDOEW:I=S;8;C32F)SALN?$GV2_N(7T'C>B
MW\1^;^#0\#MMIR]Y<>Y6Z,VPEQC:I:^VA*4E0<6D _3KJ5Z2_,-$XGQEN.O]
M"=-=ZU _97.[U(]!,]E,VH,,9!0*[W2@>/OK6KI[C5HCWY-I188TVP*DK;7.
MD!2G5,$E/<4-Q;!*?V:2<E^;7$YV6K'S1B6V0O;N\PDVOUU%2)QWY7LQ Q+4
MAH90O>6%$;!H;7MUI5)F$\!^4-A=N&-NQK=D;\52TN10T'Q+4"0G9O*?4_+1
MEC^(>D?JI@'(:<[':RDE-@VSY:E:ZZ7%ZCB?F?4OT^S[2)V+?7C6U_YKP4D
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M'([>3SW+!CMS?-T<2A,I&QM##L2<H"M?ZFL'$XS28SI7HC8;F]J<>29E,EQ
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6U?;6_P"TG]Z=,FQK^(?92FS?B*__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
